Document:

QuickLinks
 -- Click here to rapidly navigate through this document
  

Exhibit 10.36  

 
 

ALLOS THERAPEUTICS, INC.
  EMPLOYMENT AGREEMENT FOR
  PABLO J. CAGNONI    
    

        THIS EMPLOYMENT AGREEMENT (the "Agreement") is entered into as of
October 7, 2003, by and between ALLOS THERAPEUTICS, INC., (the "Company"), and  PABLO J. CAGNONI
("Executive") (collectively, the
"Parties"). 

        WHEREAS, Executive is critical to the Company's current product development activities and NDA submission, as well as the ongoing
operation of the Company; and 

        WHEREAS, the Company wishes to continue to employ Executive and assure itself of the continued services of Executive during this critical
period, on the terms set forth herein; and 

        WHEREAS, Executive wishes to be so employed under the terms set forth herein. 

        NOW, THEREFORE, in consideration of the promises, mutual covenants, the above recitals, and the agreements herein set forth, and for other
good and valuable consideration, the sufficiency of which is hereby acknowledged, the Parties agree to the following terms and conditions of Executive's employment: 

        1.    EMPLOYMENT.    The Company hereby agrees to employ Executive as  Vice President of Clinical
Development and Executive hereby accepts such employment upon the terms and conditions set forth herein. 

        2.    AT-WILL EMPLOYMENT.    It is
understood and agreed by the Company and Executive that this Agreement does not contain any promise or representation concerning the duration of Executive's employment with the Company. Executive
specifically acknowledges that his employment with the Company is at-will and may be altered or terminated by either Executive or the Company at any time, with or without cause and/or with
or without notice. The nature, terms or conditions of Executive's employment with the Company cannot be changed by any oral representation, custom, habit or practice, or any other writing. In
addition, that the rate of salary, any bonuses, paid time off, other compensation, or vesting schedules are stated in units of years or months does not alter the at-will nature of the
employment, and does not mean and should not be interpreted to mean that Executive is guaranteed employment to the end of any period of time or for any period of time.  In the event of conflict
between this disclaimer and any other statement, oral or written, present or future, concerning terms and conditions of employment, the
at-will relationship confirmed by this disclaimer shall control. This at-will status cannot be altered except in writing signed by Executive and the Chairman of the Board of
Directors.

        3.    DUTIES.    Executive shall render full-time services
to the Company as its Vice President of Clinical Development. Executive shall devote his best efforts and his full business time, skill and attention to the performance of his duties on behalf of the
Company. Of course, the Company reserves the right to modify Executive's job duties and responsibilities as necessary. 

        4.    POLICIES AND PROCEDURES.    Executive agrees that he is subject
to and will comply with the policies and procedures of the Company, as such policies and procedures may be modified, added to or eliminated from time to time at the sole discretion of the Company,
except to the extent any such policy or procedure specifically conflicts with the express terms of this Agreement. Executive further agrees and acknowledges that any written or oral policies and
procedures of the Company do not constitute contracts between the Company and Executive. 

        5.    COMPENSATION.    For all services rendered and to be rendered
hereunder, the Company agrees to pay to the Executive, and the Executive agrees to accept a base salary of $225,000 per 

1

 

annum.
Any such salary shall be payable in equal biweekly installments and shall be subject to such deductions or withholdings as the Company is required to make pursuant to law, or by further
agreement with the Executive. The Board of Directors may adjust the Executive's compensation from time to time in its sole and complete discretion. 

        6.    BONUS.    Executive will be eligible for a discretionary bonus,
based on both corporate and individual goals, in an amount equal to 25% of Executive's base salary ("Bonus"). The decision to award the Bonus and/or to
modify the amount of any bonus given is within the sole and complete discretion of the Board. 

        7.    OTHER BENEFITS.    While employed by the Company as provided
herein: 

        (a)    Executive and Employee Benefits.    The Executive shall be
entitled to all benefits to which other executive officers of the Company are entitled, on terms comparable thereto, including, without limitation, participation in the 401(k) plan, group insurance
policies and plans, medical, health, vision, and disability insurance policies and plans, and the like, which may be maintained by the Company for the benefit of its executives. The Company reserves
the right to alter and amend the benefits received by Executive from time to time at the Company's discretion. 

        (b)    Out-of-Pocket Expense
Reimbursement.    The Executive shall receive, against presentation of proper receipts and vouchers, reimbursement for direct and reasonable
out-of-pocket expenses incurred by him in connection with the performance of his duties hereunder, according to the policies of the Company. 

        (c)    Personal Time Off.    The Executive shall be entitled to
personal time off and sick leave according to the Company's benefits package. 

        8.    PROPRIETARY AND OTHER OBLIGATIONS.    Executive agrees to
continue to abide by Executive's previously executed Proprietary Information, Inventions, Non-Competition and Non-Solicitation Agreement attached hereto as  Exhibit A (the "Confidentiality Agreement"). 

        9.    TERMINATION.    Executive and the Company each acknowledge that
either party has the right to terminate Executive's employment with the Company at any time for any reason whatsoever, with or without cause or advance notice pursuant to the following: 

        (a)    Termination by Death or Disability.    Subject to applicable
state or federal law, in the event Executive shall die during the period of his employment hereunder or become permanently disabled, as evidenced by notice to the Company and Executive's inability to
carry out his job responsibilities for a continuous period of more than three months, Executive's employment and the Company's obligation to make payments hereunder shall terminate on the date of his
death, or the date upon which, in the sole determination of the Board of Directors, Executive has failed to carry out his job responsibilities for three months, except that the Company shall pay
Executive's estate any salary earned but unpaid prior to termination, all accrued but unused vacation and any business expenses that were incurred but not reimbursed as of the date of termination.
Vesting of any unvested stock options shall cease on the date of termination. 

        (b)    Voluntary Resignation by Executive.    In the event Executive
voluntarily terminates his employment with the Company (other than for Good Reason (as defined in paragraph 10(b) below)), the Company's obligation to make payments hereunder shall cease upon
such termination, except that the Company shall pay Executive any salary earned but unpaid prior to termination, all accrued but unused vacation and any business expenses that were incurred but not
reimbursed as of the date of termination. Vesting of any unvested stock options shall cease on the date of termination. 

2

 

        (c)    Termination for Just Cause.    In the event the Executive is
terminated by the Company for Just Cause (as defined in paragraph 10(a) below), the Company's obligation to make payments hereunder shall cease upon the date of receipt by Executive of written
notice of such termination (the "date of termination" for purposes of this paragraph 9(c)), except that the Company shall pay Executive any
salary earned but unpaid prior to termination, all accrued but unused vacation and any business expenses that were incurred but not reimbursed as of the date of termination. Vesting of any unvested
stock options shall cease on the date of termination. 

        (d)    Termination by the Company without Just Cause Or Resignation for Good Reason (Other Than Change
in Control).    The Company shall have the right to terminate Executive's employment with the Company at any time without Just Cause. In the event Executive is
terminated by the Company without Just Cause or Executive resigns for Good Reason (other than in connection with a Change in Control (as defined in paragraph 10(c) below)), and upon the
execution of a full general release by Executive ("Release", in the form attached hereto as  Exhibit B), releasing all claims known or unknown that
Executive may have against the Company as of the date Executive signs such release, and
upon the written acknowledgment of his continuing obligations under the Confidentiality Agreement, Executive shall be entitled to receive the following severance benefits: (i) continuation of
Executive's base salary, then in effect, for a period of six (6) months following the Termination Date, paid on the same basis and at the same time as previously paid; (ii) payment of
any accrued but unused vacation and sick leave; and (iii) the Company shall pay the premiums of Executive's group health insurance COBRA continuation coverage, including coverage for
Executive's eligible dependents, for a maximum period of six (6) months following a termination without Just Cause or resignation for Good Reason; provided,
however, that (a) the Company shall pay premiums for Executive's eligible dependents only for coverage for which those eligible dependents were enrolled immediately
prior to the termination without Just Cause or resignation for Good Reason and (b) the Company's obligation to pay such premiums shall cease immediately upon Executive's eligibility for
comparable group health insurance provided by a new employer of Executive. 

        (e)    Change in Control Severance Benefits.    In the event that the
Company terminates Executive's employment without Just Cause or Executive resigns for Good Reason within one (1) month prior to or thirteen (13) months following the effective date of a
Change in Control, ("Change in Control Termination"), and upon the execution of a Release, Executive shall be entitled to receive the following Change
in Control severance benefits: (i) continuation of Executive's base salary, then in effect, for a period of one (1) year following the Termination Date, paid on the same basis and at the
same time as previously paid; (ii) payment of any accrued but unused vacation and sick leave; (iii) a bonus in the amount equal to the bonus amount paid in the year immediately preceding
the Change in Control or 50% of the maximum bonus eligibility if the Executive was not employed by the Company during the prior year bonus period; and (iv) the Company shall pay the premiums of
Executive's group health insurance COBRA continuation coverage, including coverage for Executive's eligible dependents, for a maximum period of twelve (12) months following a Change in Control
Termination; provided, however, that (a) the Company shall pay premiums for Executive's eligible dependents only for coverage for which those
eligible dependents were enrolled immediately prior to the Change in Control Termination and (b) the Company's obligation to pay such premiums shall cease immediately upon Executive's
eligibility for comparable group health insurance provided by a new employer of Executive. If Executive obtains new employment pursuant to which he is employed on an average of 30 hours or more
each week, he may request, upon written notification to the Company, to receive any unpaid severance benefits (subject to required deductions and tax withholdings) within 14 days 

3

 

after
receipt by the company of such written notice. Executive agrees that the Company's payment of health insurance premiums will satisfy its obligations under COBRA for the period provided. No
insurance premium payments will be made following the effective date of Executive's coverage by a health insurance plan of a subsequent employer. For the balance of the period that Executive is
entitled to coverage under federal COBRA law, if any, Executive shall be entitled to maintain such coverage at Executive's own expense. 

        In
addition, notwithstanding anything contained in Executive's stock option agreements to the contrary, in the event the Company (or any surviving or acquiring corporation) terminates
Executive's employment without Just Cause or Executive resigns for Good Reason within one (1) month prior to or thirteen (13) months following the effective date of a Change in Control,
and any surviving corporation or acquiring corporation assumes Executive's stock options or substitutes similar options for Executive's stock options in accordance with the terms of the 2000 Plan
and/or the 2002 Plan, as applicable, then the vesting of Executive's stock options (or any substitute options) shall be accelerated in full and the term and the period during which such options may be
exercised shall be extended to twelve (12) months after the date of Executive's termination of employment; provided, that, in no event shall such
options be exercisable after the expiration date of such options as set forth in the grant notice and/or agreement evidencing such options. Alternatively, in connection with any Change of Control, if
any surviving corporation or acquiring corporation does not assume Executive's stock options or substitute similar options for Executive's stock options in accordance with the terms of the 2000 Plan
and/or the 2002 Plan, as applicable, then the vesting of Executive's stock options shall be accelerated in full. 

        10.    Definitions.    

        (a)    Just Cause.    As used in this Agreement,
"Just Cause" shall mean the occurrence of one or more of the following: (i) Executive's conviction of a felony or a crime involving moral
turpitude or dishonesty; (ii) Executive's participation in a fraud or act of dishonesty against the Company; (iii) Executive's intentional and material damage to the Company's property;
(iv) material breach of Executive's employment agreement, the Company's written policies, or the Confidentiality Agreement that is not remedied by Executive within fourteen (14) days of
written notice of such breach from the Board; or (v) conduct by Executive which demonstrates Executive's gross unfitness to serve the Company as Vice President of Clinical Development, as
determined in the sole discretion of the Company's Board of Directors. Executive's physical or mental disability or death shall not constitute cause hereunder. 

        (b)    Good Reason.    As used in this Agreement,
"Good Reason" shall mean any one of the following events which occurs on or after the commencement of Executive's employment without Executive's
consent: (i) any reduction of Executive's then existing annual salary base or annual bonus target by more than ten percent (10%), unless the Executive accepts such reduction in compensation
opportunity or such reduction is done in conjunction with similar reductions for similarly situated executives of the Company; (ii) any request by the Company that the Executive relocate to a
work site that would increase Executive's one-way commute distance by more than thirty-five (35) miles from his then principal residence in Colorado, unless the
Executive accepts such relocation opportunity; or (iii) for purposes of Section 9(e) only, if the Company or any surviving corporation following a Change in Control fails to offer the
Executive a position that is equivalent in pay, benefits and responsibilities. 

        (c)    Change in Control.    As used in this Agreement, a
"Change in Control" is defined as: (a) a sale, lease, exchange or other transfer in one transaction or a series of related transactions of all or
substantially all of the assets of the Company (other than the transfer of the Company's assets to a majority-owned subsidiary corporation); (b) a merger or consolidation in which the Company
is not the surviving corporation (other than a merger or 

4

 

consolidation
in which shareholders immediately before the merger or consolidation have, immediately after the merger or consolidation, greater stock voting power); (c) a reverse merger in
which the Company is the surviving corporation but the shares of the Company's common stock outstanding immediately preceding the merger are converted by virtue of the merger into other property,
whether in the form of securities, cash or otherwise (other than a reverse merger in which shareholders immediately before the merger have, immediately after the merger, greater stock voting power);
or (d) any transaction or series of related transactions in which in excess of 50% of the Company's voting power is transferred. 

        11.    TERMINATION OF COMPANY'S OBLIGATIONS.    Notwithstanding any
provisions in this Agreement to the contrary, the Company's obligations, and Executive's rights pursuant to Sections 9(d) and 9(e) herein, regarding salary continuation and the payment of COBRA
premiums, shall cease and be rendered a nullity immediately should Executive fail to comply with the provisions of the Confidentiality Agreement or if Executive directly or indirectly competes with
the Company. 

        12.    MISCELLANEOUS.    

        (a)    Taxes.    Except as specifically set forth herein, Executive
agrees to be responsible for the payment of any taxes due on any and all compensation, stock option, or benefits provided by the Company pursuant to this Agreement. 

        (b)    Modification/Waiver.    This Agreement may not be amended,
modified, superseded, canceled, renewed or expanded, or any terms or covenants hereof waived, except by a writing executed by each of the parties hereto or, in the case of a waiver, by the party
waiving compliance. Failure of any party at any time or times to require performance of any provision hereof shall in no manner affect his or its right at a later time to enforce the same. No waiver
by a party of a breach of any term or covenant contained in this Agreement, whether by conduct or otherwise, in any one or more instances shall be deemed to be or construed as a further or continuing
waiver of agreement contained in the Agreement. 

        (c)    Severability.    Whenever possible, each provision of this
Agreement will be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement is held to be invalid, illegal or unenforceable in any respect
under any applicable law or rule in any jurisdiction, such invalidity, illegality or unenforceability will not affect any other provision or any other jurisdiction, but this Agreement will be
reformed, construed and enforced in such jurisdiction as if such invalid, illegal or unenforceable provisions had never been contained herein. 

        (d)    Successors and Assigns.    This Agreement is intended to bind
and inure to the benefit of and be enforceable by Executive and the Company, and their respective successors, assigns, heirs, executors and administrators, except that Executive may not assign any of
his duties hereunder and he may not assign any of his rights hereunder without the written consent of the Company, which shall not be withheld unreasonably. 

        (e)    Notices.    All notices given hereunder shall be given by
certified mail, addressed, or delivered by hand, to the other party at his or its address as set forth herein, or at any other address hereafter furnished by notice given in like manner. Executive
promptly shall notify Company of any change in Executive's address. Each notice shall be dated the date of its mailing or delivery and shall be deemed given, delivered or completed on such date. 

        (f)    Governing Law; Personal Jurisdiction and Venue.    This
Agreement and all disputes relating to this Agreement shall be governed in all respects by the laws of the State of Colorado as such laws are applied to agreements between Colorado residents entered
into and performed entirely in Colorado. The Parties acknowledge that this Agreement constitutes the minimum contacts to establish personal jurisdiction in Colorado and agree to a Colorado 

5

 

court's
exercise of personal jurisdiction. The Parties further agree that any disputes relating to this Agreement shall be brought in courts located in the State of Colorado. 

        (g)    Entire Agreement.    This Agreement together with the Exhibits
A and B attached hereto set forth the entire agreement and understanding of the parties hereto with regard to the employment of the Executive by the Company and supersede any and all prior agreements,
arrangements and understandings, written or oral, pertaining to the subject matter hereof. No representation, promise or inducement relating to the subject matter hereof has been made to a party that
is not embodied in these Agreements, and no party shall be bound by or liable for any alleged representation, promise or inducement not so set forth. 

[Remainder of Page Intentionally Left Blank]

6

 

        IN WITNESS WHEREOF, the parties have each duly executed this Employment Agreement effective as of the day and year first above written. 

	 	 	ALLOS THERAPEUTICS, INC.
	

 	
 	
/s/  MICHAEL HART      

	 	 	By:	Michael E. Hart
	 	 	Its:	President and Chief Executive Officer

	 	 	Address:	11080 CirclePoint Road

Westminster, CO 80020

	 	 	EXECUTIVE:
	

 	
 	
/s/  PABLO J. CAGNONI      
 Pablo J. Cagnoni

	 	 	Address:	371 Birch Street

Denver, Colorado 80220

7

 
EXHIBIT A TO EMPLOYMENT AGREEMENT  

MANAGER, EXECUTIVE PERSONNEL OR ASSISTANTS'

PROPRIETARY INFORMATION, INVENTIONS,

NON-COMPETITION, AND NON-SOLICITATION AGREEMENT  

[Attach executed copy]  

8

 
EXHIBIT B TO EMPLOYMENT AGREEMENT  

RELEASE AGREEMENT  

        I understand that my position with Allos Therapeutics, Inc. (the "Company") terminated
effective                        ,            (the "Separation Date").
The Company has agreed that if I choose to sign this Release, the Company will pay me certain severance or consulting benefits pursuant to the terms of the Employment Agreement (the "Agreement")
between myself and the Company, and any agreements incorporated therein by reference. I understand that I am not entitled to such benefits unless I sign this Release and it becomes fully effective. I
understand that, regardless of whether I sign this Release, the Company will pay me all of my accrued salary and vacation through the Separation Date, to which I am entitled by law. 

        In
consideration for the severance benefits I am receiving under the Agreement, I hereby release the Company and its officers, directors, agents, attorneys, employees, shareholders,
parents, subsidiaries, and affiliates from any and all claims, liabilities, demands, causes of action, attorneys' fees, damages, or obligations of every kind and nature, whether they are now known or
unknown, arising at any time prior to the date I sign this Release. This general release includes, but is not limited to: all federal and state statutory and common law claims, claims related to my
employment or the termination of my employment or related to breach of contract, tort, wrongful termination, discrimination, wages or benefits, or claims for any form of equity or compensation.
Notwithstanding the release in the preceding sentence, I am not releasing any right of indemnification I may have for any liabilities arising from my actions within the course and scope of my
employment with the Company. 

        If
I am forty (40) years of age or older as of the Separation Date, I acknowledge that I am knowingly and voluntarily waiving and releasing any rights I may have under the federal
Age Discrimination in Employment Act of 1967, as amended ("ADEA"). I also acknowledge that the consideration given for the waiver in the above paragraph is in addition to anything of value to which I
was already entitled. I have been advised by this writing, as required by the ADEA that: (a) my waiver and release do not apply to any claims that may arise after my signing of this Release;
(b) I should consult with an attorney prior to executing this Release; (c) I have twenty-one (21) days within which to consider this Release (although I may choose to
voluntarily execute this Release earlier); (d) I have seven (7) days following the execution of this release to revoke the Release; and (e) this Release will not be effective
until the eighth day after this Release has been signed both by me and by the Company ("Effective Date"). 

	Agreed:	 	 	 
	
ALLOS THERAPEUTICS INC.	
 	

PABLO J. CAGNONI
	
By:	

	
 	

 	

 

	Name:	
	 	 	 

	Title:	
	 	 	 

	Date:	
	 	Date:	

9

QuickLinks

ALLOS THERAPEUTICS, INC. EMPLOYMENT AGREEMENT FOR PABLO J. CAGNONI<Page>

                                                                   EXHIBIT 10.37

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

--------------------------------------------------------------------------------

                        DEVELOPMENT AND SUPPLY AGREEMENT

                                 BY AND BETWEEN

                            ALLOS THERAPEUTICS, INC.

                                       AND

                          BAXTER HEALTHCARE CORPORATION

CONFIDENTIAL
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

<Page>

                                TABLE OF CONTENTS

<Table>
<Caption>
ARTICLE                                                                     PAGE
-------                                                                     ----
  <S>                                                                       <C>
  1          PROJECT MANAGEMENT
  2          DEVELOPMENT PROGRAM
  3          PRODUCT REGISTRATIONS
  4          COMMERCIAL SUPPLY
  5          MANUFACTURING FEE AND PRODUCT MAINTENANCE FEE
  6          API
  7          QUALITY MANAGEMENT AND ONGOING QUALITY RESPONSIBILITIES
  8          SALES SUPPORT AND USE OF TRADEMARKS
  9          TERM AND TERMINATION
  10         EFFECTS OF TERMINATION
  11         INTELLECTUAL PROPERTY
  12         CONFIDENTIALITY
  13         REPRESENTATIONS AND WARRANTIES
  14         INDEMNIFICATION AND INSURANCE
  15         ALTERNATE DISPUTE RESOLUTION
  16         MISCELLANEOUS
</Table>

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                        i
<Page>

                                    EXHIBITS

EXHIBIT A   PRODUCT SPECIFICATIONS
            API SPECIFICATIONS

EXHIBIT B   DEVELOPMENT PLAN (SECTION 2.1)

EXHIBIT C   REGULATORY PLAN (SECTION 2.2)

EXHIBIT D   DEVELOPMENT FEE AND DELIVERABLES (SECTION 2.1)

EXHIBIT E   MINIMUM LOT SIZES (SECTION 4.4)
            MANUFACTURING FEE AND PRODUCT MAINTENANCE FEE (SECTIONS 5.1 AND 5.2)

EXHIBIT F   CONFIDENTIAL DISCLOSURE AGREEMENT (SECTION 12.1)

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       ii
<Page>

                        DEVELOPMENT AND SUPPLY AGREEMENT

      This DEVELOPMENT AND SUPPLY AGREEMENT, (the "Agreement") is effective as
of December ____, 2003 (the "Effective Date"), between ALLOS THERAPEUTICS, INC.
a corporation organized and existing under the laws of the State of Delaware and
having its principal office at 11080 Circlepoint Road, Suite 200, Westminster,
Colorado 80020 ("Allos") and BAXTER HEALTHCARE CORPORATION, a corporation
organized and existing under the laws of the State of Delaware and having its
principal office at One Baxter Parkway, Deerfield, Illinois 60015 ("Baxter").
All references to "Allos" and "Baxter" will include their respective Affiliates.

                                   BACKGROUND

Allos is developing a synthetic allosteric modifier of hemoglobin, RSR13
("Compound"), indicated for use in cancer treatment to increase the efficiency
of cancer radiotherapy. The Compound enhances the release of oxygen from
hemoglobin making oxygen more available for use by the tissues. . Allos has
developed a solution of RSR13 in an aqueous carrier presented in a glass
container, [ * ]

Baxter manufactures and markets premix, ready-to-use solutions [ * ] for
parenteral administration of pharmaceutical preparations. [ * ].

Allos is also interested in transferring the technology for the current
production of premix RSR13 in a glass container to Baxter, such that Baxter
would manufacture and package the solution of the Compound in an aqueous carrier
in Baxter's glass container

Allos and Baxter are therefore interested in forming a relationship to develop
and manufacture premix forms of the Compound, [ * ], in accordance with the
terms and conditions set forth in this Agreement.

[ * ]

                                   DEFINITIONS

As used in this Agreement the following terms will have the following meanings:

"ADR" will have the meaning set forth in ARTICLE 15.

"AFFILIATE" will mean any corporation or business entity that controls, is
controlled by, or is under common control with, Allos or Baxter. A corporation
or business entity will be deemed to control another corporation or business
entity if it owns, directly or indirectly, fifty percent (50%) or more of the
securities or other ownership interests representing the equity, the voting
stock or general partnership interest of such corporation or business entity.

"ALLOS INVENTIONS" will have the meaning set forth in SECTION 11.1.2.

"API" will mean all active pharmaceutical ingredients supplied to Baxter by
Allos in accordance with the terms of this Agreement and the Specifications set
forth in EXHIBIT A.

"API/FORMULATION SPECIFICATIONS" will have the meaning set forth in SECTION
11.2.1.

"API SPECIFICATIONS" will mean the Baxter Procedure Specification D2-01-30-788.
Upon Regulatory Approval for the Product the API Specification will mean the
Baxter Procedure Specification 02-01-30-788.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

<Page>

"BACKGROUND INTELLECTUAL PROPERTY RIGHTS" will mean all patents, patent
applications, copyrights, trade secrets, and other intellectual property rights
owned by either Party or under which a Party otherwise has the right to grant
licenses without accounting to any third party or to the other Party, where the
inventions claimed, the works of authorship, or the know-how, trade secrets and
the like, were not made in performance of activities pursuant to, or in
anticipation of, this Agreement.

"BAXTER INVENTIONS" will have the meaning set forth in SECTION 11.1.3.

"COMMUNICATIONS" will have the meaning set forth in SECTION 3.4.

"COMPOUND" will mean the synthetic allosteric modifier of hemoglobin, RSR13,
having the chemical formula:
2-[-[[(3,5-Dimethylanilino)carbonyl]methyl]phenoxy]-2-methylpropionic acid].

"CONFIDENTIAL DISCLOSURE AGREEMENT" will mean the two-way disclosure agreement
signed by the Parties, a copy of which is attached to this Agreement as EXHIBIT
F.

"CONFIDENTIAL INFORMATION" will have the meaning set forth in ARTICLE 12.

"CONTAINER" will mean [ * ] and will mean the container portion of the Product
as described in EXHIBIT A.

"CONTRACT YEAR" will have the meaning set forth in SECTION 9.1.1.

"CONTROL" will mean possession of the ability to grant the licenses or
sublicenses as provided for herein without violating the terms of any agreement
or arrangement with any third party.

"cGMP" or "CURRENT GOOD MANUFACTURING PRACTICES" will mean (i) the good
manufacturing practices required by the FDA and set forth in the FD&C Act or FDA
regulations, policies, or guidelines in effect at a particular time, for the
manufacture and testing of pharmaceutical materials and (ii) the corresponding
regulatory requirements of each jurisdiction in the Territory relating to the
manufacture and testing of Product.

"DELIVERABLES" will mean the materials set forth on EXHIBIT D.

"DEVELOPMENT FEES" will have the meaning set forth in SECTION 2.1.5.

"DEVELOPMENT PLAN" will mean the plan for development of the Product, as set
forth in EXHIBIT B and described generally in SECTION 2.1.1.

"DEVELOPMENT PROGRAM" will mean the collaborative research and development
effort between the Parties to develop the Product which will enable Allos to
file Regulatory Submissions with Regulating Groups in the Territory and which
encompasses the tasks set forth on EXHIBIT B (Development Plan) and EXHIBIT C
(Regulatory Plan) and the Deliverables set forth on EXHIBIT D.

"DRUG ESTABLISHMENT FEE" will have the meaning set forth in SECTION 3.5.

"ESTIMATED REQUIREMENTS" will have the meaning set forth in SECTION 4.3.

"FDA" will mean the United States Food and Drug Administration and any successor
agency.

"FD&C ACT" will mean the United States Federal Food, Drug and Cosmetic Act, as
amended.

"FIELD" will mean the research for, development for, registration and
manufacture of, the Product and any

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF
1934, AS AMENDED.

                                        2
<Page>

Formulation.

"FIRST OF CODE" will mean Product resulting from the manufacture of the first
three (3) production batches intended for commercial sale.

[ * ]

"FORCE MAJEURE" will have the meaning set forth in SECTION 16.6.

"FORMULATION" will mean any and all premix ready-to-use aqueous solutions
containing the Compound that have been formulated for [ * ].

"FORMULATION SPECIFICATIONS" will mean those specifications for the final
release of the premix, ready-to-use aqueous solution that are developed and
finalized by the Parties as part of the Development Program and which, together
with the Container, are part of the Product Specifications.

[ * ]

"INFORMATION" will mean (i) techniques and data relating to the Field,
including, but not limited to, ideas (including patentable inventions),
inventions, practices, methods, knowledge, trade secrets, documents, apparatus,
clinical and regulatory strategies, test data (including pharmacological,
toxicological and clinical test data), analytical and quality control data,
manufacturing, patent and legal data, market data, financial data within the
Field and (ii) chemical formulations, compositions of matter, product samples
and assays within the Field.

"INITIAL TERM" will have the meaning set forth in SECTION 9.1.1.

"JOINT INVENTIONS" will have the meaning set forth in SECTION 11.1.4.

"MANUFACTURING FEE" will mean the fee per unit paid by Allos to Baxter for
Product manufactured under this Agreement as described in SECTION 5.1 and
EXHIBIT E.

"MANUFACTURING PROCESS(ES)" will have the meaning set forth in SECTION 6.3.

"MATTER" will have the meaning set forth in SECTION 14.3.

"NDA" will mean a New Drug Application, as defined in the FD&C Act and
applicable regulations promulgated thereunder, as amended from time to time.

"ORIGINAL PRODUCT DATA" will have the meaning set forth in SECTION 11.2.1.

"PARTY" or "PARTIES" will mean Allos and Baxter individually, and collectively,
as applicable.

"PATENT" will mean (i) valid and enforceable letters patent including any
extension, registration, continuation, reissue, reexamination or renewal thereof
and (ii) to the extent valid and enforceable rights are granted by a
governmental authority thereunder, a Patent Application.

"PATENT APPLICATION" will mean an application for letters patent.

"PRE-EXISTING SPECIFICATIONS" will have the meaning set forth in SECTION 11.2.1.

"PRODUCT" will mean a premixed solution incorporating Compound in the
Formulation which has (i) undergone the development process established under
ARTICLE 2 and (ii) been packaged and terminally

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF
1934, AS AMENDED.

                                        3
<Page>

sterilized within the Container, all in accordance with the Product
Specifications.

"PRODUCT SPECIFICATIONS" will mean the Formulation Specifications together with
the Container, which collectively describe the Product and are developed and
finalized by the Parties as part of the Development Program. The Product
Specifications are set forth on EXHIBIT A attached hereto, subject to amendment
as provided in the Quality Agreement.

"QUALITY AGREEMENT" will mean the quality agreement signed by the Parties on
even date herewith.

"REGULATING GROUPS" will mean the FDA and its successors and similar
governmental agencies outside the United States and in the Territory which are
responsible for granting manufacturing, marketing, price and/or reimbursement
price authorizations and includes applicable national, supra-national (e.g. the
European Commission or the Council of the European Union), state or local
Regulating Groups, department, bureau commission, council or other governmental
entity in the Territory that has jurisdiction over the API, Compound,
Formulation or Product, whether the development, manufacture, handling, storage,
transportation, destruction, or otherwise.

"REGULATORY APPROVAL" means (a) in the United States, approval by the FDA of any
applicable filing and satisfaction of any related applicable FDA registration
and notification requirements (if any) required to market and sell a
pharmaceutical product or device; or (b) in any country other than the United
States, approval by Regulating Groups having jurisdiction over such country of a
single application or set of applications or other applicable filing and
satisfaction of any related applicable regulatory and notification requirements,
if any, necessary to market and sell pharmaceutical products or devices
commercially in such country.

"REGULATORY PLAN" will mean the principal regulatory considerations that are
associated with Product development during the Development Program as set forth
in EXHIBIT C and described generally in SECTION 2.2.

"REGULATORY SUBMISSIONS" will mean those applications and filings identified in
the Regulatory Plan and required by FDA regulations, as amended from
time-to-time, and the equivalent applications and filing for each country or
super-national jurisdiction in the Territory, including but not limited to, the
Product's NDA or Investigational New Drug Application (INDA).

"REPORTS" will have the meaning set forth in SECTION 11.2.1.

"REQUIREMENTS" will have the meaning set forth in SECTION 4.1.

"STEERING COMMITTEE" will have the meaning set forth in SECTION 1.3.

"SUPPORTIVE DOCUMENTS" will have the meaning set forth in the Quality Agreement.

"TEAM LEADERS" will have the meaning set forth in SECTION 1.1.

"TERM OF THE AGREEMENT" will have the meaning set forth in SECTION 9.1.1.

"TERRITORY" will mean the United States, Canada, and member states of the
European Union, and any additional countries added by written agreement of the
Parties.

"USCDMF" means Baxter's United States Container Drug Master File for the
Container.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF
1934, AS AMENDED.

                                        4
<Page>

                                      TERMS

1.    PROJECT MANAGEMENT. In order to facilitate collaboration between the
Parties to achieve the objectives of this Agreement, the Parties agree to the
following organizational provisions:

            1.1     TEAM LEADER. Baxter and Allos will each identify one
employee with appropriate authority to serve as the primary contact with the
other Party about the Product and the Parties' relationship under this Agreement
(each a "Team Leader"). Each Team Leader will be responsible for obtaining
cooperation and input from other individuals within such Team Leader's
organization whose expertise and ability may be required from time to time to
maximize the potential for successful collaboration under this Agreement. The
Team Leader will be a member of the Steering Committee described in SECTION 1.3.
The Parties will determine whether or not the Team Leader during the Product's
Development Program should continue to serve as the Team Leader during the
commercialization of the Product, or whether another individual should be serve
this function under this Agreement.

            1.2     TEAM LEADER RESPONSIBILITIES. Without limiting the scope of
the Team Leader's responsibilities, particular consideration will be given to
key operational aspects of the relationship, including: (i) product development
and regulatory matters highlighted in the Development Plan (EXHIBIT B) and
Regulatory Plan (EXHIBIT C); (ii) transitioning team leadership responsibilities
to a corresponding team leader, if appropriate, once commercialization of the
Product is undertaken, including such matters as Product manufacturing, quality
and sales support considerations; (iii) coordinating pre launch inventory
assessments and inventory planning activities in connection with the launch of
the Product into the marketplace; (iv) reviewing the status of ongoing
contractual commitments under the Agreement; and (v) identifying and
implementing those actions as are permitted under the terms of this Agreement
which would improve the value of the Product to customers and the Parties. The
Team Leaders will develop a process and procedures to optimize communication and
collaboration between the Parties in order to timely refine the Development Plan
and Regulatory Plan and achieve the objectives of this Agreement. The Team
Leaders will communicate regularly during the Term of the Agreement at mutually
agreeable times (not less frequently than once per month), and when necessary
hold meetings at mutually agreeable places, to review progress and the
challenges and opportunities for effective collaboration under this Agreement.
The Team Leaders will analyze issues that arise during the Development Program
and subsequent commercialization of the Product and offer recommendations to the
Steering Committee as to the appropriate course of action.

            1.3     STEERING COMMITTEE. A steering committee, consisting of the
Team Leaders and at least one senior management representative from each Party
("Steering Committee"), will meet at least once per calendar quarter during the
Term of this Agreement, either in person or by telephone or video conference.
The Steering Committee will (i) oversee and provide management direction for the
achievement of the objectives of the collaborative effort; (ii) review the
program of research and development activities set forth in the Development Plan
and Regulatory Plan; (iii) review requests by Regulating Groups, or a Party,
that additional tests, studies or activities be performed beyond those
encompassed in the Exhibits, make recommendations, and appropriate allocations
of additional expenses in accordance with the provisions of SECTION 2.1.5.2;
(iv) be responsible for obtaining from their respective organizations approval
of the Regulatory Plan prior to Product stability batch production (the
Regulatory Plan will be finalized during the Development Program as described in
SECTION 2.2); (v) periodically review performance of the Product in the
Territory with respect to unit volume and quality, including any customer
feedback and complaints that relate to manufacturing, Formulation and/or
Container-related quality issues; (vi) develop a plan for [ * ]; (vii) be
responsible for approving any non-material changes, and obtaining from their
respective organizations approval of any material changes approved by the
Steering Committee that require amendments to this Agreement, to the Development
Plan, or Regulatory Plan set forth in EXHIBITS B and C respectively; and (viii)
attempt to resolve any issues that arise concerning activities under the
Development Plan or Regulatory Plan. The Steering Committee will

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF
1934, AS AMENDED.

                                        5
<Page>

establish a process for timely review and approval of non-material changes to
the Development Plan and Regulatory Plan submitted by the Team Leaders. Any
decisions upon which the Steering Committee is unable to reach a consensus shall
be subject to resolution pursuant to ARTICLE 15.0.

2.    DEVELOPMENT PROGRAM

      2.1   DEVELOPMENT PLAN.

            2.1.1   GENERAL. The activities and key milestones to occur during
the Development Program include, but are not limited to, the following
activities or topics: (i) technical feasibility assessment for the Product [ *
]; (ii) formulation and analytical development for the Product in the Container;
(iii) stability studies and Product batch production to support Regulatory
Submissions for the Product in the Container; (iv) Regulatory Submissions for
the Product in the Container, and (v) Regulating Groups' review and approval for
the Product in the Container. The Development Program covered by this Agreement
is solely related to presentation of the Formulation in the Container, and does
not include [ * ].

      In general, during the Term of this Agreement, Allos will be responsible
for (i) providing Information about the API that is necessary for Baxter to
conduct the Development Program, (ii) timely providing the API and applicable
reference standards required for implementation of the activities described in
the Development Plan, (iii) compliance with Regulatory Submission reporting
requirements regarding manufacture and control of the API, and (iv) timely
review, drafting and filing of all necessary submissions with Regulating Groups
consistent with Allos's obligations under the Regulatory Plan. Allos will also
be responsible for providing Baxter with (i) all information controlled by Allos
developed by or on behalf of Allos prior to the date of this Agreement related
to manufacture of the Formulation [ * ], and (ii) [ * ].

      In general, during the Term of this Agreement, Baxter will be responsible
for (a) expeditiously conducting all development studies identified as a Baxter
Deliverable in the Development Plan, (b) providing the reports described in
SECTION 11.2 of this Agreement, (c) manufacturing Product for Regulatory
Submissions and as otherwise provided in the Development Plan and pursuant to
the Regulatory Plan set forth as part of EXHIBITS B and C, respectively, (d)
preparing those portions of necessary Regulatory Submissions with Regulating
Groups consistent with Baxter's obligations under the Regulatory Plan, (e)
supporting Allos in its efforts to obtain and maintain Regulating Group approval
to sell the Product in the Territory, and (f) manufacturing Product for
commercial supply in accordance with the procedures specified in ARTICLE 4
below.

            2.1.2   DELIVERABLES. Baxter will promptly disclose to Allos during
the Term of this Agreement, in English and in writing, all Baxter materials set
forth in EXHIBIT D which include such interim progress reports and test results
agreed upon by the Parties. Allos will promptly disclose to Baxter during the
Term of this Agreement, in English and in writing, all Allos materials set forth
in EXHIBIT D. Baxter represents that the Deliverables reflect Baxter's best
estimate of what is required to obtain and maintain approval to sell the Product
in the Territory, based upon Baxter's experience and the regulations in effect
on the Effective Date, but Baxter cannot guarantee that the Deliverables will be
sufficient to fulfill the requirements of the Regulating Groups.

            2.1.3   ADDITIONAL DELIVERABLES. If the Deliverables set forth in
EXHIBIT D prove to contain insufficient Information for a Party to carry out its
responsibilities under this Agreement to obtain and maintain Regulating Group
approval and registration of the Product in the Territory in accordance with
ARTICLE 3, including information required for Allos to complete the FDA's Annual
Report and similar reports required by other Regulating Groups in the Territory,
or to obtain patent protection in accordance with ARTICLE 11.0, the Parties
will, subject to SECTION 2.1.5.2, amend EXHIBIT D to include as a Deliverable
the additional Information which is necessary for such purpose upon a Party's
reasonable request for such additional Information.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF
1934, AS AMENDED.

                                        6
<Page>

            2.1.4   PROCESS FINALIZATION AND SCALE-UP. Baxter shall conduct all
work necessary for finalization of the manufacturing process for the Product,
including all documentation specified in the Development Plan. The required
documentation includes all Supportive Documents required for stability and
consistency batches, process scale-up and validation (including but not limited
to validating cleaning, sampling and analytical methods, sterilization),
stability and consistency studies necessary to obtain regulatory approval.
Baxter shall also conduct such further work as may be needed to satisfy any
pre-approval inspection or other inspections by Regulating Groups and to
finalize any amendments or supplements to any prior Regulatory Submission. All
validation and other protocols, and all final reports, shall be reviewed and
approved by the Team Leaders for each Party. Baxter and Allos shall share
equally the costs of replicating any tests that are unsatisfactory to the
Regulating Groups, except that: (1) Baxter shall bear the costs of replicating
any tests, studies or other activities that were not performed in accordance
with protocols approved by the Team Leaders; (2) tests that must be repeated due
to deficiencies that result from the written rejection by Allos of Baxter's
recommendation shall be handled as provided in SECTION 2.1.3; and (3) Baxter
shall bear the costs of conducting any tests, studies or other activities that
Allos had recommended Baxter perform and a Regulatory Agency subsequently
requires that such tests, studies or other activities must be performed in
connection with the Regulatory Approval of the Product.

            2.1.5   DEVELOPMENT FEES; PAYMENT.

                    2.1.5.1     GENERAL. Fees payable by Allos to Baxter for the
activities set forth in EXHIBIT D that are to be performed by Baxter under this
Agreement, are described in EXHIBIT D, together with payment milestones
("Development Fees"). No payment required under EXHIBIT D is due and payable
until the Allos Team Leader confirms that the applicable milestone event has
been achieved. Any dispute regarding whether an applicable milestone event has
been achieved shall be subject to resolution pursuant to ARTICLE 15.0.

                    2.1.5.2     ADDITIONAL WORK. The activities described in the
Exhibits are the basis for determination of the Development Fees. Baxter will
not be required to perform, nor be entitled to reimbursement for, any work
beyond that described in the Exhibits unless and until the Parties reach written
agreement (coordinated through the Steering Committee under SECTION 1.3) on the
scope of any additional work and the related additional expenses.
Notwithstanding the foregoing, if any tests, studies or other activities beyond
those encompassed by the Exhibits are requested by the Steering Committee
pursuant to SECTION 1.3 which are required for obtaining or maintaining
approvals or registrations of the Product in the Territory, then such tests,
studies or other activities will be conducted as determined by the Steering
Committee, at Allos's expense. To the extent Baxter assists Allos in conducting
such additional tests, studies or other activities, Allos will pay Baxter a fee
to be negotiated in good faith between the Parties. By way of example,
additional development work might be required in response to Regulating Group
requests during review of Regulatory Submissions (such as laboratory work or
environmental assessment), additional tests to demonstrate compliance with other
compendia, or country specific import testing requirements. However, any
Deliverables, tests, studies or other activities that must be repeated due to
Baxter's negligence or that were omitted from the Exhibits due to Baxter's
negligence will be performed at Baxter's expense; any disagreement regarding
whether Baxter was negligent shall be referred to the Steering Committee and, if
the Steering Committee is unable to resolve the disagreement, shall be handled
as provided in SECTION 15.0.

                    2.1.5.3.    CHANGES TO MANUFACTURING PROCESS. Baxter will
follow its established procedures for changes (if any) which are made to its
manufacturing process and which relate to the manufacture of the Product. Any
such changes in the manufacturing process initiated by Baxter will be done at
Baxter's expense. Such established procedures shall be disclosed to Allos in
advance, subject to SECTION 12 of the Agreement. The review of changes must
follow the change control process outlined in section 12 of the Quality
Agreement.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF
1934, AS AMENDED.

                                        7
<Page>

                    2.1.5.4     PAYMENT. Development Fees and authorized
additional Development Fees will be paid by Allos in United States dollars
within [ * ] of invoicing by Baxter following completion of the designated
activities. Invoices for amounts that are not subject to good faith dispute and
not timely paid will be subject to a late payment charge of [ * ], or the
highest rate allowed by law if lower, until paid in full.

      2.2   REGULATORY PLAN. EXHIBIT C sets forth a Regulatory Plan for
obtaining Regulatory Approval of the Product. [ * ] Collaboration and approvals
will be coordinated through the Steering Committee as provided in SECTION 1.3.
Allos will be solely responsible for the reporting to Regulatory Groups adverse
experiences with respect to the Product.

      2.3   PRODUCT.

            2.3.1   PRODUCT SPECIFICATIONS. EXHIBIT A includes Product
Specifications in provisional form as of the Effective Date and will be refined
and agreed upon by the Parties prior to launch of the Product as part of the
Development Program. Allos will be responsible for and provide final approval of
Formulation Specifications, and all changes thereto, and will approve [ * ].
Baxter must obtain Allos's prior written approval of any changes to the Product
Specifications, as provided in the Quality Agreement ("CHANGES TO PRODUCT
SPECIFICATIONS"). Allos's approval of Formulation Specifications and [ * ] will
be deemed to constitute approval of Product Specifications by Allos for
regulatory purposes. Collaboration and approvals will be coordinated through the
Steering Committee as provided in SECTION 1.3.

            2.3.2   LABEL COPY. Subject to the Quality Agreement ("PRODUCT
LABELS AND LABELING"), all label copy and changes therein, on the Product label
itself and other label copy that Allos uses to market Product in the Territory,
will be the responsibility of Allos, except that Baxter will be responsible for
that portion of the Product label and other label copy related to the
description, characteristics and/or use of the Container.

3.0   PRODUCT REGISTRATIONS

      3.1   PRODUCT REGISTRATION APPLICATION OWNERSHIP. Allos will be the sole
owner of any registration applications submitted to Regulating Groups for the
Product and [ * ]. Allos will have the primary responsibility for the
documentation and submission of the registration applications to Regulating
Groups for the Product in the Territory and for completing the FDA Annual Report
and similar reports required by other Regulating Groups for Product, with
support from Baxter in the carrying out of responsibilities by Baxter in
accordance with the terms of this Agreement. Communications to and from the FDA
and other Regulating Groups that involve the NDA or any other Regulatory
Submissions to Regulating Groups for the Product are subject to the provisions
of SECTION 3.4.

      3.2   PRODUCT REGISTRATION IN THE UNITED STATES.

            3.2.1   RIGHT OF REFERENCE CONTAINER DRUG MASTER FILE. During the
Term of this Agreement, Baxter grants Allos a right of reference to relevant
elements of the USCDMF filed with the FDA for the Container, including, but not
limited to, cGMP and safety data for the Container, for the purpose of
Regulatory Submissions and obtaining Regulatory Approval or other product
registrations for the Product in the Territory in the name of Allos, and to any
other extent provided in the Development Plan and Regulatory Plan. Baxter agrees
that no change described in the USCDMF, any amendments to the USCDMF, or any
supplemental USCDMF with respect to the Container, potentially having an impact
on the Product, shall be implemented on the Product without prior written
approval from Allos. Baxter shall otherwise fully cooperate with Allos in the
preparation of Regulatory Submissions relating to manufacturing operations
conducted by Baxter.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF
1934, AS AMENDED.

                                        8
<Page>

            3.2.2   ADDITIONAL FILING DATA. During the Term of this Agreement,
Baxter will, following prior written notice to Allos, provide the FDA and all
other Regulating Groups in the Territory, with Container-related data and
information which are required for Allos to obtain and maintain registration and
approval of the Product in good standing in the Territory. Baxter reserves the
right to inform the FDA and other Regulating Groups that such information is
confidential and to advise the FDA and such Regulating Groups that Allos will be
entitled to reference such information on a confidential basis during the Term
of this Agreement.

      3.3   PRODUCT REGISTRATION OUTSIDE THE UNITED STATES. Allos recognizes
that Baxter data and information required for the purpose of obtaining Product
registrations in the Territory outside the United States is highly confidential
and agrees that it is reasonable for Baxter to use appropriate and available
means to maintain the confidentiality of such information provided that
regulatory approvals of the Product are not hindered. In this regard, Baxter
will determine which of any jurisdictions in the Territory will accept a
separate application from Baxter similar to a USCDMF. In these jurisdictions,
Baxter, in its reasonable discretion and in consultation with Allos, may [ * ].
For purposes of this SECTION 3.3, Baxter may determine, in its reasonable
discretion and in consultation with Allos, what data and information are
required for Product registration; PROVIDED that in the event that a Regulating
Group requests additional data or information in order to approve Product
registration, Baxter will fully cooperate with Allos to meet such request. In
addition, Baxter and Allos will carry out all Territory-specific strategies
described in the Regulatory Plan for obtaining Regulatory Approval in such
Territories.

      3.4   COMMUNICATIONS TO/FROM REGULATING GROUPS. In the event of any
communication from or to the FDA, or any other Regulating Groups, in connection
with the manufacture of the Product (collectively "Communications"), the Party
first becoming aware of the same will promptly notify the other Party of such
Communications and, before taking action with Regulating Groups, the Parties
will discuss and use reasonable efforts to agree on (i) whether copies of such
Communications and/or other Information should be provided to each other as
additional Deliverables pursuant to SECTION 2.1.3; (ii) which Party should
respond to Communications received; and (iii) which individuals need to
collaborate on a response to Communications received. In the event that Baxter
and Allos are unable to agree on the foregoing items, then Allos's position will
prevail as it pertains to all Communications sent to Regulating Groups relating
to the API, Formulation, and the Product, except with respect to that portion of
the responses which relates solely to the Container and then Baxter's position
will prevail. All information relating to any Communication disclosed under this
SECTION 3.4 is subject to confidential treatment pursuant to the terms of
ARTICLE 12.

      3.5   USER FEES. Baxter will pay all user and/or filing fees charged by
Regulating Groups in the Territory which relate to separate Container
submissions (including DMF submissions) and the Drug Establishment Fee ("DEF")
charged by the FDA. In the event that a Regulating Group other than the FDA
requires payment of a manufacturing facility fee similar to the DEF charged by
the FDA, then Baxter and Allos will mutually agree on an appropriate allocation
of that fee between the Parties, provided that, if the fee is solely
attributable to manufacture of the Product, Allos will pay the entire fee. Allos
will pay all user and/or filing fees charged by Regulating Groups in the
Territory which relate to the registration application and ongoing marketing of
the Product, including, but not limited to, the Application Fee and the Drug
Product Fee charged by the FDA.

4.0   COMMERCIAL SUPPLY

      4.1   EXCLUSIVE SUPPLY AND PURCHASE OBLIGATIONS DURING TERM OF AGREEMENT.
[ * ] In addition, for the Term of the Agreement, Allos shall purchase [ * ] of
its annual commercial requirements up to Allos's total projected requirements
for each Contract Year (as specified in EXHIBIT E) for sale, distribution and
use in the Territory of ready-to-use aqueous solution containing the Compound in
an intravenous form [ * ] from Baxter, and Baxter will manufacture and sell
ready-to-use aqueous solution containing the Compound in an intravenous form [ *
] exclusively for/to Allos, for sale, distribution and use

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF
1934, AS AMENDED.

                                        9
<Page>

in the Territory. Baxter agrees to maintain adequate facilities with capacity to
satisfy such requirements based upon the forecasts provided by Allos. [ * ]
Except with respect to API, Baxter shall be responsible for establishing the
necessary procedures, vendors, inventory, capacity and management practices
needed to ensure its ability to meet Allos's requirements for Product, in
accordance with SECTION 4.4.1. Allos's obligations under this SECTION 4.1 will
be waived (and Allos may thereafter purchase Product units from another
supplier) to the extent that Baxter fails to satisfy Allos's Product
requirements or if the Steering Committee identifies circumstances that which
provide a reasonable basis for concluding that Baxter will likely not be able to
satisfy Allos's Product requirements and such failure is not due to Allos's
failure to meet its obligations under this Agreement. The Parties' obligations
under this SECTION 4.1 may be terminated [ * ], or modified [ * ], as provided
in SECTION 9.2.2 of this Agreement.

      4.2   MINIMUM PURCHASE OBLIGATION. During the first Contract Year (as
defined in SECTION 9.1.1), Allos shall purchase a minimum of [ * ] of the
Product and in each Contract Year thereafter [ * ] units of the Product, subject
to adjustment in accordance with EXHIBIT E if development of the Product [ * ]
is terminated as described in SECTION 9.2.2 below (the "Minimum Purchase
Requirement"). If Allos fails to purchase the Minimum Purchase Requirement in
any Contract Year, within thirty (30) days after the end of such Contract Year,
Allos shall pay Baxter an amount equal to the amount per unit set forth in
EXHIBIT E multiplied by the shortfall in units. In such event, Allos may, upon
written notice to Baxter, request that Baxter promptly ship to Allos all or any
portion of the units of Product making up the shortfall for which Allos has paid
Baxter. Allos shall not be obligated to pay any shortfall amount if Allos's
failure to meet the Minimum Purchase Requirement is due to Baxter's inability to
supply Allos with its requirements of Product conforming to the Product
Specifications in the applicable Contract Year and Baxter's inability to supply
such requirements is not due to Allos's failure to meet its obligations under
this Agreement.

      4.3   FORECASTS. In order to assist Baxter in its production planning of
Product for supply to Allos, Allos will provide to Baxter, at least [ * ] days
before the beginning of each calendar quarter commencing with the first
submission of an NDA (or the foreign equivalent of an NDA in any country of the
Territory other than the United States) to a Regulating Group in the Territory
by Allos for the Product and continuing thereafter during the Term of this
Agreement, a statement of Allos's estimated purchase requirements ("Estimated
Requirements") and expected delivery dates for Product for such calendar quarter
and the next succeeding [ * ]. It is understood that such Estimated Requirements
will NOT constitute commitments to purchase Product or firm purchase orders.

      4.4   FIRM PURCHASE ORDERS.

            4.4.1   GENERAL. Allos will place firm purchase orders for Product
at least [ * ] days prior to the beginning of each calendar quarter. [ * ] Firm
purchase orders for Product [ * ] will be placed in increments of no less than
the minimum number of units specified in EXHIBIT E, or such other number of
units as then corresponds to the filling production lot sizes for Product [ * ].
Subject to the provisions of SECTION 4.4.2, firm purchase orders for Product [ *
] will be not less than [ * ] nor more than [ * ] of Allos's Estimated
Requirements of Product [ * ] for what was the [ * ] in the most recent prior
forecast. Notwithstanding the foregoing, Baxter will use reasonable efforts to
comply with any of Allos's unplanned changes in firm purchase orders, but will
not be held liable for its inability to do so. Subject to this Section, SECTIONS
6.3, 13.2 and 16.6, Baxter will meet Allos's requested delivery dates. Both
Parties agree to work together to reduce lead time for orders and deliveries.
Firm purchase orders will be made on such form of documentation as Baxter and
Allos agree from time to time, provided that the terms and conditions of this
Agreement will be controlling over any terms and conditions included in any
purchase order form used in ordering Product. Any term or condition of such
purchase order form that is in addition to, different from or contrary to the
terms and conditions of this Agreement will be void, unless the Parties
otherwise agree by a separate written agreement. The parties will work together
as directed by the Steering Committee to expedite the manufacture of First of
Code production and the delivery of Allos' initial Product order as soon as
possible after Regulatory approval.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF
1934, AS AMENDED.

                                       10
<Page>

            4.4.2   CANCELLATION OF PURCHASE ORDERS AND RESCHEDULING. Allos may
cancel a firm Product purchase order or reschedule requested delivery dates to a
later date by giving Baxter prior written notice to such effect. Baxter will use
reasonable efforts to comply with Allos's requests. If, however, either (i) a
cancellation of a firm purchase order or (ii) a rescheduling of delivery dates
for a firm purchase order that would cause a rescheduling by Baxter of the
Product manufacturing date, is requested by Allos thirty (30) days or less prior
to Baxter's scheduled production date for the firm purchase order, Baxter shall
so notify Allos. If after such notice, Allos still desires such cancellation or
rescheduling of delivery dates, Allos will pay Baxter a cancellation fee or
rescheduling fee equal to [ * ] of the Manufacturing Fee for that portion of
such firm Product purchase order that has been cancelled or rescheduled. Partial
cancellations must be in increments of the minimum lot size specified in EXHIBIT
E.

      4.5   DELIVERY; SHIPMENT. All Product supplied under this Agreement will
be delivered Free Carrier ("FCA" under Incoterms 2000) Baxter's manufacture site
specified in the Quality Agreement, except that Product manufactured at Baxter's
Cleveland, Mississippi site shall be delivered FCA Memphis. Baxter will make
shipping arrangements with the appropriate carriers designated in writing by
Allos from the FCA point, under the agreements that Allos has with those
carriers. Title and risk of loss passes to Allos when the Product has been
quality control released for shipment to Allos or its designee in accordance
with Product Specifications and transferred to the carrier designated by Allos,
[ * ], unless acceptance of the Baxter release is disputed in good faith by
Allos. Accordingly, Allos will be deemed the exporter of record for Product
shipped outside of the United States (which should only occur to the extent such
areas are included in the definition of "Territory"). Allos warrants that all
shipments of Product outside the United States will be in compliance with all
applicable United States export laws and regulations, including the Export
Administration Act, and all applicable import laws and regulations.

5.0   MANUFACTURING FEE AND PRODUCT MAINTENANCE FEE

      5.1   MANUFACTURING FEE. For each unit of Product requested by Allos
pursuant to a Product purchase order as set forth in SECTION 4.4.1 above, Baxter
will invoice Allos a Manufacturing Fee per unit of Product in the amount set
forth in EXHIBIT E, upon release to finished goods inventory of Product that has
been quality control released for shipment to Allos or its designee in
accordance with the Product Specifications set forth in EXHIBIT A. Baxter will
release Products to finished goods inventory not more than [ * ] days prior to
the scheduled delivery date for such Products.

      5.2   PRODUCT MAINTENANCE FEE. Baxter will invoice Allos a Product
Maintenance Fee in the amount set forth in EXHIBIT E on a calendar quarterly
basis. The Product Maintenance Fee is compensation to Baxter for expenses Baxter
incurs by having manufacturing capacity allocated to producing the Product,
including but not limited to documentation and quality control, ongoing
inventory management, regulatory support, including NDA reporting requirements,
minor label changes requested by Allos, and annual stability studies.

      5.3   ADJUSTMENTS. Baxter may, following not less than ninety (90) days
prior written notice to Allos, adjust the Manufacturing Fee and the Product
Maintenance Fee on each annual anniversary of a Contract Year beginning with the
first day of the third (3rd) Contract Year, by an amount which does not [ * ]. [
* ].

      5.4.  ADDITIONAL WORK AND FEES. The Manufacturing Fee and Product
Maintenance Fees described in SECTIONS 5.1 and 5.2. are based upon the scope of
activities that Baxter plans to undertake in the ordinary course to manufacture
and release Product in accordance with the Product Specifications and other
Exhibits, as well as the Quality Agreement. The Manufacturing Fee and Product
Maintenance Fees do not cover activities or expenses related to matters that
might arise outside the ordinary course of

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF
1934, AS AMENDED.

                                       11
<Page>

manufacturing and releasing Product in accordance with the Product
Specifications, the Development Plan (EXHIBIT B) and other Exhibits, as well as
the Quality Agreement. By way of example, additional work might be required for
Product or process changes requested by the FDA or other Regulating Groups, API
source changes or Manufacturing Process changes, USP or other regulatory
requirements changes, excessive or untimely requests by Allos for label changes
or recalls or other actions by Regulating Groups, or mutually agreed upon
expansion of the Territory. Baxter will not be required to perform, nor be
entitled to reimbursement for, any such work until the Parties, coordinated
through the Steering Committee under SECTIONS 1.3 and 2.1.5.2, reach written
agreement on the scope of the additional work and the related additional
expenses; PROVIDED that Baxter shall bear the costs of replicating any tests,
studies or other activities that were not performed by Baxter in accordance with
protocols approved by the Team Leaders or that must be repeated due to Baxter's
negligence.

      5.5   PAYMENT; LATE PAYMENT CHARGES. Allos will pay the Manufacturing Fee,
Product Maintenance Fee, and expenses for additional work under SECTION 5.4, in
United States dollars within [ * ] after the date of receipt by Allos of
Baxter's invoice, by wire transfer in United States dollars, to a bank account
designated in writing by Baxter. Invoices for amounts that are not subject to
good faith dispute and not timely paid will be subject to a late payment charge
of [ * ], or the highest amount permitted by law, if lower.

6.0   API

      6.1   GENERAL. Allos will, at its cost, supply API to Baxter at Baxter's
manufacturing facilities designated in the Development Plan or the Quality
Agreement, as applicable. API will be supplied timely, in adequate quantities to
enable Baxter to meet its obligations to develop and manufacture Product in
accordance with the terms of this Agreement, all in conformance with the API
Specifications. Baxter and Allos will agree on appropriate inventory levels for
API and Product and Baxter will manage these inventory levels; provided that
Baxter will reserve inventory space for at least two (2) calendar quarters of
Allos's forecasted API requirements (based on the API required to fill the
average quarterly Product purchase requirements stated in Allos' then most
current Product forecast pursuant to SECTION 4.3) to ensure flexibility in order
fulfillment and delivery. Each Party will promptly notify the other Party
following receipt of any information that might impact Allos's ability to supply
API. Allos will retain title to API while it is in Baxter's possession. Baxter
will not use API supplied by Allos for any purposes other than to manufacture
Product pursuant to the terms of this Agreement or as otherwise expressly
permitted under the Quality Agreement or by Allos in writing. Baxter will
provide to Allos the results and all data generated in the course of any
authorized studies or tests performed by Baxter using API.

      6.2   API REPLACEMENT. In the event of non-acceptance by Baxter of any
delivery of API due to its failure upon inspection or testing by Baxter to meet
Allos's warranties set forth in SECTION 13.2.1.1, Allos's sole obligation and
Baxter's exclusive remedy will be [ * ], provided that if the failure of API to
meet Allos's warranties is not discoverable upon reasonable physical inspection
and testing but is identified by Baxter after development or manufacturing
activities utilizing API have commenced (and such defects are not caused by
Baxter), then Allos's obligation will [ * ] under SECTION 2.1.5 attributable to
the development activities that Baxter must repeat with non-defective API or the
Manufacturing Fee per unit of Product required to be replaced using
non-defective API, as applicable. Following notice from Baxter and at the
direction of Allos, Baxter will return the then remaining defective API to Allos
or, at Baxter's option if requested by Allos, destroy the same or deliver it to
a third party qualified in such waste disposal. With respect to defective
Product and work-in-process that incorporates defective API, Baxter will, at its
option, destroy the same or deliver it to a third party qualified in such waste
disposal. Allos will bear the cost of any return of API, including freight and
handling, and the costs of destroying any defective API, Product and/or
work-in-process. Allos will, at its expense, replace defective API as
expeditiously as possible and pay Baxter for Product and work-in-process
incorporating defective API to the extent required under this SECTION 6.2 within
thirty (30) days of receipt of Baxter's detailed invoice.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF
1934, AS AMENDED.

                                       12
<Page>

      6.3   CHANGE OF API SOURCE OR MANUFACTURING PROCESS. Allos will neither
change its API source nor any Manufacturing Process that has a material impact
on Baxter's manufacture of finished Product unless and until (i) such change is
approved by the FDA and all other Regulating Groups in the Territory for the
Product and (ii) Allos provides written notice to Baxter of the proposed change
at least forty five (45) days in advance of such change. Pursuant to SECTION
5.4, Allos will reimburse Baxter for all reasonable costs incurred by Baxter
directly related to Baxter work performed in support of such API source or
Manufacturing Process change relating to the Product, including but not limited
to the cost of new stability studies, submissions to the FDA and any other
Regulating Groups and return of unused (if any) API from the prior source or
manufactured under prior Manufacturing Processes. Allos will pay Baxter in
accordance with SECTION 5.5. "Manufacturing Processes" is defined as a process
used in the manufacture of API of such a type that a change in such process
would require approval by the FDA or other Regulating Groups in the Territory in
order to market, sell and distribute the Product in the Territory.

      6.4   RISK OF LOSS OF API. Subject to SECTION 13.2.1, Baxter will have the
risk of loss or damage to API from [ * ]. In the event of loss or damage to the
API during such period, Baxter will immediately notify Allos and Allos will
provide to Baxter any API required for replacement thereof at [ * ]. Allos will
provide to Baxter appropriate documentation evidencing such costs.
Notwithstanding the foregoing, Baxter will pay no more for the additional API
than [ * ] for the API, plus duty, freight, rush surcharges and testing costs,
adjusted to account for cumulative CPI-U Change between the Effective Date and
the date of loss. For purposes of this SECTION 6.4, the amount due for loss or
damage to API shall not apply to [ * ].

      6.5   MANUFACTURING YIELD LOSSES. On an annual basis the Parties shall
calculate, for all batches of Product manufactured hereunder during the previous
year, the average yield of Product units as a percentage of the theoretical
yield of Product units based upon the amount of API incorporated in such
batches. If the average yield of Product units for the year is less than the
applicable percentage set forth in EXHIBIT E, Allos will [ * ].

7.0   QUALITY MANAGEMENT AND ONGOING QUALITY RESPONSIBILITIES.

      7.1   QUALITY AGREEMENT. The responsibilities of the Parties relating to
quality management are set forth in the Quality Agreement.

      7.2   COMPLIANCE WITH LAW; INTERFACE WITH REGULATING GROUPS.

            7.2.1   GENERAL. While the API, Formulation, and Product are in its
possession or under its control, a Party will be responsible for complying with
all applicable statutory and regulatory requirements of all applicable
Regulating Groups in the Territory regarding the API, Formulation, and Product.
These statutory and regulatory requirements include, but are not limited to, the
considerations set forth in SECTIONS 7.2.2 and 7.2.3, and the Quality Agreement.

            7.2.2   ENVIRONMENTAL; HEALTH AND SAFETY. In carrying out its
obligations under this Agreement, Baxter will comply with all applicable
environmental and health and safety laws of the United States and in the
Territory and, except as otherwise set forth in this Agreement, Baxter will be
solely responsible, in its reasonable discretion, for determining how to carry
out these obligations based upon its experience in product manufacturing. In
addition to the foregoing, at all times when Baxter has possession of the API,
work-in-process, or Product, Baxter will take all reasonable actions necessary
to avoid spills and other safety concerns to persons and damage to property or
the environment resulting from the API, Formulation, and Product or any
intermediates or raw materials thereof.

            7.2.3   OTHER ADVERSE INFORMATION. Each Party will promptly notify
the other Party following receipt of any relevant information, including but not
limited to information regarding any threatened or pending action by Regulating
Groups, that would reasonably be determined to adversely

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF
1934, AS AMENDED.

                                       13
<Page>

affect the activity under the Development Program or the production or sale of
the Product hereunder. In addition, Baxter shall promptly notify Allos of any
complaints or adverse experiences of which it becomes aware relating to any
Baxter container material used in the Container but that occur in products other
than the Product, that would reasonably be determined to adversely affect the
activity under the Development Program or the production or sale of the Product
hereunder. In the event Baxter reports to Allos any complaints or adverse
experiences relating solely to the Container, the Parties shall cooperate to
determine if such events are likely to impact the Product. Promptly upon receipt
of such notice, the Parties will consult with each other in an effort to arrive
at a mutually acceptable procedure for taking appropriate action; PROVIDED,
HOWEVER, that (a) nothing contained herein will be construed as restricting the
right of either Party to make a timely report of such matter to any Regulating
Groups or take other action that it deems to be appropriate or required by
applicable law or regulation and (b) all information disclosed under this
SECTION 7.2.3 is subject to confidential treatment pursuant to the terms of
ARTICLE 12 .

8.0   SALES SUPPORT AND USE OF TRADEMARKS

Baxter salespeople will not promote, detail or give any advice or information
regarding the Compound or its therapeutic qualities, but may advise potential
customers of the availability of the Product and may promote the Container
premix, ready-to-use delivery system aspects of the Product. Baxter will support
the promotional efforts of Allos by cooperating in the development of the
Container-related aspects of promotional materials and programs. Allos shall
make no use of any Baxter trademark, name or logo without the prior written
approval of Baxter, except as otherwise permitted under the terms of this
Agreement with respect to Product labeling and promotional materials. Baxter
shall make no use of any Allos trademark, name or logo without the prior written
approval of Allos, except as otherwise permitted under the terms of this
Agreement with respect to Product labeling and promotional materials.

9.0   TERM AND TERMINATION

      9.1   TERM AND EXPIRATION.

            9.1.1   INITIAL TERM. This Agreement will become effective as of the
Effective Date and will terminate at the end of the [ * ] Contract Year
("Initial Term"), unless earlier terminated pursuant to the provisions of
SECTION 9.2 ("Term of the Agreement.") "Contract Year" is defined as (i) the
twelve (12) month period beginning on the first day of the month in which
Regulatory Approval of the Product in the U.S. is received by Allos and (ii)
each successive twelve (12) month period. [ * ]

            9.1.2   AUTOMATIC RENEWAL. Upon expiration of the Initial Term, this
Agreement will automatically renew thereafter for consecutive [ * ] terms on the
anniversary of the Contract Year unless either Party, by not less than [ * ]
prior written notice to the other Party, signifies by such notice its intention
to terminate this Agreement effective upon the expiration of the applicable
Contract Year.

      9.2   EARLY TERMINATION

            9.2.1   TERMINATION BY EITHER PARTY. Either Party may terminate this
Agreement as follows:

                    9.2.1.1     effective immediately upon the giving of written
notice, if approval of the Product's NDA is not received within forty-eight (48)
months from the date of this Agreement;

                    9.2.1.2     effective sixty (60) days after written notice
given by the non-breaching Party of a material breach of this Agreement by the
other Party, if such breach is not cured within sixty (60) days of receipt of
the notice containing details of such breach; or

                    9.2.1.3     effective immediately upon written notice given
by the non-

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF
1934, AS AMENDED.

                                       14
<Page>

bankrupt Party, if the other Party files a petition in bankruptcy, or is
adjudicated bankrupt, makes an assignment for the benefit of creditors, is
voluntarily or involuntarily dissolved, or has a receiver, trustee or other
court officer appointed for its property.

            9.2.2   PARTIAL TERMINATION. In the event that development of [ * ],
either Party may terminate this Agreement as it relates to development of the
Product [ * ] effective [ * ] days after written notice of an intent to
terminate under this provision[ * ]. [ * ] In the event either (i) development
of [ * ] but neither Party terminates this Agreement or (ii) development of [ *
], the Parties will negotiate in good faith appropriate amendments to this
Agreement, including without limitation, amendments to the Development Plan
and/or the Regulatory Plan, to attempt to develop a technically feasible
product. The termination of this Agreement as it relates to the Product [ * ]
shall not terminate this Agreement as it relates to the Product [ * ], PROVIDED,
HOWEVER, that the Parties' obligations shall thereafter be [ * ], and the
Minimum Purchase Requirement shall be adjusted as provided in EXHIBIT E.

10.0  EFFECTS OF TERMINATION

      10.1  PAYMENTS. Termination will not relieve or release either Party from
making any payments which may be due and owing prior to the effective date of
termination under the terms of this Agreement.

      10.2  TECHNOLOGY TRANSFER. At the expiration of the Term of the Agreement,
or in the event of early termination under SECTION 9.2.1.2 due to a material
breach by Baxter or SECTION 9.2.2, at Allos's written request, Baxter shall
provide reasonable assistance in technology transfer of the manufacturing
process [ * ] to another manufacturing site as directed by Allos. For the
avoidance of doubt, Baxter's obligation to assist in technology transfer of the
manufacturing process for [ * ], pursuant to this Section 10.2, is limited to
providing documents relating solely to the Formulation and [ * ] The reasonable
costs for such technology transfer shall be reimbursed by Allos if the transfer
results from expiration of the Agreement or partial termination of the Agreement
under SECTION 9.2.2, and the costs of the transfer shall be born by Baxter if
the transfer results from a material breach by Baxter.

      10.3  DISPOSAL OF API OR PRODUCT. Upon termination of this Agreement,
Baxter will promptly return all then remaining API to Allos, or if requested by
Allos and at Baxter's option, destroy such API or deliver it for destruction to
a third party qualified in such waste disposal. Return or destruction of API
will be at Allos's expense if (i) this Agreement terminates at the expiration of
its Term; (ii) termination of the Agreement arises under SECTION 9.2.1.1
(failure of Product NDA to timely issue); or (iii) termination of the Agreement
is initiated by Baxter pursuant to SECTIONS 9.2.1.2 due to an act or omission of
Allos or event affecting Allos under SECTION 9.2.1.3. Return or destruction of
API will be at Baxter's expense if termination is initiated by Allos pursuant to
SECTIONS 9.2.1.2 due to an act or omission of Baxter or an event affecting
Baxter under SECTION 9.2.1.3. If upon termination of the Agreement the Parties
are unable to negotiate a mutually acceptable approach to disposition of Product
and work-in-process, subject to SECTION 10.4 below, Baxter shall promptly
destroy such remaining Product and work-in-process. The expense of such
disposition will be borne by the Parties under the same circumstances as
provided above with respect to responsibility for the expense of disposition of
API. If Allos is responsible for the expense of disposition of API, Product, or
work-in process, Allos shall pay Baxter all amounts due Baxter under this
Section within thirty (30) days after the date of Baxter's detailed invoice
following completion of the designated return or destruction.

      10.4  DELIVERY OF CERTAIN ITEMS. Upon termination of this Agreement,
Baxter will promptly deliver to Allos all Deliverables that have been completed
or that are in process as of the date of such termination, subject to Allos'
payment of the applicable Development Fee for any such completed Deliverable or
a pro-rated Development Fee for any partially-completed Deliverable as mutually
agreed upon by the Parties. The Parties agree that any firm purchase orders that
have been issued pursuant to

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF
1934, AS AMENDED.

                                       15
<Page>

SECTION 4.4 prior to the effective date of termination will continue to be
binding on the Parties and subject to all applicable terms and conditions of
this Agreement after termination.

      10.5  SURVIVAL. Expiration or termination of the Agreement will not
relieve the Parties of any obligation accruing prior to such expiration or
termination, and the provisions of SECTIONS 3.1 (Product Registration
Application Ownership), 13.2 (Allos Warranty), and 13.3 (Baxter Warranties), and
ARTICLES 10 (Effects of Termination), 11 (Intellectual Property), 12
(Confidentiality), 14 (Indemnification), and 16 (Miscellaneous) will survive the
expiration or termination of the Agreement. Any expiration or termination of
this Agreement will be without prejudice to the rights of either Party against
the other accrued or accruing under this Agreement prior to expiration or
termination.

11.0  INTELLECTUAL PROPERTY

      11.1  OWNERSHIP OF INVENTIONS.

            11.1.1. OWNERSHIP OF BACKGROUND INTELLECTUAL PROPERTY RIGHTS.
Ownership of Background Intellectual Property Rights will remain in the Party
owning them on the Effective Date.

            11.1.2  ALLOS INVENTIONS. The entire right, title and interest in
all discoveries, inventions and improvements which are conceived or reduced to
practice during the course of the work being performed pursuant to this
Agreement solely by Allos or its employees, independent contractors, agents or
other representatives (the "Allos Inventions") will be owned solely by Allos.

            11.1.3  BAXTER INVENTIONS. The entire right, title and interest in
all discoveries, inventions and improvements which are conceived or reduced to
practice during the course of work being performed pursuant to this Agreement
solely by Baxter or its employees, independent contractors, agents or other
representatives (the "Baxter Inventions") will be owned solely by Baxter,
subject to SECTIONS 11.2.2 and 11.3, except as provided in this SECTION 11.1.3.
[ * ]

            11.1.4  JOINT OWNERSHIP. Subject to SECTIONS 11.1.2 and 11.1.3, the
entire right, title and interest in all discoveries, inventions and improvements
which are conceived or reduced to practice during the course of the work being
performed pursuant to this Agreement by (i) Allos or its employees, agents or
other representatives and (ii) Baxter or its employees, agents or other
representatives (the "Joint Inventions") will be jointly owned by Allos and
Baxter, each of which will own an undivided one-half (1/2) interest in such
invention where such employees, agents or other representatives are considered
"joint inventors" under United States patent laws. Each Party will cooperate
with the other in completing any patent applications relating to Joint
Inventions.

      11.2  REPORTS: INFORMATION DEVELOPED DURING PROJECT.

            11.2.1  CONTENT OF REPORTS. Baxter will provide to Allos reports
containing the data, test results, and specifications or procedures for the
Product developed specifically for the Compound and/or the Formulation
("API/Formulation Specifications"), all as described in detail under the heading
"Reports" in the Deliverables set forth in EXHIBIT D. The Reports may also
contain references to (i) pre-existing Baxter standard operating procedures,
specifications, material codes and their specifications, and other information
developed by Baxter prior to the execution of this Agreement ("Pre-Existing
Specifications") that fall within Baxter's Background Intellectual Property
Rights and (ii) original laboratory notebooks and other Good Laboratory
Practices documentation generated by Baxter or its agents pursuant to this
Agreement ("Original Product Data.")

            11.2.2  OWNERSHIP OF REPORTS AND CONTENTS. The Reports, and the
data, test results, and API/Formulation Specifications therein, will become the
property of Allos and will be treated as Allos's Confidential Information and be
subject to the provisions of ARTICLE 12 of this Agreement. Pre-

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF
1934, AS AMENDED.

                                       16
<Page>

Existing Specifications, Baxter Background Intellectual Property Rights, as well
as Original Product Data, will remain the property of Baxter and will constitute
Baxter's Confidential Information and be subject to the provisions of ARTICLE 12
of this Agreement, subject further to SECTION 11.3.

            11.2.3  ARCHIVAL COPY OF REPORTS. Baxter may retain a copy of the
Reports for archival purposes.

      11.3  LICENSES.

            11.3.1  TO BAXTER FROM ALLOS. [ * ] During the Term of this
Agreement, Allos grants to Baxter a worldwide, nonexclusive, royalty free
license, without a right to sublicense, within the Territory, to make, use,
sell, offer for sale, and import the Product [ * ] under Allos's Background
Intellectual Property Rights and Allos Inventions, in accordance with and only
to the extent necessary for Baxter to fulfill Baxter's obligations under this
Agreement. Allos grants to Baxter a perpetual worldwide, nonexclusive, royalty
free license, with a right to sublicense, under the Formulation Inventions,
provided Baxter does not use such license to develop, commercialize or
manufacture the Compound or any other allosteric modifier of hemoglobin on its
own behalf or on behalf of any third party.

            11.3.2  TO ALLOS FROM BAXTER. During the Term of this Agreement,
Baxter grants to Allos a, nonexclusive, royalty free license, without a right to
sublicense, within the Territory, to make, use, sell, offer for sale, and import
the Product in a Container under Baxter's Background Intellectual Property
Rights and Baxter's Inventions, in accordance with and only to the extent
necessary for Allos to fulfill Allos's obligations under this Agreement. For the
avoidance of doubt, the license granted to Allos under this Section includes any
such license rights necessary for Allos's customers, distributors, resellers,
and collaboration partners to promote, use, sell, distribute and re-sell
Products manufactured by Baxter for Allos under this Agreement. Baxter will (i)
make Pre-Existing Specifications referenced in the Reports and Original Product
Data available to Regulating Groups as required by such Regulating Groups and as
provided in ARTICLE 3, and (ii) upon Allos's reasonable request, provide copies
of Pre-Existing Specifications referenced in the Reports and relevant portions
of Original Product Data (but excluding data or information which is unrelated
to the Product) to Allos for Allos's retention and use in Regulatory Submissions
outside the United States if, pursuant to ARTICLE 3, such information is
reasonably required for Allos's Regulatory Submission for the Product in the
Territory, provided that Allos will treat all such information as Baxter's
Confidential Information under the provisions of ARTICLE 12.

      11.4  PATENTS.

            11.4.1  PATENT FILINGS ON SOLELY-OWNED INVENTIONS. Each Party will,
in its sole discretion, prepare, file, prosecute and maintain Patent
Applications for inventions as to which it has sole ownership under SECTIONS
11.1.2 and 11.1.3 above and will be responsible for related interference
proceedings. Each Party will endeavor to ensure that such Patent Applications
are filed before any public disclosure by either Party in order to maintain the
validity of Patent Applications filed outside of the United States. Each Party
shall provide the other Party with a copy of any Patent Application that
discloses any Information of the other Party at least sixty (60) days prior to
its filing in any patent agency in the Territory in order to give such Party an
opportunity to object to remove references to such Party's Confidential
Information. Each Party will bear all costs under this Section for inventions as
to which it has sole ownership. Baxter will cooperate with Allos's perfection of
filings relating to API/Formulation Specifications.

            11.4.2  JOINT INVENTIONS AND PATENT FILINGS. With respect to all
Patent Applications on Joint Inventions ("Joint Patent Applications"), Baxter
will prepare and file Patent Applications specifically directed to the Field on
behalf of both Parties and will diligently prosecute same. At least thirty (30)
days prior to the contemplated filing, Baxter will submit a substantially
completed draft of all such Joint Patent Applications to Allos for its approval,
which will not be unreasonably withheld. The Parties

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF
1934, AS AMENDED.

                                       17
<Page>

will share equally the costs of the preparation, filing, prosecution and
maintenance of any Joint Patent Applications and will share equally the costs of
any related interference proceedings. Baxter will confer with Allos and make
reasonable efforts to adopt Allos's suggestions regarding the prosecution of
such Patent Applications and will copy Allos with any official actions and
submissions in such Patent Applications. If either Party elects not to pay its
portion of any shared costs for a Joint Patent Application, the other Party may
proceed with such Joint Patent Application in its own name and at its sole
expense, in which case the Party electing not to pay its share of costs will
assign its entire right, title and interest in and to such Joint Patent
Application to the other Party.

            11.4.3  PUBLIC DISCLOSURE. Each Party agrees to delay any public
disclosure of the subject matter of any Patent Application until after filing of
such Patent Application, but in no event less than one hundred eighty (180) days
after notice to the other Party of the intent to disclose such subject matter.

12.0  CONFIDENTIALITY

      12.1  PRE-EXISTING CONFIDENTIALITY AGREEMENT. The Parties have previously
signed a two-way disclosure agreement ("Confidential Disclosure Agreement"), a
copy of which is attached to this Agreement as EXHIBIT F to cover the exchange
of confidential information and materials relating to the Compound, Formulation,
API, and the development of the Product. The Parties agree that all information
exchanged under that agreement prior to the Effective Date will continue to be
covered by terms of the that agreement. The provisions of this ARTICLE 12
supersede those with regard to information exchanged between the Parties on or
after Effective Date.

      12.2  CONFIDENTIALITY. All Information or other information furnished by
one Party to the other Party pursuant to this Agreement, either in writing or
other tangible form, marked "Confidential" or, if disclosed orally or visually,
reduced to writing and labeled "Confidential" by the disclosing Party and sent
to the receiving Party within thirty (30) days of the initial disclosure thereof
will be deemed to be the disclosing Party's "Confidential Information". The fact
that Baxter is [ * ] shall also be deemed to be Baxter Confidential Information.
Information which is not disclosed in the manner required by this Section will
be conclusively presumed not to be Confidential Information under this
Agreement. Except as otherwise permitted by this Agreement, the receiving Party
will keep the disclosing Party's Confidential Information confidential, will not
disclose, or otherwise make available the same to any person, firm, corporation
or other entity, will not use the same for any purpose other than specifically
authorized by this Agreement, and will in all respects treat such Confidential
Information at least as carefully as it treats its own confidential and
proprietary information but in no event using less than commercially reasonable
efforts to protect such Confidential Information against unauthorized disclosure
or use. Allos and Baxter each may disclose the other's Confidential Information
to those of its officers, employees, Affiliates and consultants (other than
competitors of the disclosing Party), whose review is necessary for the purposes
of this Agreement and who have undertaken confidentiality, non-disclosure and
non-use obligations to Allos or Baxter, as the case may be, reasonably identical
in substance to those undertaken herein.

      If the other Party is acquired by, or merges with, another party having a
substantial conflict of interest with the non-acquired Party in respect of the
subject matter of this Agreement, or sells or transfers a substantial part of
its assets to such party, the acquired Party shall take any action reasonably
requested by the non-acquired Party to protect any Confidential Information from
disclosure to or use by any Affiliate of the acquired Party during the period
commencing with the acquisition or merger and continuing through the end of the
Term (and thereafter, if appropriate).

      12.3  EXCEPTIONS. The confidentiality and non-use obligations of this
ARTICLE 12 will not apply to information, including without limitation
Confidential Information, which the receiving Party is able to demonstrate:

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF
1934, AS AMENDED.

                                       18
<Page>

          (a) was in its possession prior to receipt from the disclosing Party,
              and was not acquired, directly or indirectly from the disclosing
              Party;

          (b) was in the public domain at the time of receipt from the
              disclosing Party through no fault of the receiving Party:

          (c) became part of the public domain through no fault of the receiving
              Party;

          (d) was lawfully received by the receiving Party from a third party
              who has no obligation of confidentiality to the disclosing Party;

          (e) was independently developed by the receiving Party as evidenced by
              its written records; or

          (f) was released from the restrictions of this Article by the express
              written consent of the disclosing Party.

      12.4  AUTHORIZED DISCLOSURES. Each Party may disclose Confidential
Information belonging to the other Party to the extent such disclosure is
reasonably necessary in the following instances:

      (a)   to the extent required to be disclosed by applicable law or
regulation, to the relevant Regulating Groups; or

      (b)   complying with applicable court orders or governmental regulations.

      Notwithstanding the foregoing, in the event that a Party is required to
make a disclosure of the other Party's Confidential Information pursuant to this
SECTION 12.4, it will give the other Party reasonable prior notice thereof and a
copy of the disclosure proposed to be made, and will also reasonably cooperate
with the other Party to prevent or to limit such disclosure. The Parties will
consult with each other on the provisions of this Agreement to be redacted in
any filings made by the Parties with the United States Securities and Exchange
Commission or as otherwise required by law.

      12.5  PUBLICITY. The Parties agree that any public announcement of the
execution of this Agreement will be by one or more press releases mutually
agreed to in advance by the Parties.

      12.6  SURVIVAL. The obligations under this Article will extend for the
longer of the term of this Agreement or ten (10) years from the date of the
disclosure of the Confidential Information in question.

13.0  REPRESENTATIONS AND WARRANTIES

      13.1  MUTUAL REPRESENTATIONS AND WARRANTIES. Each Party hereby represents
and warrants to the other Party that (i) this Agreement is legal and valid and
the obligations binding upon such Party are enforceable in accordance with their
terms, (ii) the execution, delivery and performance of this Agreement does not
conflict with any agreement, instrument or understanding, oral or written, to
which such Party may be bound, nor violate any law or regulation of any court,
governmental body or administrative or other agency having jurisdiction over it,
and (iii) the Party owns, controls, or has the right to grant to the other Party
the licenses and other rights to use the intellectual property it authorizes the
other Party to use in carrying out the objectives of this Agreement; and (iv) as
of the Effective Date, the Party is not aware of any restrictions, limitations
or interests superior to the Party's intellectual property rights which would
prevent the other Party from using such intellectual property in carrying out
the objectives of this Agreement or which would cause the other Party to
infringe the rights of others. During the Term of this Agreement, if a Party
becomes aware of any events or circumstances that are reasonably likely to cause
its representations and warranties to be untrue, the Party will promptly provide
the other Party with written

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF
1934, AS AMENDED.

                                       19
<Page>

notice of such events or circumstances, including details reasonably requested
by the other Party in order to evaluate the impact of such events or
circumstances on this Agreement.

      13.2  WARRANTIES OF ALLOS.

            13.2.1  GENERAL. Allos warrants that API, when delivered to Baxter
hereunder, (i) will be manufactured, tested, and packaged in accordance with
applicable cGMP regulations and all applicable laws and regulations of the FDA
and other applicable Regulating Groups in the Territory; (ii) will meet the API
Specifications; and (iii) will not be adulterated or misbranded within the
meaning of the FD&C Act or any similar laws or regulations of applicable
Regulating Groups in the Territory. NO OTHER EXPRESSED OR IMPLIED WARRANTY
EXISTS REGARDING API, INCLUDING ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A
PARTICULAR PURPOSE, AND ALLOS EXPRESSLY DISCLAIMS ANY SUCH WARRANTIES.

            13.2.2  REPLACEMENT. Subject to Allos's indemnification obligation
under SECTION 14.1, Allos's sole obligation and Baxter's exclusive remedy for
breach of Allos's warranty set forth in SECTION 13.2.1 will be [ * ] and [ * ],
or the Manufacturing Fee per unit of Product required to be replaced using
non-defective API, as applicable. Following notice from Baxter and at the
direction of Allos, Baxter will return any then remaining defective API to Allos
or, at Baxter's option if requested by Allos, destroy the same or deliver it to
a third party qualified in such waste disposal. With respect to defective
Product and work-in-process that incorporates defective API, Baxter will, at its
option, destroy the same or deliver it to a third party qualified in such waste
disposal. Allos will bear the cost of any return of API, including freight and
handling, and the costs of destroying any defective API, Product and/or
work-in-process. Allos will, at its expense, replace defective API as
expeditiously as possible and pay Baxter for Product and work-in-process
incorporating defective API to the extent required under this SECTION 13.2.2
within thirty (30) days of receipt of Baxter's detailed invoice.

      13.3  WARRANTIES OF BAXTER.

            13.3.1  GENERAL. Baxter warrants that Product manufactured under
this Agreement, at the time of release at Baxter's manufacturing facility (i)
will be manufactured, tested, and packaged in accordance with applicable cGMP
regulations and all other applicable regulations of the FDA and other applicable
Regulating Groups in the Territory; (ii) will meet the Product Specifications;
and (iii) will not be adulterated or misbranded within the meaning of the FD&C
Act or any similar laws or regulations of applicable Regulating Groups in the
Territory. Notwithstanding the foregoing, this warranty will not extend to the
API or the Formulation Specifications (except to the extent covered in SECTION
13.3.1 (i) and (ii), above)) nor to Product labeling (to the extent the correct
revision of the Product labeling is used,). NO OTHER EXPRESSED OR IMPLIED
WARRANTY EXISTS, INCLUDING ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A
PARTICULAR PURPOSE, AND BAXTER EXPRESSLY DISCLAIMS ANY SUCH WARRANTIES.

            13.3.2  REPLACEMENT. Subject to Baxter's indemnification obligation
under SECTION 14.2, Baxter's sole obligation and Allos's exclusive remedy for
breach of Baxter's warranty set forth in SECTION 13.3.1 will be limited to a
prompt replacement of the Product at no cost to Allos. Following Baxter's notice
to Allos that additional API will be required to replace defective Product,
Allos will promptly provide to Baxter any API necessary for replacement of such
Product at the actual replacement cost of the API paid by Allos to its supplier
including duty, freight, rush surcharges and testing costs. Allos will provide
to Baxter appropriate documentation evidencing such costs. Notwithstanding the
foregoing, Baxter will pay no more for the additional API than [ * ] for the
API, plus duty, freight, rush surcharges and testing costs, adjusted to account
for [ * ].

      13.4  LIMITATION OF WARRANTIES. Except as provided in ARTICLE 14, or as
otherwise expressly stated in this Agreement, neither Party will be liable to
the other Party for any special, indirect, incidental

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF
1934, AS AMENDED.

                                       20
<Page>

or consequential damages arising from a breach of warranty under this Agreement.

14.0  INDEMNIFICATION AND INSURANCE

      14.1  INDEMNIFICATION BY ALLOS. Allos, on its own behalf, and on behalf of
its Affiliates, will defend, indemnify and hold harmless Baxter and its
Affiliates and their respective directors, officers, shareholders, employees and
agents, and each of their successors and permitted assigns, from and against any
and all third party claims, actions or causes of action ("Claims") and all
resulting liabilities, losses, damages, costs or expenses incurred in connection
with the defense of such Claims, and resulting settlements, awards or judgments,
including reasonable attorneys' fees, which arise out of or relate to (i) the
failure of API provided by Allos hereunder to meet the warranties set forth in
SECTION 13.2; (ii) a breach by Allos of any of its other representations,
warranties, covenants, agreements or obligations under this Agreement; (iii)
negligence or willful misconduct of Allos in the performance or nonperformance
of Allos's obligations under this Agreement; (iv) personal injury or property
damage caused directly by the use of the Product (including the API) at any time
before or after first commercial sale (except to the extent covered by Baxter's
indemnification obligations set forth in SECTION 14.2); or (v) any patent, trade
name, trademark, service mark or copyright infringement or misuse, or any claim
or judgment of such infringement or misuse thereof, relating to the Compound or
the Formulation, or the intellectual property licensed to Baxter under SECTION
11.3.1, or the use or printing of any trademark(s), trade names or copyrightable
materials of Allos or its Affiliates, as authorized by this Agreement.

      14.2  INDEMNIFICATION BY BAXTER. Baxter will defend, indemnify and hold
harmless Allos and its Affiliates, and their respective directors, officers,
shareholders, employees and agents, and each of their successors and permitted
assigns, from and against any and all third party claims, actions or causes of
action ("Claims") and all resulting liabilities, losses, damages, costs or
expenses incurred in connection with the defense of such Claims, and resulting
settlements, awards or judgments, including reasonable attorneys' fees, which
arise out of or relate to (i) the failure of Product provided by Baxter
hereunder to meet the warranties set forth in SECTION 13.3; (ii) a breach by
Baxter of any of its other representations, warranties, covenants, agreements or
obligations under this Agreement; (iii) the negligence or willful misconduct of
Baxter in manufacturing Product or in the performance or nonperformance of any
of Baxter's obligations under this Agreement; (iv) personal injury or property
damage caused directly by the Container or any contaminants introduced by Baxter
into the Product during its manufacture; or (v) any patent, trade name,
trademark, service mark or copyright infringement or misuse, or any claim or
judgment of such infringement or misuse thereof, relating to the Container or
the manufacturing processes or equipment used by Baxter to manufacture the
Product (except to the extent covered by Allos's indemnification obligations set
forth in SECTION 14.1) or the intellectual property licensed to Allos under
SECTION 11.3.2, or the use of any trademark(s), trade names or copyrightable
materials of Baxter or its Affiliates as authorized by this Agreement.

      14.3  NOTICE; PROCEDURE. The indemnified Party will give the indemnifying
Party prompt written notice of any claim, proceeding or suit for which it seeks
indemnification under SECTIONS 14.1 or 14.2 (hereafter, a "Matter"). The
indemnifying Party will have fifteen (15) business days after receipt of the
indemnified Party's notice to notify the indemnified Party that the indemnifying
Party elects to conduct and control the defense of such Matter. If the
indemnifying Party does not give the foregoing notice, the indemnified Party
will have the right to defend or settle such Matter in the exercise of its
exclusive discretion, and the indemnifying Party will, upon request from the
indemnified Party, promptly pay to it in accordance with SECTIONS 14.1 or 14.2,
as the case may be, the amount of any liabilities, losses, damages, costs and
expenses, including reasonable attorneys' fees, resulting from such Matter. If
the indemnifying Party GIVES the foregoing notice, the indemnifying Party will
have the obligation and sole authority to undertake, conduct and control,
through counsel of its own choosing and at the sole expense of the indemnifying
Party, the conduct and control of the defense and any settlement of such Matter
and the indemnified Party will cooperate with the indemnifying Party in
connection therewith; provided that: (a) the indemnifying Party will not thereby
permit any lien, encumbrance or other adverse charge upon any

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF
1934, AS AMENDED.

                                       21
<Page>

asset of the indemnified Party; (b) the indemnifying Party will permit the
indemnified Party to participate in the defense or settlement through counsel
chosen by the indemnified Party, but the fees and expenses of such counsel will
be borne by the indemnified Party except as provided in clause (c) below; and
(c) the indemnifying Party will agree to reimburse promptly under SECTIONS 14.1
or 14.2, as the case may be, the indemnified Party for the full amount of any
liabilities, losses, damages, costs and expenses, including reasonable
attorneys' fees, resulting from the Matter, except for any fees and expenses of
counsel for such indemnified Party incurred after the assumption of the conduct
and control of such Matter by the indemnifying Party. So long as the
indemnifying Party is contesting any Matter in good faith, the indemnified Party
will not pay or settle any such Matter; except that such indemnified Party will
have the right to pay or settle any such Matter but in so doing such indemnified
Party will be deemed to have waived any right to indemnity therefore by the
indemnifying Party under SECTION 14.1 or 14.2, as the case may be.

      14.4  NO CLAIM FOR LOSSES. Except for those liabilities, losses, damages,
cost or expenses payable by a Party pursuant to this Article 14, in no event
will either Party or their respective Affiliates be liable for any special,
indirect, incidental or consequential damages arising out of this Agreement.

      14.5  RECALL EXPENSES. If a recall or withdrawal is initiated due to any
of the matters for which Baxter is indemnifying Allos under SECTION 14.2 of the
Agreement, then Baxter will, in addition to its other obligations under this
Agreement, reimburse Allos for (i) all API incorporated into the recalled or
withdrawn Product at the price set forth in SECTION 6.4 of the Agreement, (ii)
the Manufacturing Fees and Product Maintenance Fees paid by Allos associated
with the number of units of recalled or withdrawn Product; and (iii) all direct,
out-of-pocket expenses which are incurred and documented by Allos in connection
with such recall or withdrawal. If a recall or withdrawal is initiated due to
any of the matters for which Allos is obligated to indemnify Baxter under
SECTION 14.1 of the Agreement, then Allos will, in addition to its other
obligations hereunder, reimburse Baxter for all direct, out-of-pocket expenses
which are incurred and documented by Baxter in connection with such recall or
withdrawal.

      14.6  INSURANCE. Baxter is self-insured for the types of liabilities for
which by Baxter is likely to arise under SECTION 14.2. Allos will obtain and
keep in force at its sole expense during the Term of this Agreement, the
following insurance covering Allos and its agents, employees, representatives
and subcontractors: (i) Comprehensive or Commercial General Liability in an
amount not less that [ * ] each occurrence combined single limit for bodily
injury and property damage for products/completed operations (including vendors
coverage), blanket contractual liability, personal injury and independent
contractors protective insurance, which name Baxter as an additional insured and
require at least thirty (30) days written notice to Baxter prior to any
cancellation, non-renewal or material change in coverage. Allos will provide
Baxter with a certificate of insurance evidencing compliance with this insurance
obligation.

15.0  ALTERNATE DISPUTE RESOLUTION

      The Parties will attempt to settle any claim or controversy arising out of
this Agreement through good faith negotiations and in the spirit of mutual
cooperation. Any issues that cannot be resolved by the Steering Committee
pursuant to SECTION 1.3 will be referred to a senior management representative
from each of the Parties who has the authority to resolve the dispute. In the
event such senior management representatives cannot resolve the dispute, the
dispute will be mediated by a mutually acceptable mediator to be chosen by the
Parties within thirty (30) days after written notice by the Party demanding
mediation. Neither Party may unreasonably withhold consent of the selection of
the mediator and the Parties will share the costs of the mediation equally. The
Parties may agree to replace mediation with some other form of Alternative
Dispute Resolution ("ADR"), such as neutral fact-finding or a mini-trial. Any
dispute which cannot be resolved by the Parties through mediation or another
form of ADR within ninety (90) days of the date of the initial written demand
for mediation may then, and only then, be submitted to the Federal or state
courts, as appropriate, for resolution. Nothing in this Section will prevent
either Party from resorting to judicial process if (i) good faith efforts to
resolve the dispute under these procedures have been unsuccessful or (ii)
injunctive relief from a court is necessary to prevent serious and irreparable
injury to

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF
1934, AS AMENDED.

                                       22
<Page>

one Party or to others.

16.0  MISCELLANEOUS

      16.1  ASSIGNMENT AND BINDING EFFECT. This Agreement will be binding upon
and inure to the benefit of the Parties and their successors and permitted
assigns. All rights of either Party under this Agreement are personal and will
not be assigned, nor will the performance of either Party's duties be delegated,
without the prior written consent of the other Party, except that upon prior
written notice either Party may assign its rights and obligations under the
Agreement to any of its Affiliates, and either Party may (subject to the
provisions of SECTION12.2) assign its rights in connection with the sale or
assignment of substantially its entire business or in connection with the merger
or corporate reorganization of a Party. An assignment permitted under this
Section will not be effective, however, unless the purchaser, assignee, or
transferee assumes such Party's obligations under this Agreement and the
assignment will not relieve the assigning Party of its responsibilities under
this Agreement.

      16.2  ENTIRE AGREEMENT. This Agreement together with its Exhibits,
including the separate Confidential Disclosure Agreement set forth in EXHIBIT F,
and the Quality Agreement, together contain the entire agreement between the
Parties relating to the subject matter hereof and all prior written or verbal
proposals, discussions, and writings by and between the Parties and relating to
the subject matter, are superseded hereby. None of the terms of this Agreement
will be deemed to be waived by either Party or amended, unless such waiver or
amendment is in writing executed by both Parties and such writing recites
specifically that it is a waiver of or an amendment to the terms of this
Agreement. In addition to the matters referenced in the text of this Agreement
as set forth in attached EXHIBITS A through F, the Parties agree to be bound by
the additional terms and conditions set forth in all other Exhibits, if any,
attached to this Agreement, to the same extent as if such provisions were
referenced in and incorporated into the text of this Agreement. In the event of
a conflict between any of the provisions of the Quality Agreement and this
Agreement, the provisions of this Agreement shall govern.

      16.3  GOVERNING LAW. This Agreement will be deemed to have been entered
into in the State of Illinois and its interpretation and construction and the
remedies for its enforcement or breach are to be applied pursuant to and in
accordance with the laws of the State of Illinois without reference to any rules
of conflict of laws.

      16.4  SEVERABILITY. In the event that any one or more of the provisions
contained in this Agreement should be held invalid, illegal or unenforceable in
any respect, the validity, legality and enforceability of the remaining
provisions contained herein will not in any way be affected or impaired thereby,
unless the absence of the invalidated provision(s) adversely affect the
substantive rights of the Parties. The Parties agree to replace any invalid
provision or parts thereof by new provision(s) which closely approximate the
economic and proprietary results intended by the Parties.

      16.5  WAIVER. The waiver by either Party hereto of any right hereunder or
of a breach by the other Party will not be deemed a waiver of any other right
hereunder or of any other breach by said other Party whether of a similar nature
or otherwise.

      16.6  FORCE MAJEURE.

            16.6.1  GENERAL. Neither Party will be liable, or deemed in breach
of its obligations under this Agreement, for a delay in performance or
nonperformance as the result of an act of governmental authority (excluding any
act occasioned by a breach of the terms of this Agreement or willful misconduct
of a Party or where such acts could have been prevented by reasonable measures
of the affected Party), war, acts of terrorism, riot, fire, explosion,
hurricane, flood, strike, lockout, or injunction or any other similar cause
beyond its reasonable control preventing the manufacture, shipment, or
acceptance, of the Product, or any component thereof ("Force Majeure") provided
that the affected Party (i) promptly

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF
1934, AS AMENDED.

                                       23
<Page>

notifies the other Party of the Force Majeure event as provided in SECTION
16.6.2 (ii) uses reasonable diligence and efforts to remedy the situation if
reasonably capable of being remedied by that Party, (iii) continues performance
of its obligations to the extent the Force Majeure event permits, and (iv)
resumes performance of its obligations delayed by Force Majeure events as soon
as possible. This requirement that any Force Majeure be remedied with all
reasonable dispatch will not require settlement of strikes or labor
controversies by acceding to the demands of the opposing parties.

            16.6.2  NOTICE. A Party affected by Force Majeure will promptly
notify the other explaining the nature, details, and expected duration thereof.
The affected Party will advise the other Party from time to time as to progress
in remedying the situation and as to the time when the affected Party expects to
resume its obligations and will notify the other Party as to the expiration of
any Force Majeure as soon as the affected Party knows the date thereof. If a
Party anticipates that a Force Majeure is reasonably likely to occur, that Party
will notify the other immediately, explaining the nature, details, and expected
duration thereof.

            16.6.3  REMEDY. If Baxter becomes subject to an event of Force
Majeure which interferes with or prevents production of Product at its current
production plant, the Parties shall within thirty (30) days of the event meet to
discuss and attempt to mutually agree on implementation of an action plan,
including, if appropriate, the possible transfer of production of Product to
another Baxter plant. If no alternative plant is available or if Baxter is
unable to reasonably project that within three (3) months of the event it will
be able to achieve at least a ninety percent (90%) production level recovery,
Allos may choose to terminate this Agreement on thirty (30) days written notice.
Notwithstanding any of the preceding or any other terms of this Agreement, if
beginning three (3) months after the initial onset of the event of Force Majeure
Baxter is unable to timely deliver at least ninety percent (90%) of Product
ordered by Allos for two (2) months out of any three (3) month period, Allos may
choose to terminate this Agreement on thirty (30) days written notice.

      16.7  RELATIONSHIP OF THE PARTIES. It is expressly acknowledged and agreed
that Baxter and Allos will be independent contractors and that the relationship
between the two Parties will not constitute a partnership, joint venture or
agency. Despite the collaborative relationship between Baxter and Allos under
this Agreement, neither Party, nor its agents or employees, will be deemed
agents or representatives of the other Party. Neither Party will have the right
to enter into any contracts or commitments in the name of or on behalf of the
other Party, without the prior written consent of the other Party to do so.
Nothing herein will be construed as granting any license or right under any
patent or trademark right of either Party, by implication or otherwise, to the
other except as expressly provided herein.

      16.8  NOTICES. All notices or other communications which are required or
permitted under this Agreement will be in writing and deemed delivered at the
time they are personally delivered, or on the business day next following the
date of transmission when sent by confirmed facsimile transmission, or two (2)
business days after being sent by a nationally-recognized overnight courier, and
addressed as follows:

      If to Baxter:

      Baxter Healthcare Corporation
      Global Drug Delivery
      Route 120 and Wilson Road
      Round Lake, Illinois 60073
      Attention: Joel A. Tune
                   General Manager
      Fax No: 847-270-3410

      With a copy to:

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF
1934, AS AMENDED.

                                       24
<Page>

      Baxter Healthcare Corporation
      One Baxter Parkway
      Deerfield, Illinois  60015

      Attention: Thomas Sabatino, Esq.
                  General Counsel
      Fax No: 847-948-2450

      If to Allos:

      Allos Therapeutics, Inc.
      11080 CirclePoint Road, Suite 200
      Westminster, CO  80020
      Attention: Douglas Johnson
               VP of Manufacturing
      Fax No:  303-412-9162

      With a copy to:

      Cooley Godward LLP
      380 Interlocken Crescent, Suite 900
      Broomfield, CO  80021
      Attention: Steven Dupont
      Fax No: 720-566-4099

      16.9  EXPORT. Each Party will adhere to the United States Export
Administration Laws and Regulations and will not export or re-export any
technical data or Information received from the disclosing Party or the direct
product of such technical data or Information to any proscribed country listed
in the United States. Export Administration Regulations, unless properly
authorized by the United States Government.

      16.10 REVIEW WITH COUNSEL. Each Party agrees that it has had the
opportunity to review this Agreement with its legal counsel. Accordingly, the
rule of construction that any ambiguity in this Agreement is to be construed
against the drafting party will not apply.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF
1934, AS AMENDED.

                                       25
<Page>

      IN WITNESS WHEREOF, the Parties have executed this Agreement by their duly
authorized representative as of the date first set forth above.

BAXTER HEALTHCARE CORPORATION               ALLOS THERAPEUTICS, INC.

By:/s/ Joel A. Tune                         By:/s/ Michael E. Hart
   ---------------------------------           ---------------------------------
Printed Name:  Joel A. Tune                 Printed Name: Michael E. Hart

Title: Vice President and General Manager   Title: President and Chief Financial
       Global Drug Delivery                        Officer

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF
1934, AS AMENDED.

                                       26
<Page>

                                    EXHIBIT A

                             PRODUCT SPECIFICATIONS

      Product Label:            Standard label - Identifying Information to be
                                determined

      Dose:                     75 - 100 mg/kg

      Nominal Volume:           [ * ]

      Concentration:            20 mg/mL

      Diluent:                  Water for Injection, USP

      Buffer:                   [ * ] phosphate (Na2HPO4 and NaH2PO4), USP

      Osmotic adjuster:         [ * ] NaCl, USP

      pH:                       Final product pH [ * ]

      Premix Container:         Type I Glass [ * ]

      Closure:                  [ * ] West Gray Bull's Eye non-siliconized
                                stopper

                                [ * ]

      Sterilization:            [ * ]

      Packaging:                Pack Factor of 6 intermediate cartons, each
                                containing one 500mL unit, per shipper carton

      Minimum Shelf Life:       24 Months [ * ]

      Storage Conditions:       Controlled Room temperature (20 - 25 DEG. C)

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       A-1
<Page>

                                    EXHIBIT B

                                DEVELOPMENT PLAN

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       B-1
<Page>

BAXTER [LOGO]

                                                                   APPROVAL FORM

Baxter Healthcare Corporation
Scientific Affairs
Round Lake, Illinois 60073                                 Reference SOP # [ * ]

Project Title:
                 RSR13 Intravenous Injection

Project Number:  [ * ]        PQA Number:  [ * ]

    /X/ FORMULATION PLAN     / / ANALYTICAL STRATEGY     / / ANALYTICAL PLAN

Check box of document being approved.

     APPROVAL SIGNIFIES THAT THE ENTIRE DOCUMENT HAS BEEN REVIEWED AND THAT THE
     REQUIREMENTS OF THE APPROVER'S FUNCTIONAL AREA HAVE BEEN ADEQUATELY
     ADDRESSED BY THE STRATEGY OR PLAN.

<Table>
<Caption>
                   Name                           Signature            Date
--------------------------------------------------------------------------------
<S>                                           <C>                   <C>
Author: S. Brynjelsen                         /s/ S. Brynjelsen     9-13-02

Technical Leader: S. Brynjelsen               /s/ S. Brynjelsen     9-13-02

Product Development: S. Vincent               /s/ S. Vincent        9-16-02

Stability Operations: J. Fosco                /s/ J. Fosco          9-16-02

Pharmaceutical Company: D. Johnson, Allos     /s/ D. Johnson        9-17-02

Pharmaceutical Technology: Rao Chilamkurti    /s/ R. Chilamkurti    9-17-02
</Table>

                              -BAXTER CONFIDENTIAL-
Reference Document:  [ * ]                             Form Number:  [ * ]
                     (current revision)             Form Issue Date: 08/22/2001

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF
1934, AS AMENDED.

                                  Page 1 of 13
<Page>

Formulation Plan [ * ]

I.   PROJECT INFORMATION

PRODUCT TYPE: Premix Injection

DRUG COMPANY/ALLIANCE COMPANY: Allos Therapeutics, Inc.

INTENDED MARKET:     US, Europe, Canada

DESCRIBE PROPOSED PRODUCT:

<Table>
<Caption>
  PRODUCT TYPE                               PROPOSED
--------------------------------------------------------------------------------
<S>                 <C>
                    RSR13 is a synthetic allosteric modifier of hemoglobin. The
                    product is intended to be sterile and non-pyrogenic. The
Description         formulation will be packaged in Type I Glass containers.

                                   500 mL fill in 500 mL container

Concentration                             20.0 mg/mL RSR13

                                  Tonicity agent: [ * ] Sodium Chloride

                                       Buffer: [ * ] phosphate

Excipients          [ * ] Sodium Phosphate, Monobasic, Monohydrate, USP
                    [ * ] Sodium Phosphate, Dibasic, Anhydrous, USP

pH                                            [ * ]

pH Adjusters                               0.1 N NaOH/HCl

Administration      Infused via central catheter line 30 minutes prior to daily
                    radiation therapy for the duration of the treatment.
</Table>

                              -BAXTER CONFIDENTIAL-
Reference Document:  [ * ]                             Form Number:  [ * ]
                     (current revision)             Form Issue Date: 08/22/2001

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF
1934, AS AMENDED.

                                  Page 2 of 13
<Page>

Formulation Plan [ * ]

DESCRIBE EXISTING LIMITS:

<Table>
<Caption>
               ATTRIBUTE                             METHOD                                 LIMITS
-----------------------------------------------------------------------------------------------------------------------
<S>                                           <C>                           <C>
Physical description                           Visual Examination                   Clear, colorless solution

                                                     HPLC RT                Consistent with reference
                                                                            material
Identification                                                              Consistent with reference
                                                                            material
                                                  UV Spectrum

pH                                                  USP (791)                                [ * ]

Osmolality                                          USP (785)                            [ * ] mOsm/kg

Assay                                         HPLC external standard                       90.0-110.0%

Process Impurities                                     HPLC
     [ * ]                                      area normalization                           NMT 0.05%
     [ * ]                                      area normalization                           NMT 0.10%
     [ * ]                                      area normalization                           NMT 0.05%
     [ * ]                                      area normalization                           NMT 0.05%
     Total process impurities                   area normalization                           NMT [ * ]
Degradants
     [ * ]                                       external standard                           NMT [ * ]
     [ * ]                                       external standard                           NMT [ * ]
     Unidentified individual degradant          area normalization                           NMT 0.05%
     Total Degradants                           area normalization                             Report

Total of Impurities and Degradants                                                           NMT [ * ]

Sterility                                            USP (71)                                Sterile

Bacterial Endotoxin                                  USP (85)                              NMT 1.0 EU/mL

Particulate Matter                               USP (788) for LVP          LESS THAN OR EQUAL TO 3 particles/mL GREATER THAN OR
                                                                                                EQUAL TO 25 um
                                                                            LESS THAN OR EQUAL TO 25 particles/mL GREATER THAN OR
                                                                                                EQUAL TO 10 um
</Table>

Note: NMT = Not More Than         Source of Limits: Allos Therapeutics, Inc.

DESCRIBE EXISTING LABELING:
Please see Attachment I for a copy of the Product Label.

RSR13 Intravenous Injection
For Clinical Trial Use Only
Store at controlled room temperature 15 DEG. - 25 DEG.C (59 DEG. - 77 DEG.F).
Protect from light.
See protocol for dosage and administration.
Each mL contains:

<Table>
     <S>                                          <C>
     RSR13 Acid (added as RSR13 sodium salt)      20 mg
     [ * ]                                        [ * ] mg
     Dibasic Sodium Phosphate, USP                [ * ] umoles
     Monobasic Sodium Phosphate, USP              [ * ] umoles
     Hydrochloric Acid and/or Sodium Hydroxide may have been added to adjust pH
</Table>

                              -BAXTER CONFIDENTIAL-
Reference Document:  [ * ]                             Form Number:  [ * ]
                     (current revision)             Form Issue Date: 08/22/2001

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF
1934, AS AMENDED.

                                  Page 3 of 13
<Page>

Formulation Plan [ * ]

COMPENDIAL REQUIREMENTS FOR FINISHED PRODUCT:

     No USA (USP) or European (EP) monograph exists for RSR13.

II.  BACKGROUND INFORMATION:

RSR13 is a synthetic allosteric modifier of hemoglobin. It is used as an adjunct
radiation sensitizer in the treatment of brain metastases. RSR13 enhances the
efficacy of radiation therapy by binding to the central water cavity of the
hemoglobin tetramer, reducing its oxygen-binding affinity and increasing oxygen
release to hypoxic cells within the tumor. Subsequent radiation therapy creates
free radicals from the oxygen, increasing tumor sensitivity and apoptosis in
tumor cells.

Allos therapeutics has conducted past clinical studies using RSR13 formulation
previously manufactured by Akorn Incorporated. Allos intends to engage Baxter
International to manufacture RSR13 Injection as well. RSR13 Injection is a
sterile, non-pyrogenic solution of RSR13 in [ * ] NaCl diluent with [ * ]
phosphate buffer. Each mL contains 20.0mg RSR13 (free acid), [ * ] sodium
chloride, [ * ] Na(SUB 2)HPO(SUB 4) and [ * ] NaH(SUB 2)PO(SUB 4).H(SUB 2)O.
The pH limit is from [ * ] in the RSR13 formulation. Injection volumes of 500
mL will be packaged in Type I Glass containers with West [ * ] gray [ * ]
stoppers.

[ * ] REQUIREMENTS:

     [ * ]

                              -BAXTER CONFIDENTIAL-
Reference Document:  [ * ]                             Form Number:  [ * ]
                     (current revision)             Form Issue Date: 08/22/2001

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF
1934, AS AMENDED.

                                  Page 4 of 13
<Page>

Formulation Plan [ * ]

                             CONSIDERATIONS FOR API

                                    (see [ * ])

<Table>
<Caption>
       DESCRIPTION                              COMMENTS
--------------------------------------------------------------------------------
<S>                         <C>
    Literature Search       No compendial requirements have been found. Refer to
                            limits established by Allos Therapeutics, Inc.

   MSDS and EHS Hazard      Category [ * ] Pharmaceutical agent. Please refer to
      Classification        Attachments II and III.

                            RSR13 (efaproxiral) is a synthetic allosteric
                            modifier of hemoglobin. It is obtained as a [ * ]
                            crystalline powder with MW 363.4 (Na salt) and 341.4
    Physical-Chemical       (free acid). Allos Therapeutics, Inc. has reported
       Description          the existence of [ * ] polymorphic forms of RSR13,
                            designated as forms [ * ]. The [ * ] the drug
                            substance of interest corresponds to [ * ]. RSR13
                            melts over the range 242 - 248 DEG.C. Please see
                            Attachment IV for the chemical structure of RSR13.

                            Please see Attachment V for the solubility profile
        Solubility          of RSR13 Sodium Salt as a function of pH and
                            temperature. The aqueous solubility of RSR13 at 25.5
                            DEG. C ([ * ]) has been reported as [ * ].

                            The following process impurities have been identified:
                               I.      [ * ]
        Impurities             II.     [ * ]
                               III.    [ * ]
                               IV.     [ * ]

       Degradation          When exposed to extreme temperatures or with
    Products/Mechanism      extended exposure to intense light RSR13 degradation
                            may occur.

     pH/Rate Profile        Refer to Magellan report [ * ].

    Concentration/Rate      No information on concentration/rate profile for
                            RSR13 was found in the Profile literature.

 Storage Requirements and   Store the solid RSR13 material [ * ]C and [ * ]
                            relative humidity. Protect from Hygroscopicity
                            light. RSR13 is [ * ] hygroscopic.

      Optical Purity        RSR13 does not have a chiral center, hence it is not
                            optically active.

       Pyrogenicity         NMT [ * ]. Obtained from technical package provided
                            by Allos Therapeutics, Inc.

   Stability-Indicating
Procedures and Validation   Please refer to the Analytical Plan.
           Data

         Disposal           Please refer to Attachment II.

      Eutectic Point        No information is available.
</Table>

                              -BAXTER CONFIDENTIAL-
Reference Document:  [ * ]                             Form Number:  [ * ]
                     (current revision)             Form Issue Date: 08/22/2001

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF
1934, AS AMENDED.

                                  Page 5 of 13
<Page>

Formulation Plan [ * ]

                       CONSIDERATIONS FOR FINISHED PRODUCT

<Table>
<Caption>
       DESCRIPTION                              COMMENTS
--------------------------------------------------------------------------------
<S>                            <C>
       Light Sensitive         Slight degradation under extended exposure with
                               intense light. Reference photostability report for
                               Allos/Magellan entitled, "Photostability, Thermal
                               Cycling and Freeze/Thaw Stability of RSR13" for
                               protocol TTP-ATB-C0016 (issued January 11, 2002).

      [ * ] Sensitive          [ * ] may play a role in the [ * ] of RSR13,
                               [ * ]. Reference Allos Therapeutics report
                               entitled, "Kinetics Investigation of Impurity
                               Formation inRSR13 for Injection" for protocol
                               TTP-ATB-C0011 (issued December 19, 2001).

                               Container - 500 mL Type I Glass Bottle (Kimble);
                               28 mm w/out graduations.
        Compatible             Closure - 28 mm West Gray Saftiflask [ * ]Stopper
  Container/Closure System     ([ * ]).
                               Crimp - 28 mm 3 piece aluminum cap with
                               polypropylene coated disk.

         Degradant             [ * ]

 Thermal Stability Capable of  [ * ]
   Terminal Sterilization?

    Terminal Sterilization     [ * ]
           Losses

        Optimum Diluent        The proposed product contains [ * ] NaCl as the
                               diluent. Product solvent is Water for Injection
                               (WFI).

       Color Formation         The proposed product is clear and colorless. The
                               photostability study (TTP-ATB-C0016 by
                               Magellan/Allos) revealed [ * ] exposure to
                               excessive light.

   Osmolality Requirements     [ * ] mOsm/kg

                               The proposed product incorporates a [ * ]
                               phosphate buffer, comprised of:
        Optimum Buffer         -    sodium phosphate, monobasic, monohydrate
                               -    sodium phosphate, dibasic, anhydrous
                                    (or sodium phosphate, dibasic, heptahydrate)

         Anticipated           [ * ]
 Stability-Limiting Factors

    Container Adsorption       Not applicable. The container is a Type I Glass
      Characteristics          Bottle.

    Storage Requirements       Store at controlled room temperature 15 DEG. -
                               25 DEG.C (59 DEG. - 77 DEG.F).

   Optimum Formulation pH      The proposed product limits indicate a pH range
                               of [ * ].

Stability w/Respect to Buffer  [ * ]
         Catalysis

 Sensitivity to Trace Metals   [ * ]
</Table>

                              -BAXTER CONFIDENTIAL-
Reference Document:  [ * ]                            Form Number:  [ * ]
                     (current revision)             Form Issue Date: 08/22/2001

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF
1934, AS AMENDED.

                                  Page 6 of 13
<Page>

Formulation Plan [ * ]

III. CONCLUSIONS & SUMMARY OF PREVIOUS WORK

(EXCERPT FROM ALLOS THERAPEUTICS DEVELOPMENT REPORT ENTITLED "PHARMACEUTICAL
DEVELOPMENT REPORT FOR RSR13 INJECTION" ISSUED 13 SEPTEMBER 2002)

FORMULATION DEVELOPMENT
The five formulations used during the clinical development program are outlined
in the proceeding table. The basis for their selection and reasons leading to
modifications will be presented subsequently. Formulation 5 represents the
commercial product and was the product used in the pivotal clinical trial.

RSR13 INJECTION FORMULATIONS

<Table>
<Caption>
                                                        FORMULATION
                            -------------------------------------------------------------------
        PROPERTY                 1             2             3             4             5
-----------------------------------------------------------------------------------------------
      Manufacturer              PDC           PDC           PDC          Akorn         Akorn
-----------------------------------------------------------------------------------------------
<S>                         <C>           <C>           <C>           <C>           <C>
        Contents            [ * ] mg/mL   [ * ] mg/mL   [ * ] mg/mL   [ * ] mg/mL   [ * ] mg/mL
      Efaproxiral
  (added as sodium salt)
        NaCl, USP              [ * ]         [ * ]         [ * ]         [ * ]         [ * ]
    Phosphate buffer           [ * ]         [ * ]         [ * ]       [ * ]           [ * ]

     Volume of unit            50 mL        100 mL         100 mL       100 mL        500 mL

       Osmolality              [ * ]         [ * ]         [ * ]         [ * ]         [ * ]
       (mOsmol/L)
      (calculated)

  pH post-sterilization        [ * ]         [ * ]         [ * ]         [ * ]         [ * ]
        (actual)

                                                                         RT-004
                                             RT-004       RT-007         RT-007
                                HV-001       RT-006       RT-007b        RT-007b       RT-009
Clinical trials supported       RT-002       CV-020       RT-008         RT-008        RT-010
                               SBL-010       CV-021       HV-002         RT-010        CT-001
                                             CPB-011                     CPB-012
                                                                         CV-021

                                                                                     11219-02,
                                                           CTM-612,                   AL0-01,
                                            CTM-550,       CTM-622,                   AL0-02,
                                            CTM-575,       CTM-626,      41348        AL0-03,
                                            CTM-577,       CTM-630,      61458        AL0-04,
 Clinical lots produced       CTM-451,      CTM-591,       CTM-631,      121058       AL1-01,
                              CTM-480       CTM-602,       CTM-632,      31719        AL1-02,
                                            CTM-604,       CTM-634,                   AL1-03,
                                            CTM-611        CTM-635                    AL1-04
</Table>

                              -BAXTER CONFIDENTIAL-
Reference Document:  [ * ]                            Form Number:  [ * ]
                     (current revision)             Form Issue Date: 08/22/2001

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF
1934, AS AMENDED.

                                  Page 7 of 13
<Page>

Formulation Plan [ * ]

<Table>
   <S>                         <C>       <C>              <C>               <C>                 <C>
                                                                                                RS13.000005-01,
                                                                                                RS13.000008-01,
                                          2088-30696A,                                          RS13.000010-01,
   API Lots Used               DL04,      2088-16497A,    RS13.000001-01,   RS13.000005-01,     RS13.000012-01,
                               DL02      RS13.000001-01   RS13.000005-01    RS13.000007-01-01   RS13.000013-01
</Table>

                       Reference: Allos Therapeutics, Inc.

During the clinical program of product usage, several minor characteristics were
found to require adjustment to achieve a more acceptable commercial product. The
simplicity of the formulation facilitated optimization through relatively
straightforward techniques. The principal areas of investigation included:

 -   drug concentration
 -   physical stabilization
       -   [ * ] control
       -   [ * ] control
 -   [ * ] of efaproxiral
 -   total volume

DRUG CONCENTRATION

Initially (Formulation 1) the concentration was [ * ] mg/mL efaproxiral (or [ *
] mg/mL efaproxiral sodium). This concentration was chosen because it was about
[ * ] of RSR13-Na. The solution was then diluted with [ * ] saline to the
appropriate concentration for administration in the clinic. For Formulations 2-4
the concentration was decreased to [ * ]. This was done in order to move the
concentration of the drug product further from the aqueous solubility limit
which was measured as approximately [ * ]. For indications where the dosing
instructions call for administering efaproxiral injection via a central line the
final formulation (Formulation 5) is [ * ] administration from the bottle.

PHYSICAL STABILIZATION

The formation of [ * ] occurred in early lots of RSR13 Injection. Some of the
batches of [ * ] failed to meet the USP requirements for particulate matter in
small-volume parenterals. During clinical trials these [ * ] required filtration
prior to use [ * ] the very small quantities of [ * ]. While the [ * ] drug was
enough to cause several [ * ] requirements for [ * ] the amount of efaproxiral
removed from solution [ * ] relative to the 20 mg/mL. Studies demonstrated that
[ * ] potency occurred and also that [ * ] the units would [ * ].
The [ * ] Fourier-transform infrared spectroscopy (FTIR) as efaproxiral or a
salt thereof. [ * ]. This is consistent with the solubility properties of the
acid and salt forms. The pKa for [ * ] of about [ * ] does not afford [ * ] a pH
greater than [ * ]. Beginning with [ * ], buffering agents

                              -BAXTER CONFIDENTIAL-
Reference Document:  [ * ]                            Form Number:  [ * ]
                     (current revision)             Form Issue Date: 08/22/2001

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF
1934, AS AMENDED.

                                  Page 8 of 13
<Page>

Formulation Plan [ * ]

were introduced, first at [ * ] and then at [ * ]. The [ * ] concentration of [
* ] provided the [ * ] of the formulation. The pH is adjusted to an [ * ] of [ *
] (after the addition of [ * ]), which decreases to [ * ] following [ * ]. [ * ]
batches have been made of [ * ]. Since introducing the [ * ] buffer, there have
been [ * ] at any stability interval. (As of [ * ] this represents [ * ]
intervals at [ * ], [ * ] intervals at [ * ] and [ * ] intervals at [ * ].)

HYDROLYSIS OF EFAPROXIRAL

While efaproxiral is [ * ] in aqueous solution, [ * ] degradation through [ * ]
does occur to produce [ * ] and [ * ]. The reaction, [ * ], is accelerated [ * ]
and proceeds slowly during storage at [ * ].

                                      [ * ]

Stability studies of [ * ] have shown that the [ * ] reaction is [ * ] with this
[ * ]. At [ * ], where the [ * ], the [ * ] over [ * ] months is about [ * ].
The molecular weight of the [ * ] is approximately [ * ] that of the molecular
weight of [ * ]. Thus, [ * ] amounts of [ * ] and [ * ] form [ * ]. The figure
below shows the growth of [ * ] and [ * ] from four different lots of RSR13
Injection.

                              -BAXTER CONFIDENTIAL-
Reference Document:  [ * ]                            Form Number:  [ * ]
                     (current revision)             Form Issue Date: 08/22/2001

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF
1934, AS AMENDED.

                                  Page 9 of 13
<Page>

Formulation Plan [ * ]

                                      [ * ]

       Reference: Allos Therapeutics Pharmaceutical Development Report for
                                 RSR13 Injection
                           (Issued 13 September 2002)

                              -BAXTER CONFIDENTIAL-
Reference Document:  [ * ]                            Form Number:  [ * ]
                     (current revision)             Form Issue Date: 08/22/2001

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF
1934, AS AMENDED.

                                  Page 10 of 13
<Page>

Formulation Plan [ * ]

IV.  CONCLUSIONS FROM FEASIBILITY AND DEVELOPMENT STUDIES

GLASS CONTAINER STUDIES:

<Table>
<Caption>
PROTOCOL NO.                       TITLE                                         CONCLUSION
--------------------------------------------------------------------------------------------------------------------
<S>             <C>                                         <C>
                                                            RSR13 solubility in [ * ] is influenced by [ * ].  From
[ * ]             Determination of the pH-Solubility        [ * ] at 25.5 DEG.C, the solubility of RSR13 in water is
                     Profile for RSR13 Solutions            [ * ].  Below [ * ], the solubility in [ * ] due to the
                                                            formation of [ * ] acid.

                                                            The titration of RSR13 test articles [ * ]
                Determination of Titratable Acidity in      w/standardized 0.0009N NaOH showed [ * ].  Thus, the
[ * ]                       RSR13 Solutions                 titratable acidity [ * ] be determined by the titration
                                                            method.

[ * ]             Determination of the Effect of [ * ]      Results indicate that [ * ] inhibits [ * ].  This [ * ]
                  Sterilization on RSR13 Formulations       may be due to [ * ].

                 Feasibility Batch Production of RSR13      A RSR13 Premix batch was successfully mixed and filled
     [ * ]      Premix in 500 mL Type I Glass Containers    at the Round Lake Pilot Plant Facility on [ * ], and
                      at the Round Lake Pilot Plant         then [ * ] on [ * ] at Baxter's Cleveland, MS
                                Facility                    Manufacturing Facility. This batch was filled into 500
                                                            mL Type I Glass containers. The processed units will be
                                                            evaluated by Allos Therapeutics and Round Lake Product
                                                            Development.

     [ * ]           Formulation of a 20 mg/mL RSR13        Three [ * ] units were tested by instrumental [ * ] and
                   Formulation in 500 mL Type I Glass       pH after storage for approximately [ * ] months at [ * ]
                               Bottles                      DEG.C. The mean pH was [ * ] and the instrumental
                                                            particle counts per mL were within the USP [ * ] limits
                                                            for [ * ] volume injection solutions.
</Table>

[ * ]

                              -BAXTER CONFIDENTIAL-
Reference Document:  [ * ]                            Form Number:  [ * ]
                     (current revision)             Form Issue Date: 08/22/2001

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF
1934, AS AMENDED.

                                  Page 11 of 13
<Page>

Formulation Plan [ * ]

FORMULATION STUDY OBJECTIVES:

<Table>
<Caption>
                  OBJECTIVE                                MEANS TO ACHIEVE OBJECTIVE
----------------------------------------------------------------------------------------------------
 <S>                                        <C>
    Demonstrate chemical and physical       Formulation study evaluating the stability of the
       stability of proposed [ * ]          formulation batches completed by [ * ] and Akorn
                                            Pharmaceuticals, Inc. Final formulation [ * ] by Baxter
                                            Healthcare.

       Demonstrate compatibility of         -   Completed.
       formulation(s) with proposed         -   Formulation in 500 mL Type I Glass Containers.
        container/closure system(s)         -   Please refer to Protocol #(s): [ * ]

 Demonstrate drug has no effect on [ * ]
 levels (compare levels in water blanks     Not applicable. Type I Glass Container will be used.
         and formulation units)

                                            Completed by Allos Therapeutics, Inc. Formulation study
                                            evaluating the effect of light exposure on RSR13
  Evaluate photo-degradation of product     injection at inherent pH [ * ]. Reference photostability
                                            report for Allos/Magellan entitled, "Photostability,
                                            Thermal Cycling and Freeze/Thaw Stability of RSR13" for
                                            protocol TTP-ATB-C0016 (issued [ * ]).

                                            -   [ * ].  Determined by Allos Therapeutics, Inc.
 Establish the need for overage of drug     -   There are [ * ] in the formulation and manufacture
      in the proposed formulation.              of RSR13 injection.

                                            -   Determination of Titratable Acidity in RSR13
     Define pH adjustment procedure             Solutions performed in Final Report [ * ]
    through titration curve or other        -   pH will be adjusted to specified limits [ * ] with
          appropriate means.                    0.1 N HCl or 0.1 N NaOH

  Determine control for protection from     -   [ * ] manufacturing.
                  [ * ]                     -   Protection from [ * ].

      Competitor product comparison         None.

            Evaluate Vendor(s)              Hovione Sociedade Quimica, S.A.

                                            Completed by Allos Therapeutics, Inc. via Magellan
                                            Laboratories. Concluded that Freeze/Thaw and Thermal
   Evaluate the effect of Freeze-Thaw       Cycling had [ * ] on samples.
   temperature cycling on formulation
               stability.                   -See study report entitled "Photostability, Thermal
                                            Cycling and Freeze/Thaw Stability of RSR13" Protocol
                                            TTP-ATB-C0016 (Magellan Labs, [ * ])

                                            [ * ] limit determination and associated data is
                                            detailed in Allos Therapeutics Pharmaceutical
                                            Development Report for RSR13 (2002) and the following
                                            studies:
         [ * ] extreme stability            -See study report entitled "[ * ] Stability Report",
                                            Code 3200 (Akorn Incorporated, April 2000)
                                            -See study report entitled "[ * ] Kinetic Studies on
                                            RSR13 in Different Formulations" Protocol [ * ]
                                            (Magellan Labs, April 2002)

         Extractables (Stopper)             See study report "Extractables Profile of Rubber
                                            Stoppers" Protocol TTP-ATB-M0008 (Magellan Labs Feb
                                            2002)
</Table>

                              -BAXTER CONFIDENTIAL-
Reference Document:  [ * ]                            Form Number:  [ * ]
                     (current revision)             Form Issue Date: 08/22/2001

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF
1934, AS AMENDED.

                                  Page 12 of 13
<Page>

Formulation Plan [ * ]

CONCLUSION:

No [ * ] formulation development will be performed. The [ * ] formulation has
been described in this document (section I & II) and will be [ * ] for the large
scale manufacture of RSR13 Injection.

                              -BAXTER CONFIDENTIAL-
Reference Document:  [ * ]                            Form Number:  [ * ]
                     (current revision)             Form Issue Date: 08/22/2001

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF
1934, AS AMENDED.

                                  Page 13 of 13
<Page>

Formulation Plan for RSR13 Premix Injection - [ * ]

                                  ATTACHMENT I.

                             RSR13 PREMIX INJECTION
                                  PRODUCT LABEL

                                    (1 page)

                              -BAXTER CONFIDENTIAL-
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF
1934, AS AMENDED.

<Page>

<Table>
<Caption>
GENERIC TEST  500 ML        PROOF#9  4/24  /02      LABEL SIZE:  3-3/8" X 7-1/8"
<S>                                      <C>        <C>

                                         [ * ]

[ * ]
</Table>

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF
1934, AS AMENDED.

<Page>

Formulation Plan for RSR13 Premix Injection - [ * ]

                                                                        14 of 17

                                 ATTACHMENT II.

                                 MSDS FOR RSR13
                                (SUPPLIER: [ * ])

                                    (8 pages)

                              -BAXTER CONFIDENTIAL-
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF
1934, AS AMENDED.

<Page>

Formulation Plan for RSR13 Premix Injection - [ * ]

                           MATERIAL SAFETY DATA SHEET

     PREPARED TO U.S. OSHA, CMA, ANSI, CANADIAN WHMIS AND EUROPEAN COMMUNITY
                                    STANDARDS

PART I    WHAT IS THE MATERIAL AND WHAT DO I NEED TO KNOW IN AN EMERGENCY?

                            1. PRODUCT IDENTIFICATION

TRADE NAME (AS LABELED):        EFAPROXIRAL SODIUM SALT

CHEMICAL NAME/CLASS:            2-(4-{[(3,5-Dimethylanilino)carbonyl]methyl}
                                phenoxy)-2-methylpropionic Acid, Sodium Salt
SYNONYMS:                       RSR13 Sodium Salt
PRODUCT USE:                    Research and Clinical Trial Use Only

MANUFACTURER'S NAME:            ALLOS THERAPEUTICS
ADDRESS:                        11080 Circle Point Road, Suite 200
                                Westminster, CO  80020

DISTRIBUTOR'S NAME:             ALLOS THERAPEUTICS
ADDRESS:                        11080 Circle Point Road, Suite 200
                                Westminster, CO  80020
EMERGENCY PHONE:                1-303-881-7934
BUSINESS PHONE:                 1-303-426-6262

DATE OF PREPARATION:            November 30, 1998

                  2. COMPOSITION AND INFORMATION ON INGREDIENTS

RSR13 SODIUM SALT is not included in the TSCA inventory. In accordance with 40
CFR 720.36, RSR13 SODIUM SALT must be used only for research and development
purposes; RSR13 SODIUM SALT must be used by a technically qualified person or
under the direct supervision of a technically qualified person. RSR13 SODIUM
SALT is manufactured only in small quantities for research and development use.
Other requirements may apply.

<Table>
<Caption>
CHEMICAL NAME                     CAS #    EINECS #    % w/w                      EXPOSURE LIMITS IN AIR
                                                               --------------------------------------------------------------
                                                                      ACGIH                      OSHA
                                                               --------------------- -----------------------------
                                                                   TLV       STEL        PEL       STEL     IDLH     OTHER
                                                                 mg/m(3)    mg/m(3)    mg/m(3)    mg/m(3)  mg/m(3)  mg/m(3)
-----------------------------------------------------------------------------------------------------------------------------
<S>                                <C>        <C>       <C>    <C>            <C>    <C>            <C>      <C>      <C>
RSR13 SODIUM SALT                  NE         NE        100        10         NE          5         NE       NE       NE
                                                               (Inhalable            (Respirable
2-(4-{[(3,5-                                                   Particulate)           Fraction)
Dimethylanilino)carbonyl]methyl}
phenoxy)-2-methylpropionic                                          3                 15 (Total
Acid, Sodium Salt                                              (Respirable              dust)
                                                               Particulate)
(exposure    limits   are   for
"Particulates,   Not  Otherwise
Classified"   unless  otherwise
indicated)
</Table>

NE = Not Established. C = Ceiling Limit. See Section 16 for Definitions of Terms
Used.

NOTE: All Canadian WHMIS and European Community required information is
included. It is located in appropriate sections based on the ANSI Z400.1-1993
format.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF
1934, AS AMENDED.

                             RSR13 SODIUM SALT MSDS
                                   PAGE 1 OF 8
<Page>

Formulation Plan for RSR13 Premix Injection - [ * ]

                            3. HAZARD IDENTIFICATION

EMERGENCY OVERVIEW: This product is an odorless, white to off-white powder. THE
TOXICOLOGICAL PROPERTIES OF THIS COMPOUND HAVE NOT BEEN FULLY INVESTIGATED; ALL
EXPOSURE MUST BE MINIMIZED. This product requires substantial pre-heating before
ignition occurs. When involved in a fire, this material may decompose and
produce irritating vapors and toxic compounds (including carbon monoxide, carbon
dioxide, and nitrogen and sodium oxides). This product is not reactive.
Emergency responders must wear personal protective equipment suitable for the
situation to which they are responding.

                      HAZARDOUS MATERIAL INFORMATION SYSTEM

<Table>
<S>                      <C>         <C>
HEALTH                   (BLUE)      2

FLAMMABILITY             (RED)       1

REACTIVITY               (YELLOW)    0

PROTECTIVE EQUIPMENT                 X

<Caption>
EYES         RESPIRATORY       HANDS       BODY
--------------------------------------------------
<S>          <C>            <C>          <C>
[GRAPHIC]       See         [GRAPHIC]       See
             Section 8                   Section 8
</Table>

                              For research use only

                    SEE SECTION 16 FOR DEFINITION OF RATINGS

SYMPTOMS OF OVEREXPOSURE BY ROUTE OF EXPOSURE: The main routes of occupational
overexposure to this product are via inhalation of dusts and contact with skin
or eyes. The anticipated symptoms of overexposure, via route of exposure, are as
follows:

INHALATION: If dusts of this product are inhaled, they may mildly irritate the
nose and upper respiratory system. Symptoms of such overexposure may include
sneezing, coughing, and nasal congestion. It is currently not known if other
health effects may be experienced after inhalation of this product.

CONTACT WITH SKIN OR EYES: The toxicological properties of this product have not
been fully investigated. It is anticipated that this product may irritate
contaminated skin or eyes. Symptoms of eye contact can include redness, pain,
and watering. Symptoms of skin contact may include itching and redness. It is
currently not known if other human health effects may be experienced after skin
or eye contact with this product. All exposures to this product must be
minimized.

SKIN ABSORPTION: The toxicological properties of this compound have not been
fully investigated; it is not known if direct skin absorption is a significant
route of overexposure. All exposures to this product must be minimized.

INGESTION: Ingestion of this product is not anticipated to be a significant
route of occupational overexposure. The toxicological properties of this product
have not been fully investigated. Ingestion of this product (i.e., through poor
hygiene practices) may irritate the mouth, throat, and other tissues of the
gastrointestinal system. It is currently not known if other health effects may
be experienced after ingestion of this product. All exposures to this product
must be minimized.

INJECTION: Accidental injection of this product, via laceration or puncture by a
contaminated object may cause irritation, pain, and reddening in addition to the
wound.

HEALTH EFFECTS OR RISKS FROM EXPOSURE (AN EXPLANATION IN LAY TERMS).

POTENTIAL HEALTH EFFECTS: THE TOXICOLOGICAL PROPERTIES OF RSR13 SODIUM SALT HAVE
NOT BEEN CHARACTERIZED VIA THE INHALATION, DERMAL, OCULAR, OR ORAL (INGESTION)
ROUTES OF ADMINISTRATION. THEREFORE, LABORATORY CONTROL SYSTEMS AND WORK
PRACTICES SHOULD BE IN PLACE TO MINIMIZE THE POTENTIAL FOR SKIN CONTACT, EYE
CONTACT, INHALATION AND INGESTION WHEN WORKING WITH THIS MATERIAL.

ACUTE: The toxicological properties of this product have not been fully
investigated. It is anticipated that this product may irritate contaminated
skin, eyes, mucous membranes, and other contaminated tissue.

CHRONIC: It is currently not known if health effects may be experienced after
long-term or prolonged overexposure to this product. All exposures to this
product must be minimized.

TARGET ORGANS: The toxicological properties of this product have not been fully
investigated. It is anticipated that the eyes and skin may be target organs.
Animal studies indicate that the circulatory and respiratory systems may be
affected by this product.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF
1934, AS AMENDED.

                             RSR13 SODIUM SALT MSDS
                                   PAGE 2 OF 8
<Page>

Formulation Plan for RSR13 Premix Injection - [ * ]

PART II   WHAT SHOULD I DO IF A HAZARDOUS SITUATION OCCURS?

                              4. FIRST-AID MEASURES

SKIN EXPOSURE: If this product contaminates the skin, IMMEDIATELY begin
decontamination with warm, running water. MINIMUM flushing is for 15 minutes.
Remove exposed or contaminated clothing, taking care not to contaminate eyes.
Victim must seek medical attention if any adverse effect occurs.

EYE EXPOSURE: If this product's dusts or powders enter the eyes, open victim's
eyes while under gently running water. Use sufficient force to open eyelids.
Have victim "roll" eyes. MINIMUM flushing is for 15 minutes. Victim must seek
medical attention.

INHALATION: If dusts of this product are inhaled, remove victim to fresh air. If
necessary, use artificial respiration to support vital functions. Remove or
cover gross contamination to avoid exposure to rescuers.

INGESTION: If this product is swallowed, CALL PHYSICIAN OR POISON CONTROL CENTER
FOR MOST CURRENT INFORMATION. If professional advice is not available, do not
induce vomiting. Victim should drink milk, egg whites, or large quantities of
water. Never induce vomiting or give diluents (milk or water) to someone who is
UNCONSCIOUS, HAVING CONVULSIONS, OR UNABLE TO SWALLOW.

Victims of chemical exposure must be taken for medical attention. Rescuers
should be taken for medical attention if necessary. Take a copy of the label and
the MSDS to health professional with victim.

                            5. FIRE-FIGHTING MEASURES

                                   NFPA RATING

<Table>
<S>             <C>
HEALTH          2

FLAMMABILITY    1

REACTIVITY      0

OTHER
</Table>

                    SEE SECTION 16 FOR DEFINITION OF RATINGS

FLASH POINT:  Not flammable.
AUTOIGNITION TEMPERATURE:  Not applicable.
FLAMMABLE LIMITS (IN AIR BY VOLUME, %):  Not applicable.
FIRE EXTINGUISHING MATERIALS:

    WATER SPRAY:  OK
    OTHER:  "ABC" type
    DRY CHEMICAL:  OK
    CARBON DIOXIDE:  OK
    FOAM:  OK
    HALON:  OK

UNUSUAL FIRE AND EXPLOSION HAZARDS: This material must be substantially
pre-heated before ignition can occur. When involved in a fire, this material may
decompose and produce irritating vapors and toxic compounds (including carbon
monoxide, carbon dioxide, and nitrogen and sodium oxides).

          EXPLOSION SENSITIVITY TO MECHANICAL IMPACT:  Not applicable.
          EXPLOSION SENSITIVITY TO STATIC DISCHARGE:  Not applicable.

SPECIAL FIRE-FIGHTING PROCEDURES: Structural firefighters must wear
Self-Contained Breathing Apparatus and full protective equipment. All personal
protective gear and contaminated fire-response equipment should be
decontaminated with soapy water before being returned to service. Move
fire-exposed containers if it can be done without risk to firefighters. If
possible, prevent runoff water from entering storm drains, bodies of water, or
other environmentally sensitive areas.

                         6. ACCIDENTAL RELEASE MEASURES

SPILL AND LEAK RESPONSE: Uncontrolled releases should be responded to by trained
personnel using pre-planned procedures. Proper protective equipment should be
used. In case of a spill, clear the affected area and protect people.

The proper personal protective equipment for incidental releases (e.g., 10 - 100
g) should be gloves, safety glasses, and a lab coat. In the event of a
non-incidental release (e.g., 1000 g in which excessive dust can be generated),
minimum Personal Protective Equipment should be LEVEL B: TRIPLE-GLOVES (RUBBER
GLOVES AND DOUBLE NITRILE GLOVES), CHEMICAL RESISTANT SUIT AND BOOTS, HARD HAT,
AND SELF-CONTAINED BREATHING APPARATUS.

Wet spilled solid with water before clean up to minimize the generation of
airborne dusts. Sweep up or vacuum spilled material carefully, avoiding the
generation of dusts. Rinse the contaminated area with soapy water. Decontaminate
the area thoroughly. Place all spill residue in an appropriate, labeled
container and seal. Dispose of in accordance with U.S. Federal, State, and local
standards, Canadian hazardous waste disposal regulations, or the appropriate
standards of EC member nations (see Section 13, Disposal Considerations).

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF
1934, AS AMENDED.

                             RSR13 SODIUM SALT MSDS
                                   PAGE 3 OF 8
<Page>

Formulation Plan for RSR13 Premix Injection - [ * ]

PART III  HOW CAN I PREVENT HAZARDOUS SITUATIONS FROM OCCURRING?

                             7. HANDLING AND STORAGE

WORK PRACTICES AND HYGIENE PRACTICES: As with all chemicals, avoid getting this
product ON YOU or IN YOU. Do not eat or drink while handling this material.
Appropriate personal protective equipment must be worn (see Section 8,
Engineering Controls and Personal Protection).

STORAGE AND HANDLING PRACTICES: This product must be used by a technically
qualified person or under the direct supervision of a technically qualified
person. All employees who handle this material should be thoroughly trained to
handle it safely. Areas in which this product is used should be wiped down, so
that this product does not accumulate. Minimize all exposures to this product.
Ensure this product is used with adequate ventilation (refer to Section 8,
Exposure Controls-Personal Protection). Open containers slowly on a stable
surface in areas which have been designated for use of this product. Containers
of this product must be properly labeled.

Store at 25-30 DEG. C (77-86 DEG. F). Store containers in a cool, dry
location, away from direct sunlight and sources of intense heat and moisture.
Store away from incompatible materials (see Section 10, Stability and
Reactivity). Material should be stored in secondary containers. Keep containers
tightly closed when not in use. Inspect all incoming containers before storage,
to ensure containers are properly labeled and not damaged. Empty containers may
contain residual product; therefore, empty containers should be handled with
care.

PROTECTIVE PRACTICES DURING MAINTENANCE OF CONTAMINATED EQUIPMENT: Follow
practices indicated in Section 6 (Accidental Release Measures). If necessary,
make certain application equipment is locked and tagged-out safely.

                   8. EXPOSURE CONTROLS - PERSONAL PROTECTION

VENTILATION AND ENGINEERING CONTROLS: Ensure eyewash/safety shower stations are
in areas where this product is used. Ventilation must be adequate to ensure that
exposures to this product are kept below the limits recommended in Section 2
(Composition and Information on Ingredients).

RESPIRATORY PROTECTION: Respiratory protection is generally not needed for
operations involving this product. If excessive dusts or particulates of this
product will be generated during use, use only protection authorized in 29 CFR
1910.134 or applicable State regulations. Always use supplied air respiration
protection during emergency response situations and under circumstances in which
oxygen levels are below 19.5% or are unknown. Respiratory protection is required
for firefighters, as authorized in the U.S. Federal OSHA Standard (29 CFR
1910.134) or applicable U.S. State, Canadian, or the European Standard EN149.

EYE PROTECTION:  Splash goggles or safety glasses.

HAND PROTECTION: Wear gloves such as latex, for routine use. Use triple gloves
for spill response, as stated in Section 6 (Accidental Release Measures) of this
MSDS.

BODY PROTECTION:  Use body protection appropriate for task (i.e., lab coat).

                       9. PHYSICAL AND CHEMICAL PROPERTIES

RELATIVE VAPOR DENSITY (AIR = 1):  Not applicable.
SPECIFIC GRAVITY (WATER = 1):  Not established.
SOLUBILITY IN WATER (20 DEG. C):  0.5 g/mL
VAPOR PRESSURE, MM HG @ 20 DEG. C:  Not applicable.
FLASH POINT:  Not applicable.
ODOR THRESHOLD:  Not applicable.
EVAPORATION RATE (N-BUAC = 1):  Not applicable.
ODOR THRESHOLD:  Not applicable.
BOILING POINT:  Not established.
PH:  7.3-7.8 (20 DEG. C, 5% solution)
FORM:  Solid.
VISCOSITY:  Not applicable.
COLOR:  White to off-white.
MELTING/FREEZING POINT:  Melts at 242-248 DEG. C (467.6-478.4 DEG. F)
COEFFICIENT OF OIL/WATER DISTRIBUTION (PARTITION COEFFICIENT):  Not determined.
APPEARANCE AND COLOR:  This product is an odorless, white to off-white powder.
HOW TO DETECT THIS SUBSTANCE (WARNING PROPERTIES): The appearance may be a
distinguishing characteristic of this product.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF
1934, AS AMENDED.

                             RSR13 SODIUM SALT MSDS
                                   PAGE 4 OF 8
<Page>

Formulation Plan for RSR13 Premix Injection - [ * ]

                          10. STABILITY AND REACTIVITY

STABILITY: Stable under normal conditions of use and storage, or as directed by
the manufacturer.

DECOMPOSITION PRODUCTS: When exposed extreme temperatures, this product may
generate carbon monoxide, carbon dioxide, and nitrogen and sodium oxides.

MATERIALS WITH WHICH SUBSTANCE IS INCOMPATIBLE: Strong acids, strong bases.

HAZARDOUS POLYMERIZATION: Will not occur.

CONDITIONS TO AVOID: Exposure to or contact with extreme temperatures, excessive
light, incompatible chemicals.

PART IV   IS THERE ANY OTHER USEFUL INFORMATION ABOUT THIS MATERIAL?

                          11. TOXICOLOGICAL INFORMATION

TOXICITY DATA: The toxicological effects of RSR13 SODIUM SALT have not been
characterized by the dermal, ocular, inhalation, or oral (ingestion) routes of
exposure. Consequently, the hazards associated via these routes are unknown.

Mutation in Microorganisms Assay (SALMONELLA TYPHIMURIUM AND ESCHERICHIA COLI,
   bacteria) = 250-5000 ug/plate; no effect
Lymphoma Mutagenesis Assay (L5178Y TK+/- lymphoma cells, mouse) = 100-5000
   ug/plate; no effect
Induction of Micronucleated Polychromatic Erythrocytes Assay (intraperitoneal,
   CD-1 mouse) = 80-500 mg/kg; no effect
Irritancy (intradermal, mouse) = 2-4 mg; moderate
Irritancy (intravascular/perivascular, rabbit) = 10-40 mg/mL; histopathologic,
   dermal effects
TD (intravenous, rat) = 100-800 mg/kg/15-30 minutes; blood, skin, vascular
   effects
TD (intravenous, dog) = 100-800 mg/kg/15-30 minutes; cardiovascular,
   gastrointestinal effects
LD (intravenous, dog) = 800 mg/kg/30 minutes/supplemental oxygen; cardiovascular
   effects
LD (intravenous, dog) = 400 mg/kg/15 minutes/supplemental oxygen;
   gastrointestinal effects
TD (intravenous, rat) = 600-1600 mg/kg/7 days; ocular effects
TD (intravenous, rat) = 1000-1600 mg/kg/7 days; lethargy, excessive thirst,
   respiratory effects
LD (intravenous, rat) = 1200-1600 mg/kg/7 days
LD (intravenous, rat) = 1000 mg/kg
TD (intravenous, rat) = 800-1000 mg/kg/14 days; biochemical effects
LD (intravenous, dog) = 600 mg/kg/5 days
TD (intravenous, dog) = 200-600 mg/kg/7 days; gastrointestinal, cardiovascular,
   blood effects
TD (intravenous, dog) = 200-400 mg/kg/14 days; gastrointestinal, cardiovascular
   effects
NOEL (intravenous, dog) = 100 mg/kg
NOEL (intravenous, rabbit) = 10 mg/mL
TD (intravenous, dog) = 21.8 mg/kg/hour/5 days/continuous; cardiovascular
   effects
TD (intravenous, dog) = 0.5 mg/kg/minute/5 days/continuous; cyanosis, pale
   mucous membranes

SUSPECTED CANCER AGENT: This product is not found on the following lists:
FEDERAL OSHA Z LIST, NTP, IARC, or CAL/OSHA and therefore is neither considered
to be nor suspected to be a cancer-causing agent by these agencies.

IRRITANCY OF PRODUCT: It is anticipated that this product may irritate the
respiratory system, mucous membranes, skin, and eyes.

SENSITIZATION TO THE PRODUCT: It is currently not known if this product produces
sensitization effects in humans.

REPRODUCTIVE TOXICITY INFORMATION: It is currently not known if this product
produces reproductive effects in humans.

   MUTAGENICITY: There are currently no human mutagenicity data available for
   this product.
   EMBRYOTOXICITY: There are currently no human embryotoxicity data available
   for this product.
   TERATOGENICITY: There are currently no human teratogenicity data available
   for this product.
   REPRODUCTIVE TOXICITY: There are currently no human reproductive toxicity
   data available for this product.

A MUTAGEN IS A CHEMICAL WHICH CAUSES PERMANENT CHANGES TO GENETIC MATERIAL (DNA)
SUCH THAT THE CHANGES WILL PROPAGATE THROUGH GENERATIONAL LINES. AN EMBRYOTOXIN
IS A CHEMICAL WHICH CAUSES DAMAGE TO A DEVELOPING EMBRYO (I.E. WITHIN THE FIRST
EIGHT WEEKS OF PREGNANCY IN HUMANS), BUT THE DAMAGE DOES NOT PROPAGATE ACROSS
GENERATIONAL LINES. A TERATOGEN IS A CHEMICAL WHICH CAUSES DAMAGE TO A
DEVELOPING FETUS, BUT THE DAMAGE DOES NOT PROPAGATE ACROSS GENERATIONAL LINES. A
REPRODUCTIVE TOXIN IS ANY SUBSTANCE WHICH INTERFERES IN ANY WAY WITH THE
REPRODUCTIVE PROCESS.

BIOLOGICAL EXPOSURE INDICES: Currently, there are no Biological Exposure Indices
(BEIs) associated with this compound.

MEDICAL CONDITIONS AGGRAVATED BY EXPOSURE: The toxicological properties of this
product have not been fully investigated. Skin, cardiovascular, and blood
disorders may be aggravated by exposure to this product. It is not currently
known if other medical conditions may be aggravated by overexposures to this
product.

RECOMMENDATIONS TO PHYSICIANS: Treat symptoms and eliminate overexposure.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF
1934, AS AMENDED.

                             RSR13 SODIUM SALT MSDS
                                   PAGE 5 OF 8
<Page>

Formulation Plan for RSR13 Premix Injection - [ * ]

                           12. ECOLOGICAL INFORMATION

ALL WORK PRACTICES MUST BE AIMED AT ELIMINATING ENVIRONMENTAL CONTAMINATION.

ENVIRONMENTAL STABILITY: This product will slowly degrade under ambient
environmental conditions to generate a variety of organic compounds.

EFFECT OF MATERIAL ON PLANTS OR ANIMALS: This product may be harmful to
contaminated plant and animal life.

EFFECT OF CHEMICAL ON AQUATIC LIFE: Releases of large quantities of this product
may be detrimental to an aquatic environment.

                           13. DISPOSAL CONSIDERATIONS

PREPARING WASTES FOR DISPOSAL: Waste disposal must be in accordance with
appropriate U.S. Federal, State, and local regulations or with regulations of
the EC and its member states or Canada and its Provinces. This product, if
unaltered by use, may be disposed of by treatment at a permitted facility or as
advised by your local hazardous waste regulatory authority.

EPA WASTE NUMBER: Not applicable to wastes consisting only of this product.

                         14. TRANSPORTATION INFORMATION

THIS MATERIAL IS NOT HAZARDOUS AS DEFINED BY 49 CFR 172.101 BY THE U.S.
DEPARTMENT OF TRANSPORTATION. This is a tentative assignment pending further
toxicological testing.

PROPER SHIPPING NAME:                     Not applicable.
HAZARD CLASS NUMBER AND DESCRIPTION:      Not applicable.
UN IDENTIFICATION NUMBER:                 Not applicable.
PACKING GROUP:                            Not applicable.
DOT LABEL(S) REQUIRED:                    Not applicable.
NORTH AMERICAN EMERGENCY RESPONSE GUIDEBOOK NUMBER, 1996:  Not applicable.
MARINE POLLUTANT: This product is not designated as a marine pollutant, per
Appendix B to 49 CFR 172.101.
TRANSPORT CANADA, TRANSPORTATION OF DANGEROUS GOODS REGULATIONS: THIS MATERIAL
IS NOT CONSIDERED AS DANGEROUS GOODS. This is a tentative assignment pending
further toxicological testing.

INTERNATIONAL AIR TRANSPORT ASSOCIATION (IATA): This material is not considered
as dangerous goods. This is a tentative assignment pending further toxicological
testing.

INTERNATIONAL MARITIME ORGANIZATION (IMO): This material is not considered as
dangerous goods. This is a tentative assignment pending further toxicological
testing.

EUROPEAN AGREEMENT CONCERNING THE INTERNATIONAL CARRIAGE OF DANGEROUS GOODS BY
ROAD (ADR): This material is not considered by the United Nations Economic
Commission for Europe to be dangerous goods. This is a tentative assignment
pending further toxicological testing.

                           15. REGULATORY INFORMATION

ADDITIONAL U.S. REGULATIONS:

U.S. SARA REPORTING REQUIREMENTS: This product is not subject to the reporting
requirements of Sections 302, 304, and 313 of Title III of the Superfund
Amendments and Reauthorization Act.

U.S. SARA THRESHOLD PLANNING QUANTITY: Not applicable.

U.S. TSCA INVENTORY STATUS: This substance is not included in the TSCA
inventory. In accordance with 40 CFR 720.36, this substance must be used only
for research and development purposes. Other requirements may apply.

U.S. CERCLA REPORTABLE QUANTITY (RQ): Not applicable.

OTHER U.S. FEDERAL REGULATIONS: Not applicable

U.S. STATE REGULATORY INFORMATION: This product is not covered under specific
State regulations, as denoted below:

ALASKA - DESIGNATED TOXIC AND HAZARDOUS SUBSTANCES:  No.
CALIFORNIA - PERMISSIBLE EXPOSURE LIMITS FOR CHEMICAL CONTAMINANTS:  No.
FLORIDA - SUBSTANCE LIST:  No.
ILLINOIS - TOXIC SUBSTANCE LIST:  No.
KANSAS - SECTION 302/313 LIST:  No.
MASSACHUSETTS - SUBSTANCE LIST:  No.
MICHIGAN - CRITICAL MATERIALS REGISTER:  No.
MINNESOTA - LIST OF HAZARDOUS SUBSTANCES:  No.
MISSOURI - EMPLOYER INFORMATION/TOXIC SUBSTANCE LIST:  No.
NEW JERSEY - RIGHT TO KNOW HAZARDOUS SUBSTANCE LIST:  No.
NORTH DAKOTA - LIST OF HAZARDOUS CHEMICALS, REPORTABLE QUANTITIES:  No.
PENNSYLVANIA - HAZARDOUS SUBSTANCE LIST:  No.
RHODE ISLAND - HAZARDOUS SUBSTANCE LIST: No.
TEXAS - HAZARDOUS SUBSTANCE LIST:  No.
WEST VIRGINIA - HAZARDOUS SUBSTANCE LIST:  No.
WISCONSIN - TOXIC AND HAZARDOUS SUBSTANCES:  No

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF
1934, AS AMENDED.

                             RSR13 SODIUM SALT MSDS
                                   PAGE 6 OF 8
<Page>

Formulation Plan for RSR13 Premix Injection - [ * ]

CALIFORNIA PROPOSITION 65: This product is not on the California Proposition 65
lists.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF
1934, AS AMENDED.

                             RSR13 SODIUM SALT MSDS
                                   PAGE 7 OF 8
<Page>

Formulation Plan for RSR13 Premix Injection - [ * ]

                     15. REGULATORY INFORMATION (CONTINUED)

ANSI LABELING (Z129.1, PROVIDED TO SUMMARIZE OCCUPATIONAL HAZARD INFORMATION):
WARNING! THE TOXICOLOGICAL PROPERTIES OF THIS COMPOUND HAVE NOT BEEN FULLY
INVESTIGATED. MAY CAUSE RESPIRATORY SYSTEM, EYE, AND SKIN IRRITATION. FOR
RESEARCH USE ONLY. ALL EXPOSURE MUST BE MINIMIZED. Do not take internally. Avoid
contact with skin, eyes, and clothing. Keep container closed. Wear gloves,
goggles, and suitable body protection. FIRST-AID: If swallowed, do not induce
vomiting. Never give anything by mouth to an unconscious person. In case of
contact, immediately flush skin with copious amounts of warm water for 15
minutes. Remove contaminated clothing and shoes. If inhaled, remove to fresh
air. If not breathing, give artificial respiration. If breathing is difficult,
give oxygen. If ingested, do not induce vomiting. Seek medical attention. IN
CASE OF FIRE: Use water fog, dry chemical or CO2, or alcohol foam. IN CASE OF
SPILL: Sweep up or vacuum spilled product. Decontaminate area with soapy water.
Place in a suitable container. Refer to MSDS for additional information.

ADDITIONAL CANADIAN REGULATIONS:

CANADIAN DSL/NDSL STATUS: This substance is not included in the DSL/NDSL. This
substance must be used only for research and development purposes. Other
requirements may apply.

OTHER CANADIAN REGULATIONS: Not applicable.

CANADIAN ENVIRONMENTAL PROTECTION ACT (CEPA) PRIORITIES SUBSTANCES LISTS: The
components of this product are not on the CEPA Priorities Substances Lists.

CANADIAN WHMIS SYMBOLS: Currently, the WHMIS classification for this product is
unassigned, pending further toxicological studies.

EUROPEAN COMMUNITY INFORMATION FOR PRODUCT:

EC LABELING/CLASSIFICATION: This product does not meet the definition of any
hazard class as defined by the European Community Council Directive 67/548/EEC.
Additionally, this Directive is not applicable to medicinal products (per
Article 1, 88/379/EEC).

EC HAZARD CLASSIFICATION: Not applicable.
EC RISK PHRASES: Not applicable.
EC SAFETY PHRASES: Not applicable.
EUROPEAN ECONOMIC COMMUNITY ANNEX II HAZARD SYMBOL: Not applicable.

NOTE:  This product's components are classified by the EC, as follows:

2-(4-{[(3,5-DIMETHYLANILINO)CARBONYL]METHYL}PHENOXY)-2-METHYLPROPIONIC ACID,
SODIUM SALT:
EC EINECS/ELINCS NUMBER: Not established.
EC CLASSIFICATION: An official classification for this substance has not been
published in Commission Directives 93/72/EEC, 94/69EC, and 96/54/EC.

                              16. OTHER INFORMATION

PREPARED BY:                  CHEMICAL SAFETY ASSOCIATES, Inc.
                              9163 Chesapeake Drive, San Diego, CA 92123-1002
                              (619)  565-0302

DATE OF PRINTING:             August 29, 2002

THE VENDEE (OR ANY OTHER THIRD PARTY) ASSUMES FULL RISK AND RESPONSIBILITY FOR
ANY INJURY OR DAMAGE THAT MAY OCCUR FROM THE MANUFACTURE, USE OR OTHER EXPOSURE
TO THE MATERIAL. NO WARRANTY IS EXPRESSED OR IMPLIED REGARDING THE ACCURACY OF
THE DATA SET FORTH HEREIN OR THE RESULTS THAT MAY BE OBTAINED FROM THE USE OR
RELIANCE THEREOF. ALLOS THERAPEUTICS ASSUMES NO RESPONSIBILITY FOR ANY INJURY
THAT MAY ARISE FROM THE MANUFACTURE, USE OR OTHER EXPOSURE TO THE MATERIAL IF
REASONABLE SAFETY PROCEDURES ARE NOT ADHERED TO AS STIPULATED IN THE DATA SHEET
ATTACHED HERETO. ADDITIONALLY, ALLOS THERAPEUTICS ASSUMES NO RESPONSIBILITY FOR
INJURY TO ANY PERSON PROXIMATELY CAUSED BY THE INAPPROPRIATE OR UNINTENDED USE
OF THE MATERIAL EVEN IF SUCH REASONABLE SAFETY PROCEDURES ARE FOLLOWED.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF
1934, AS AMENDED.

                             RSR13 SODIUM SALT MSDS
                                   PAGE 8 OF 8
<Page>

Formulation Plan for RSR13 Premix Injection - [ * ]

                              DEFINITIONS OF TERMS

A large number of abbreviations and acronyms appear on a MSDS. Some of these
which are commonly used include the following:

CAS #: This is the Chemical Abstract Service Number which uniquely identifies
each constituent. It is used for computer-related searching.

EXPOSURE LIMITS IN AIR:
ACGIH - American Conference of Governmental Industrial Hygienists, a
professional association which establishes exposure limits.

TLV - THRESHOLD LIMIT VALUE - an airborne concentration of a substance which
represents conditions under which it is generally believed that nearly all
workers may be repeatedly exposed without adverse effect. The duration must be
considered, including the 8-hour TIME WEIGHTED AVERAGE (TWA), the 15-minute
SHORT TERM EXPOSURE LIMIT, and the instantaneous CEILING LEVEL. Skin adsorption
effects must also be considered.

OSHA - U.S. Occupational Safety and Health Administration.

PEL - PERMISSIBLE EXPOSURE LIMIT - This exposure value means exactly the same as
a TLV, except that it is enforceable by OSHA. The OSHA Permissible Exposure
Limits are based in the 1989 PELs and the June, 1993 Air Contaminants Rule
(FEDERAL REGISTER: 58: 35338-35351 and 58: 40191). Both the current PELs and the
vacated PELs are indicated. The phrase, "Vacated 1989 PEL," is placed next to
the PEL which was vacated by Court Order.

IDLH - IMMEDIATELY DANGEROUS TO LIFE AND HEALTH - This level represents a
concentration from which one can escape within 30-minutes without suffering
escape-preventing or permanent injury. THE DFG - MAK is the Republic of
Germany's Maximum Exposure Level, similar to the U.S. PEL. NIOSH is the National
Institute of Occupational Safety and Health, which is the research arm of the
U.S. Occupational Safety and Health Administration (OSHA). NIOSH issues exposure
guidelines called Recommended Exposure Levels (RELs). When no exposure
guidelines are established, an entry of NE is made for reference.

HAZARD RATINGS:
HAZARDOUS MATERIALS IDENTIFICATION SYSTEM: HEALTH HAZARD: 0 (minimal acute or
chronic exposure hazard); 1 (slight acute or chronic exposure hazard); 2
(moderate acute or significant chronic exposure hazard); 3 (severe acute
exposure hazard; onetime overexposure can result in permanent injury and may be
fatal); 4 (extreme acute exposure hazard; onetime overexposure can be fatal).
FLAMMABILITY HAZARD: 0 (minimal hazard); 1 (materials that require substantial
pre-heating before burning); 2 (combustible liquid or solids; liquids with a
flash point of 38-93 DEG. C [100-200 DEG. F]); 3 (Class IB and IC flammable
liquids with flash points below 38 DEG. C [100 DEG. F]); 4 (Class IA
flammable liquids with flash points below 23 DEG. C [73 DEG. F] and boiling
points below 38 DEG. C [100 DEG. F]). REACTIVITY HAZARD: 0 (normally
stable); 1 (material that can become unstable at elevated temperatures or which
can react slightly with water); 2 (materials that are unstable but do not
detonate or which can react violently with water); 3 (materials that can
detonate when initiated or which can react explosively with water); 4 (materials
that can detonate at normal temperatures or pressures).

NATIONAL FIRE PROTECTION ASSOCIATION: HEALTH HAZARD: 0 (material that on
exposure under fire conditions would offer no hazard beyond that of ordinary
combustible materials); 1 (materials that on exposure under fire conditions
could cause irritation or minor residual injury); 2 (materials that on intense
or continued exposure under fire conditions could cause temporary incapacitation
or possible residual injury); 3 (materials that can on short exposure could
cause serious temporary or residual injury); 4 (materials that under very short
exposure could cause death or major residual injury). FLAMMABILITY HAZARD AND
REACTIVITY HAZARD: Refer to definitions for "Hazardous Materials Identification
System".

FLAMMABILITY LIMITS IN AIR:
Much of the information related to fire and explosion is derived from the
National Fire Protection Association (NFPA). LEL - the lowest percent of vapor
in air, by volume, that will explode or ignite in the presence of an ignition
source. UEL - the highest percent of vapor in air, by volume, that will explode
or ignite in the presence of an ignition source.

TOXICOLOGICAL INFORMATION:
Possible health hazards as derived from human data, animal studies, or from the
results of studies with similar compounds are presented. Definitions of some
terms used in this section are: LD50 - Lethal Dose (solids & liquids) which
kills 50% of the exposed animals; LC50 - Lethal Concentration (gases) which
kills 50% of the exposed animals; PPM concentration expressed in parts of
material per million parts of air or water; MG/M(3) concentration expressed in
weight of substance per volume of air; MG/KG quantity of material, by weight,
administered to a test subject, based on their body weight in kg. Data from
several sources are used to evaluate the cancer-causing potential of the
material. The sources are: IARC - the International Agency for Research on
Cancer; NTP - the National Toxicology Program, RTECS - the Registry of Toxic
Effects of Chemical Substances, OSHA and CAL/OSHA. IARC and NTP rate chemicals
on a scale of decreasing potential to cause human cancer with rankings from 1 to
4. Subrankings (2A, 2B, etc.) are also used. Other measures of toxicity include
TDLO, the lowest dose to cause a symptom and TCLO the lowest concentration to
cause a symptom; TDO, LDLO, and LDO, or TC, TCO, LCLO, and LCO, the lowest dose
(or concentration) to cause death. BEI - Biological Exposure Indices, represent
the levels of determinants which are most likely to be observed in specimens
collected from a healthy worker who has been exposed to chemicals to the same
extent as a worker with inhalation exposure to the TLV.

REGULATORY INFORMATION:
This section explains the impact of various laws and regulations on the
material. EPA is the U.S. Environmental Protection Agency. WHMIS is the Canadian
Workplace Hazardous Materials Information System. DOT and TC are the U.S.
Department of Transportation and the Transport Canada, respectively. Other
acronyms used are: SUPERFUND AMENDMENTS AND REAUTHORIZATION ACT (SARA); the
TOXIC SUBSTANCE CONTROL ACT (TSCA); Marine Pollutant status according to the
DOT; California's Safe Drinking Water Act (PROPOSITION 65); the COMPREHENSIVE
ENVIRONMENTAL RESPONSE, COMPENSATION, AND LIABILITY ACT (CERCLA OR SUPERFUND);
and various state regulations. This section also includes information on the
precautionary warnings which appear on the materials package label.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF
1934, AS AMENDED.

                             RSR13 SODIUM SALT MSDS
                                   PAGE 9 OF 8
<Page>

Formulation Plan for RSR13 Premix Injection - [ * ]

                                                                   Page 15 of 17

                                 Attachment III.

                                 EHS ASSESSMENT
                           FOR RSR13 PREMIX INJECTION

                                    (2 PAGES)

                              -BAXTER CONFIDENTIAL-
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF
1934, AS AMENDED.

<Page>

R&D TESTING PROTOCOL NUMBER [ * ]

    Environmental, Health and Safety Requirements for RSR13 Premix Injection

BAXTER                            Interoffice Memorandum - For Internal Use Only

To:   Christine Rebbeck                  Date:  April 11, 2000

                                         From:  Environmental, Health and Safety

Cc:   Frank White
      EHS Pharmaceutical File

                                         Re:    WAP/PPE Assessment for RSR-13

Michael Finnamore performed a Personal Protective Equipment (PPE) and Workplace
(WAP) assessment of the Pilot Plant operations on January 8, 2000. The review
included those tasks associated with the manipulation of RSR-13 raw materials as
well as solutions. RSR-13 is considered a Category [ * ] pharmaceutical agent.
This assessment was performed to ensure that the proper procedures and PPE are
used when handling RSR-13 powders and solutions.

After reviewing the operations Environmental, Health and Safety have the
following recommendations:

                    1.   Good laboratory practices should be followed; Safety
                         glasses with side shields, latex or nitrile gloves and
                         a lab coat should be worn at all times when working
                         with drug solutions. When working with the dry powder
                         disposable tyvek lab coats or aprons shall be utilized.
                         The drug powder must be handled in a hood (Class II,
                         Type B2 100% Exhaust) at all times except during oven
                         drying operations. When handling RSR-13 solutions and
                         second pair of gloves shall be worn to prevent possible
                         skin contact.

                    2.   Powdered Air Purifying Respirator (PAPR) with HEPA
                         filter cartridges will be worn during the weighing of
                         the powder and the charging of the vessel. Once the
                         powder is in solution respiratory protection may be
                         removed.

                    3.   If a spill of greater than 500 grams occurs,
                         immediately contact security at ext. 4444, for spill
                         response. All spills must be reported to EHS.

                    4.   The RSR-13 waste solutions may not be disposed of down
                         sink drains. In accordance with SOP [ * ], solutions
                         must be collected in a 5-gallon polyethylene pail. The
                         container must be labeled with a "Waste Product
                         Identification Label", stating "aqueous drug solution
                         containing RSR-13" and any additional contents in
                         solution. All disposable materials used in the RSR-13
                         process must be disposed of as Pharmaceutical Research
                         Debris (PRD) and placed into a 40 gallon, red, reusable
                         sharps container. Please refer to SOP [ * ] for
                         procedure on submitting pharmaceutical research debris
                         on the materials for disposition form. Dry powder waste
                         must be handled in the same manner as the disposable
                         materials.

                              -BAXTER CONFIDENTIAL-
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF
1934, AS AMENDED.

<Page>

R&D TESTING PROTOCOL NUMBER [ * ]

                    5.   In case of contact with solution or powder, the
                         contaminated PPE should be removed and any exposed skin
                         should be washed thoroughly. The occupational nurse
                         should be notified immediately after washing the skin.

                    6.   After cleaning the area, the employee should wash hands
                         thoroughly for good personal hygiene.

                    7.   All glassware, which comes in touch with the powder
                         drug material, must be first rinsed with proper solvent
                         prior to being transported to glass laundry. All
                         rinse-aid may be disposed of down the drain.

                    8.   All employees must participate in a Level 1 health
                         surveillance screening. If an employee is has not
                         completed a Level 1 screening, is using prescription
                         medications, or is under a physicians care, they should
                         contact Lena Kalemba at extension 5725.

                    9.   All employees must receive training on hazard
                         communication prior to working with RSR-13 powders or
                         solutions. Contact the occupational health nurse to
                         complete this training.

These recommendations are only valid for this specific drug and process. Any
changes in the process or material being tested will need to be reassessed.
Please contact EHS to obtain new assessment.

CHARACTERISTICS OF RSR-13

RSR-13 has not been shown to be incompatible with other chemical materials.

Absorbed readily through the skin. Avoid contact when working with material.

Large acute exposures may lead to hypoxemia.

Chronic effects of exposure (therapeutic):

     -    Vomiting
     -    Decreased red blood counts
     -    Anemia
     -    Thrombrosis

These are not all of the symptoms. Contact EHS for a more extensive list.

There are no carcinogenic, mutagenic or teratogenic effects at levels consistent
with the occupational setting.

The recommended occupational exposure to airborne RSR-13 is 5.0 ms/m (TO THE
POWER OF 3. Monitoring will be conducted to ensure that exposures during the
weighing and slurry tasks are below this occupational exposure level.

                              -BAXTER CONFIDENTIAL-
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF
1934, AS AMENDED.

<Page>

R&D TESTING PROTOCOL NUMBER [ * ]

If you have any questions about these recommendations or concerns contact Jeff
Wynveen at ext. 4912 or Michael Finnamore at ext. 4720.

                              -BAXTER CONFIDENTIAL-
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF
1934, AS AMENDED.

<Page>

Formulation Plan for RSR13 Premix Injection - [ * ]

                                                                        16 of 17

                                 ATTACHMENT IV.

                           CHEMICAL STRUCTURE OF RSR13

                                   (FREE ACID)

                                      [ * ]

                              -BAXTER CONFIDENTIAL-
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF
1934, AS AMENDED.

<Page>

Formulation Plan for RSR13 Premix Injection - [ * ]

                                                                        17 of 17

                                  ATTACHMENT V.

                     SOLUBILITY PROFILE OF RSR13 SODIUM SALT
                       AS A FUNCTION OF pH AND TEMPERATURE

                                      [ * ]

                              -BAXTER CONFIDENTIAL-
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF
1934, AS AMENDED.

<Page>

                                    EXHIBIT C
                                 REGULATORY PLAN

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF
1934, AS AMENDED.

                                       C-1
<Page>

TO:  Distribution                                     DATE:  Dec. 10, 2002

                                                      FROM:  Stacey Thompson
                                                             ext. 5829, RLT-10
                                                             /s/ Stacey Thompson

DISTRIBUTION:  RLT-08: R. Crombie, M. Kray, T. Turkula
               RLT-10: P. Barsanti, M. Sadowski, K. Paddock
               WG3-1S: J. Fosco, E. Chess, L. Best, L. Baker
               WG3-3S: S. Brynjelsen, N. Raghavan, R. Chilamkurti, F. White
               MPWG-E1: P. Hartman
               Cleveland, MS: M. Kessler, T. Smith, M. Jackson, C. Cascio
               Nivelles, Belgium: V. Lemoine, E. Behets
               Mississauga, Canada: P. Bonnici
               Allos Therapeutics, Inc.: D. Johnson, J. Etter, M. Herzig

RE:  REGULATORY PLAN FOR RSR13 INJECTION (EFAPROXIRAL SODIUM), ALLOS
     THERAPEUTICS, INC., ISSUED DEC. 9, 2002

A copy of the issued Regulatory Plan for RSR13 Injection is attached for your
records.

Thank you.

Stacey S. Thompson
Med. Del. Regulatory Affairs

                     Allos Confidential/Baxter Confidential
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF
1934, AS AMENDED.

<Page>

                         RSR13 Injection (efaproxiral sodium) in Glass Container
                                                                 Regulatory Plan
                                                                          Page 1

                                 REGULATORY PLAN

                                                            REF. PROCEDURE [ * ]

PROJECT TITLE: RSR13 Injection (efaproxiral sodium) in Glass Container

PROJECT NUMBER: [ * ]                   PQA NUMBER: [ * ]

SUBMISSION TYPE: USA: NDA
                 EU: MAA using the centralized procedure
                 Canada: NDS

USA REVIEWING AGENCY/DIVISION: FDA Division of Oncologic Drug Products

                                   APPROVALS*

PREPARER (S. THOMPSON): /S/ S. THOMPSON                          DATE: 9/16/02

USA REGULATORY AFFAIRS (P. BARSANTI): /S/ P. BARSANTI            DATE: 9/30/02

TECHNICAL LEADER (S. BRYNJELSEN): /S/ S. BRYNJELSEN              DATE: 9/26/02

STABILITY OPERATIONS (J. FOSCO): /S/ J. FOSCO                    DATE: 10/10/02

PRODUCT DEVELOPMENT (N. RAGHAVAN): /S/ N. RAGHAVAN               DATE: 10/10/02

TECHNICAL SERVICES (L. BEST): /S/ L. BEST                        DATE: 9/24/02

PHARM. TECHNOLOGY (R. CHILAMKURTI): /S/ R. CHILAMKURTI           DATE: 10/18/02

STERILITY ASSURANCE (M. SADOWSKI): /S/ M. SADOWSKI               DATE: 9/20/02

ENVIRON. AFFAIRS (P. HARTMAN): /S/ P. HARTMAN                    DATE: 9/19/02

TECHNICAL RESOURCES (E. CHESS): /S/ E. CHESS                     DATE: 9/18/02

PLANT QUALITY MGMT. (M. JACKSON): /S/ M. JACKSON                 DATE: 10/14/02

PLANT MANUFACTURING (T. SMITH): /S/ T. SMITH                     DATE: 10/10/02

USA PROJECT MGMT./BUSINESS UNIT (R. CROMBIE): /S/ R. CROMBIE     DATE: 9/26/02

EU REGULATORY AFFAIRS (V. LEMOINE): /S/ V. LEMOINE               DATE: 9/26/02

CANADA REGULATORY AFFAIRS (P. BONNICI): /S/ P. BONNICI           DATE: 10/9/02

     *APPROVAL SIGNIFIES THAT THE DOCUMENT HAS BEEN REVIEWED TO ENSURE THAT IT
     ACCURATELY REFLECTS THE DATA, SPECIFICATIONS, AND REGULATORY AND COMPENDIAL
     REQUIREMENTS BASED UPON AREA OF EXPERTISE.

                     Allos Confidential/Baxter Confidential
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF
1934, AS AMENDED.

<Page>

                         RSR13 Injection (efaproxiral sodium) in Glass Container
                                                                 Regulatory Plan
                                                                          Page 2

             ALLOS THERAPEUTICS, INC. CONCURRENCE ON REGULATORY PLAN

Allos has reviewed the attached document and concurs with its contents.

Signature: /s/ Douglas G. Johnson                  Date:  Dec. 6, 2002
           --------------------------------------        ------------------

Douglas G. Johnson
Vice President, Manufacturing

Signature: /s/ Jeffrey B. Etter                    Date:  Dec. 2, 2002
           --------------------------------------        ------------------

Jeffrey B. Etter
Director, Drug Product

Signature: /s/ Marcus Herzig                       Date:  Dec. 9, 2002
           --------------------------------------        ------------------

Marcus Herzig
Vice President, Regulatory Affairs

                     Allos Confidential/Baxter Confidential
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF
1934, AS AMENDED.

<Page>

                         RSR13 Injection (efaproxiral sodium) in Glass Container
                                               Regulatory Plan - Issued 12/09/02
                                                                          Page 3

                                 REGULATORY PLAN

REGULATORY APPROACH/GENERAL INFORMATION

I.   OVERVIEW

     Allos Therapeutics, Inc. has contracted with Baxter to manufacture RSR13
     Injection (efaproxiral sodium) in a glass container. RSR13 Injection is
     presently in Phase III clinical trials to demonstrate safety and efficacy
     as an adjunct to radiation treatment of solid tumors. RSR13 Injection
     consists of 20 mg/mL efaproxiral free acid in a diluent of [ * ] sodium
     chloride and [ * ] phosphate buffer at pH [ * ]. The product is packaged in
     a 500 mL glass bottle ([ * ], Type I) with a gray stopper (West Formulation
     [ * ]).

     Allos has already initiated stability and clinical studies using RSR13
     Injection manufactured at Akorn [ * ] to [ * ] to [ * ] manufactured by
     Baxter. Production for North America will occur at Baxter's Cleveland,
     Mississippi facility. Production for the European Union will occur
     initially at the Cleveland, Mississippi facility and a European facility
     may also be brought on line. Stability and clinical production at Baxter is
     targeted for [ * ]. Allos intends to submit stability data from [ * ] in
     the regulatory submissions and [ * ].

     The development of RSR13 Injection is the responsibility of a project team
     that includes representatives from Baxter (USA, Europe, Canada) and Allos.
     The objective of the project team is to develop a product that will meet
     the requirements of the intended markets of the USA, European Union (EU),
     and Canada.

II.  REGULATORY CONSIDERATIONS

     A.   Types of New Drug Submissions

          The overall regulatory strategy for this product is the responsibility
          of Allos. Allos will own and be responsible for making the regulatory
          submissions for RSR13 Injection in US, EU, and Canada. The submissions
          will be made in the Common Technical Document (CTD) format on paper
          with an electronic version provided to facilitate review. In each
          region, RSR13 Injection is categorized as a new drug; therefore, the
          submissions will be as follows:

        US: New Drug Application (NDA) - submitted in modules as follows:
                             Pharm/Tox - [ * ] 2003

                     Allos Confidential/Baxter Confidential
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF
1934, AS AMENDED.

<Page>

                         RSR13 Injection (efaproxiral sodium) in Glass Container
                                               Regulatory Plan - Issued 12/09/02
                                                                          Page 4

                                CMC - [ * ] 2003
                              Clinical - [ * ] 2003

                    EU:  Marketing Authorization Application (MAA) using
                         centralized procedure, with [ * ] as the likely
                         rapporteur state (the sponsor's choice for the
                         rapporteur state is not guaranteed). Submission is
                         planned approximately [ * ] after US clinical
                         submission.

                    Canada: New Drug Submission (NDS)

     B.   Master Files

          Baxter has US Drug Master File [ * ] for the manufacture of [ * ] at
          Cleveland, MS. Baxter will update the DMF to reflect the RSR13
          Injection container-closure system and [ * ] process. For the US
          submission, Baxter will supply Allos a summary of the [ * ] (to
          facilitate comparison with the [ * ]) and a cross-reference
          authorization letter to DMF [ * ] for detailed information about the [
          * ]. For the EU and Canadian regulatory submissions, the appropriate
          information will be supplied directly to Allos at a level of detail
          necessary to meet the regulatory requirements in each region.

          The API supplier, [ * ] a DMF for efaproxiral sodium in the affected
          regions. The required information concerning the manufacture of the
          API will be submitted [ * ].

     C.   INDs and Applications for Clinical Studies

          Allos has filed an IND for RSR13 Injection in the US. Allos will be
          responsible for updating its US IND and any other non-US applications
          to allow for the use of Baxter-manufactured product in its clinical
          studies.

          For the IND, Baxter is anticipated to provide the following to Allos:

               -    A narrative description of the manufacturing process.
               -    A flow diagram of the manufacturing process.
               -    Brief description of manufacturing equipment.
               -    Release testing results in COA form.
               -    List of raw materials, suppliers, and specifications.
               -    Description of container/closure components (if different
                    from [ * ]).
               -    [ * ].

                     Allos Confidential/Baxter Confidential
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF
1934, AS AMENDED.

<Page>

                         RSR13 Injection (efaproxiral sodium) in Glass Container
                                               Regulatory Plan - Issued 12/09/02
                                                                          Page 5

               -    Appropriate Qualified Person (QP) Documents for release of
                    clinical trial material in Europe.

     D.   CTD Submission Development and Review

          Regulatory submission documents prepared by Baxter will be reviewed
          and approved by [ * ].

          The official regulatory submission documents released [ * ] will be
          provided to Allos on hard copy (i.e., paper). Documents that are
          available electronically will be prepared as Microsoft WORD documents
          and forwarded to Allos on a CD-ROM as a courtesy to facilitate
          preparation of the CTD. Some Baxter records are only available in hard
          copy (e.g., stability data tables, supplier COAs, executed batch
          records from Cleveland). These will be supplied as hard copy only and
          can then be scanned by Allos into suitable electronic format (e.g.,
          .pdf), if desired. Alternate document preparation arrangements are
          acceptable if requirements are mutually agreed to beforehand.

          The Chemistry, Manufacturing, and Controls (CMC) information for the
          regulatory submissions in the CTD format will be developed jointly by
          Allos and Baxter based on their relative areas of expertise and
          involvement in the development program. In general, Baxter will supply
          information to reflect Baxter-manufactured product, such as, but not
          limited to:

               -    The manufacturing process for the finished product at
                    Baxter.
               -    The analytical methods Baxter has developed and associated
                    validation information, if applicable.
               -    Method transfer packages for methods developed by Allos and
                    incorporated at Baxter.
               -    The analytical methods and validation information for
                    methods developed by Allos, but for which Baxter modified
                    and/or conducted supplemental validation work.
               -    Information supporting the [ * ] process for the finished
                    product manufactured at Baxter (and/or DMF reference).
               -    Executed batch records for batches manufactured at Baxter.
               -    Stability data for product tested at Baxter.

          Allos intends to submit information in the CTD supporting [ * ] as
          manufacturing sites. ADDENDUM 1, SUBMISSION CONTENTS AND
          RESPONSIBILITIES (TABLE 1 - 3) outlines the information that Baxter
          will deliver to Allos. Allos will be responsible for incorporating the
          Baxter-supplied information into the file, which will also include [ *
          ] manufacturing site. Alternate document preparation arrangements are
          acceptable if requirements are mutually agreed to beforehand.

                     Allos Confidential/Baxter Confidential
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF
1934, AS AMENDED.

<Page>

                         RSR13 Injection (efaproxiral sodium) in Glass Container
                                               Regulatory Plan - Issued 12/09/02
                                                                          Page 6

          Baxter US will prepare the relevant CMC sections reflecting US
          requirements for the US NDA and reference Baxter's DMF for
          confidentiality reasons. Baxter US will also prepare one modified CMC
          section to reflect European requirements, with input from Baxter
          Europe, and one CMC section reflecting Canadian requirements, with
          input from Baxter Canada. Both Baxter Europe and Baxter Canada will
          provide a consultative role in the preparation of the relevant CMC
          sections to be provided to Allos.

          The EU and Canadian CMC information will not include a reference to
          Baxter's DMF, but will include the appropriate information at a level
          of detail necessary to meet the regulatory requirements in each
          region. The completed Baxter CMCs will be forwarded to Allos for
          incorporation into the CTDs for each region. Alternate preparation
          arrangements are acceptable if requirements are mutually agreed to
          beforehand.

          Baxter will provide additional regulatory documents, if needed by
          Allos for registration, within 60 days of request from Allos. These
          documents include, but are not limited to, Certificates of Analysis,
          Technical Agreements, GMP Certificates and/or Declarations.

          Baxter will provide timely support to Allos to address questions
          raised by regulatory authorities during review or post-approval
          related to CMC information for product manufactured at Baxter.

     E.   Manufacturing Facility/Regulatory Inspections

          The product will be manufactured at Baxter's Cleveland, Mississippi
          facility. Pre-approval inspections of the Cleveland facility are
          likely by regulators and may occur soon after submission, especially
          in the US where the product may receive a "priority review" (i.e., 6
          month review) by FDA. The facility must comply with the requirements
          of US, EU, and Canadian cGMPs.

          [ * ] the Cleveland facility [ * ] inspected by EU regulatory
          authorities, and an audit from EU authorities will be scheduled, a [ *
          ] is recommended [ * ] of the EU [ * ].

          Cleveland's FDA compliance status should satisfy Canadian GMP
          requirements.

          Allos and Baxter will collaborate to support the Cleveland, MS and
          Round Lake, IL facilities with regard to regulatory inspections
          (pre-approval and/or post-approval).

                     Allos Confidential/Baxter Confidential
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF
1934, AS AMENDED.

<Page>

                         RSR13 Injection (efaproxiral sodium) in Glass Container
                                               Regulatory Plan - Issued 12/09/02
                                                                          Page 7

     F.   Pre-submission Regulatory Meetings

          Allos plans on having a CMC pre-NDA meeting with FDA in early 2003. In
          addition, EMEA emphasizes the importance of pre-submission meetings
          with EU applicants at least 4 to 6 months prior to the anticipated
          date of the submission. A meeting with the Canadian TPD is also
          recommended.

          For the FDA meeting, where Allos intend to discuss [ * ], Baxter is
          anticipated to provide the following to Allos:

               -    A narrative description of the manufacturing process.
               -    A flow diagram of the manufacturing process.
               -    Brief description of manufacturing equipment.
               -    Release testing results in COA form.
               -    List of raw materials, suppliers, and specifications.
               -    Description of container/closure components (if
                    different [ * ].
               -    Available stability data.
               -    Outline of what will be presented in the NDA.
               -    Description of the [ * ], including supporting information
                    to make the case stronger for [ * ] with the [ * ] units.

     G.   Regulatory Fees/Approval Times

          In many regions, fees are required at the time of filing.
          Responsibilities for regulatory fees will be addressed in the business
          contract.

          In the US, RSR13 Injection has received "fast track" designation
          [ * ]. [ * ].

          Approval in Europe by the centralized procedure [ * ].

          In Canada, the initial regulatory review is [ * ]. Application may be
          made for an expedited approval process 2 months prior to submission
          with justification why the product is unique and deserves special
          treatment. Expedited approval reduces the initial review [ * ].

                     Allos Confidential/Baxter Confidential
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF
1934, AS AMENDED.

<Page>

                         RSR13 Injection (efaproxiral sodium) in Glass Container
                                               Regulatory Plan - Issued 12/09/02
                                                                          Page 8

     H.   Labeling

          Baxter and Allos will collaborate on the development of clinical,
          stability, and commercial product labels for the drug product. In
          addition, Baxter will provide support, as needed, for the development
          of the package insert for the product with respect to information
          pertaining to the product manufactured at Baxter.

III.      RAW MATERIAL CONSIDERATIONS

          The active pharmaceutical ingredient (efaproxiral sodium) will be
          supplied by Allos. The API is manufactured by [ * ]. Allos intends to
          manufacture product at Baxter using [ * ] API [ * ]. The API
          supplier(s) will [ * ].

          Baxter will accept the API from Allos [ * ] with a commitment to
          perform an ID test. Baxter may also determine potency for formulation
          purposes using the final product HPLC assay and a [ * ] assay (e.g., [
          * ]). After approval, for commercial product in Canada, appropriate
          confirmatory testing of the API must be conducted by the manufacturing
          facility (i.e., Baxter) according to the product specifications.
          Acceptance on COA plus an identification test [ * ].

          Efaproxiral sodium is a new molecular entity and there are no
          compendial monographs for the material.

          RSR13 Injection manufactured at Baxter has the following inactive
          components: monobasic sodium phosphate monohydrate, dibasic sodium
          phosphate anhydrous (or alternatively the heptahydrate form), sodium
          chloride, and Water for Injection. Hydrochloric acid and/or sodium
          hydroxide solutions may be used to adjust the pH. All of these
          components will need to meet the USP/NF requirements for the US and EP
          requirements for the EU. For stability production, EP compliance may
          be [ * ] the supplier certifying that the material meets EP and by the
          supplier providing a test-by-test list of the EP results for the
          material. Europe also requires the name of all inactive ingredient
          suppliers.

          Water for Injection used to manufacture the stability units should be
          tested for compliance to both USP and EP requirements so that the
          batches may be utilized to support both US and EU submissions, if
          technically feasible. For commercial production at the Cleveland
          facility, it may be necessary for [ * ] to be tested for EP compliance
          [ * ], not simply in relationship to the production

                     Allos Confidential/Baxter Confidential
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF
1934, AS AMENDED.

<Page>

                         RSR13 Injection (efaproxiral sodium) in Glass Container
                                               Regulatory Plan - Issued 12/09/02
                                                                          Page 9

          [ * ], based on an inspectional observation [ * ] facility
          manufacturing product for [ * ].

          The container and the finished product will need to meet the
          requirements of the USP and EP, where applicable. Europe requires COAs
          for container/closure components.

          Canadian requirements can be supported with compliance to either USP
          or EP requirements.

     IV.  MANUFACTURING CONSIDERATIONS

          The Cleveland facility must comply with the requirements of US, EU,
          and Canadian cGMPs for commercial production.

          [ * ] the Cleveland facility [ * ] inspected by EU regulatory
          authorities, and an audit from EU authorities will be scheduled, a [ *
          ] is recommended [ * ] of the EU [ * ].

          Cleveland's FDA compliance status should satisfy Canadian GMP
          requirements.

          Baxter will prepare a Summary of Process Validation for submission in
          the EU. For any parts of the process that have not been validated on a
          commercial scale at the time of submission (i.e., the mixing process
          via chemical process validation), a summary of process evaluation data
          and/or a process validation scheme will be prepared in accordance with
          EU requirements.(1)

          Allos will assess whether the product meets the criteria for a
          categorical exclusion from an Environmental Assessment (EA). According
          to Allos, if total annual production of the drug substance is less
          than [ * ], the product will qualify for a categorical exclusion. If
          an EA is required, Baxter will provide information to support the
          container and manufacturing facility for inclusion in the EA.

          The submissions will include a statement that [ * ] products are not
          reprocessed at Baxter.

----------
(1)  Notes for Guidance on Process Validation, CPMP/QWP/848/96, 9/2001.

                     Allos Confidential/Baxter Confidential
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF
1934, AS AMENDED.

<Page>

                         RSR13 Injection (efaproxiral sodium) in Glass Container
                                               Regulatory Plan - Issued 12/09/02
                                                                         Page 10

     V.   STERILIZATION [ * ]

          The product will be [ * ] sterilized and [ * ]. Sterilization
          validation and qualification studies for Cleveland, MS will be
          required for the regulatory submissions. Baxter's standard [ * ] for
          US submissions is [ * ]. The [ * ] process for European product must
          be justified using the sterilization Decision Trees.(2) In addition,
          the [ * ] validation/qualification for European product must use [ * ]
          as the [ * ] to meet compendial requirements. The Sterility Test will
          need to be performed as part of import testing for Europe because
          Europe does [ * ] at foreign facilities. Import testing arrangements
          are the responsibility of Allos. The stability batches must be [ * ]
          using a [ * ] that imparts at least as much [ * ] as the [ * ] used
          for commercial product. In addition, each stability batch must be
          [ * ] in a different [ * ] because Europe does not accept the
          definition of a [ * ] to only [ * ] to different active [ * ].

          Baxter has US Drug Master File [ * ] for the manufacture of [ * ] at
          Cleveland, MS. Baxter will update the DMF to reflect the RSR13
          Injection container-closure system and [ * ] process. For the US
          submission, Baxter will supply Allos a summary of the [ * ] (to
          facilitate comparison with the [ * ]) and a cross-reference
          authorization letter to DMF [ * ] for detailed information about the [
          * ]. For the EU and Canadian regulatory submissions, the appropriate
          information will be supplied directly to Allos at a level of detail
          necessary to meet the regulatory requirements in each region.

VI.       STABILITY CONSIDERATIONS

          Stability data from a minimum of three batches, two of which should be
          at least pilot scale (i.e., GREATER THAN OR EQUAL TO 10% of maximum
          batch volume) will be required to support approval of Baxter as a
          manufacturing site for the US file. The [ * ] batch volume at
          Cleveland is currently [ * ]. In addition, stability data from at
          least [ * ] batches per each supplier of active ingredient (only
          Hovione is being considered for Baxter product at this time) may be
          required to support approval of the original regulatory submissions.
          Separate stability batches may be necessary to support US and European
          approval (Refer to OUTSTANDING ISSUES).

          Multiple lots of efaproxiral sodium API should be incorporated into
          the batches, if available.

----------
(2)  Decision Trees for the Selection of sterilization Methods (CPMP/QWP/054/98)

                     Allos Confidential/Baxter Confidential
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF
1934, AS AMENDED.

<Page>

                         RSR13 Injection (efaproxiral sodium) in Glass Container
                                               Regulatory Plan - Issued 12/09/02
                                                                         Page 11

          Since the proposed product will be labeled for storage at 25 DEG. C
          and is packaged in container/closure system that is designed to
          provide a permanent barrier to water loss, relative humidity will not
          impact the stability studies; therefore, the following long-term
          storage conditions are appropriate: 25+/-2 DEG. C/60+/-5%RH, the
          accelerated storage condition should be 40+/-2 DEG. C/75+/-5%RH, and
          the intermediate storage condition should be 30+/-2 DEG. C/60+/-5%RH.
          These conditions are in accordance with FDA's draft stability guidance
          and ICH requirements. The specific storage conditions to meet these
          requirements will be specified in the Stability Plan to be provided by
          Allos, with concurrence from Baxter.

          The effect of bottle storage orientation (upright, inverted) [ * ]
          part of the stability studies.

          Allos will use a contract laboratory (i.e., [ * ]) to conduct
          stability testing for product made at Baxter. The tabulation and
          assessment of stability data, and the setting of expiration dating,
          will be the responsibility of Allos. Allos will share with Baxter the
          justification for the shelf-life determination based on the stability
          data.

          Allos intends to submit [ * ] months of 25 DEG. C data and 6 months of
          40 DEG. C data from three lots produced at [ * ] and 6 months of 25
          DEG. C data and 6 months of 40 DEG. C data from three lots produced at
          [ * ] and [ * ]. In Europe and Canada, submission of 12 months of 25
          DEG. C data and 6 months of 40 DEG. C data for each supplier is
          generally required to extrapolate to a [ * ] month shelf-life.
          Furthermore, it is especially important to demonstrate that the
          manufacturing process at each site is similar for the EU submission.

          Stability studies at 30 DEG. C on at least two batches may be
          necessary to [ * ]. Stability data for product tested full term at 25
          DEG. C and 6 months at 40 DEG. C supports a label statement of "store
          at USP controlled room temperature". Additional stability data, 12
          months at 30 DEG. C, is required for products exhibiting a significant
          change during 6 months storage at 40 DEG. C. Longer-term studies at 30
          DEG. C (up to the shelf life) may also be required to [ * ].

          Allos has conducted an ICH photostability study on product
          manufactured at [ * ]. The need to perform additional photostability
          evaluations on the product [ * ] should be [ * ].

          Allos will identify the required number of finished product units
          needed from Baxter for its clinical studies prior to stability
          production to ensure that enough

                     Allos Confidential/Baxter Confidential
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF
1934, AS AMENDED.

<Page>

                         RSR13 Injection (efaproxiral sodium) in Glass Container
                                               Regulatory Plan - Issued 12/09/02
                                                                         Page 12

          units are manufactured. Allos will also identify any requirements for
          registration samples (retention units) of finished product, raw
          materials, etc, required prior to stability production to ensure that
          enough units are manufactured for regulatory registration in the US,
          EU, and Canada.

          For the US, Allos recommends that four (4) identical sets of materials
          be reserved. Each set should include one lot each of the drug
          substance, reference standards, and drug product. Each of the four
          sets should contain sufficient material to perform full analytical
          testing in triplicate.

          An FDA pre-approval inspection of Stability Operations is possible and
          may occur immediately following NDA submission.

VII.      PRODUCT SPECIFICATIONS AND ANALYTICAL METHOD CONSIDERATIONS

          Product specifications, impurity assessment, residual solvents, etc.
          are the responsibility of Allos and should comply with current ICH and
          FDA guidances. Baxter will provide input, where needed.

          It has been Baxter's experience that for [ * ] product the [ * ] for
          the finished product should not exceed [ * ] for [ * ] and [ * ] for [
          * ] (if applicable) unless there is appropriate justification(3) These
          requirements also apply to [ * ].

          The analytical methods used to assess the quality of the finished
          product should comply with USP/EP requirements, where appropriate.
          Compendial and non-compendial methods should be evaluated and/or
          validated as appropriate.

          Baxter will be responsible for the development and/or validation of
          the bacterial endotoxins test that can be run at the manufacturing
          facility and meet the requirements of the USP and EP. This test, along
          with the bioburden and sterility tests have already been validated by
          Allos. Baxter will assess the work to determine if it meets Baxter's
          requirements and matches the plant's equipment.

          Baxter will prepare summaries of any non-compendial methods developed
          solely by Baxter as determined to be necessary. Baxter will also
          prepare method validation summaries for these methods if determined to
          be necessary.

          Allos will be responsible for all other methods and method validations
          required for the submissions. If it is necessary for Baxter to conduct
          additional development/validation work, Baxter will provide validation
          information, as

----------
(3)  Directive 75/318/EEC and CPMP/QWP/486/95

                     Allos Confidential/Baxter Confidential
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF
1934, AS AMENDED.

<Page>

                         RSR13 Injection (efaproxiral sodium) in Glass Container
                                               Regulatory Plan - Issued 12/09/02
                                                                         Page 13

          appropriate. Baxter will provide the method transfer packages for
          Allos methods that were internalized.

          Requirements for import testing of commercial product into Europe and
          Canada will be identified by Allos, with Baxter assistance as
          requested. The Sterility Test will need to be performed as part of
          import testing for Europe because Europe does [ * ] at foreign
          facilities.

VIII.     CONTAINER/CLOSURE CONSIDERATIONS

          The proposed product will be packaged in a 500 mL glass bottle ([ * ],
          Type I) with a gray stopper (West Formulation [ * ]). Baxter's DMF [ *
          ] will need to be updated to support the new stopper.

          Magellan has conducted USP testing on [ * ] stopper material. Baxter
          will conduct USP and EP testing on [ * ] material according to its
          standard procedure [ * ] to support the regulatory submissions.

          Europe requires the submission of COAs demonstrating EP compliance for
          container/closure components.

          The formulation is in a glass container. Allos had assessed
          extractables from the stopper material and concluded that negligible [
          * ] present for [ * ] extracts; therefore, monitoring of [ * ] for
          this container-closure system. The stopper material (i.e., West
          Formulation [ * ]) used on the [ * ] product is the same.

IX.       CLINICAL CONSIDERATIONS

          See SECTION II.C.

                     Allos Confidential/Baxter Confidential
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF
1934, AS AMENDED.

<Page>

                         RSR13 Injection (efaproxiral sodium) in Glass Container
                                               Regulatory Plan - Issued 12/09/02
                                                                         Page 14

OUTSTANDING ISSUES

The development of the [ * ] for the US and Europe is ongoing and separate [ * ]
may be necessary. If practicable and technically defendable, one set of
stability batches [ * ] should be produced to meet the requirements of both
regions. One option would be to use [ * ] that would satisfy both US and EU
requirements [ * ].

REGULATORY CONTACTS

<Table>
             <S>                                   <C>
             BAXTER (USA):                         BAXTER (EUROPE):
             Stacey S. Thompson                    Valentin Lemoine
             Manager, Regulatory Affairs           Associate Director of Regulatory Affairs
             Baxter Healthcare Corporation         Baxter Healthcare Corporation
             Route 120 & Wilson Road               Nivelles, Belgium
             Round Lake, IL  60073                 Phone: 32-67-882-468
             Phone: (847) 270-5829                 Fax:     32-67-882-562
             Fax:      (847) 270-4668              e-mail: lemoniv@baxter.com
             e-mail: thompss@baxter.com

             BAXTER (CANADA):                      ALLOS THERAPEUTICS, INC.
             Paul Bonnici                          Doug Johnson, Ph.D.
             Director of Regulatory Affairs        Vice President, Manufacturing
             Baxter Healthcare Corporation         Allos Therapeutics, Inc.
             Mississauga, Ontario, Canada          11080 CirclePoint Road, Suite 200
             Phone: (905) 281-6342                 Westminster, CO  80020
             Fax:     (905) 281-6420               Phone: (303) 426-6262
             e-mail: bonnicpa@baxter.com           Fax:     (303) 412-9162
                                                   e-mail: djohnson@allos.com
</Table>

                     Allos Confidential/Baxter Confidential
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF
1934, AS AMENDED.

<Page>

                         RSR13 Injection (efaproxiral sodium) in Glass Container
                                               Regulatory Plan - Issued 12/09/02
                                                                         Page 15

SUBMISSION CONTENTS AND RESPONSIBILITIES

The CURRENT issues of the following documents are some of those that will be
considered in preparation of the CTD for the USA:

     -    Compendial Requirements (USP for US)
     -    Guideline for the Format and Content of the Chemistry, Manufacturing,
          and Controls Section of an Application (2/87)
     -    FDA Guidance for Industry: Container Closure Systems for Packaging
          Human Drugs and Biologic - Chemistry, Manufacturing, and Controls
          Documentation (5/99)
     -    Guidance for Industry for the Submission Documentation for
          Sterilization Process Validation in Applications for Human and
          Veterinary Drug Products (11/94)
     -    Guideline for Submitting Documentation for the Stability of Human
          Drugs and Biologics (2/87)
     -    Guideline for Submitting Samples and Analytical Data for Methods
          Validation (2/87)
     -    Guideline for Submitting Documentation in Drug Applications for the
          Manufacture of and Controls for Drug Products (2/87)
     -    Guideline for Submitting Supporting Documentation in Drug Applications
          for the Manufacturing of Drug Products (2/87)
     -    FDA Guidance for Industry: Analytical Procedures and Methods
          Validation - Chemistry, Manufacturing, and Controls Documentation
          (Draft, 8/00)
     -    FDA Guidance for Industry: Stability Testing of Drug Substances and
          Drug Products (Draft, 6/98)
     -    FDA Guidance for Industry: Environmental Assessment of Human Drug and
          Biologics Applications (7/98)
     -    FDA Guidance for Industry: Submitting Marketing Applications According
          to the ICH-CTD Format - General Considerations (Draft, 8/01)
     -    ICH Q1A(R) -Guidance on Stability Testing of New Drug Substances and
          Products (Draft 11/00)
     -    ICH Q1B Guidance on Photostability Testing of New Drug Substances and
          Products (11/96)
     -    ICH Q2A Guidance: Text on Validation of Analytical Procedures (3/95)
     -    ICH Q2B Guidance: Validation of Analytical Procedures - Methodology
          (11/96)
     -    ICH Q3A(R) Guidance: Impurities in New Drug Substances (02/02)
     -    ICH Q3B Guidance: Impurities in New Drug Products (11/96)
     -    ICH Q3C Guidance: Impurities - Residual Solvents (12/97)
     -    ICH Q6A Guidance: Specifications: Test Procedures and Acceptance
          Criteria for New Drug Substances and New Drug Products: Chemical
          Substances (10/99).
     -    ICH Harmonized Tripartite Guideline: M4: ORGANIZATION OF THE CTD
     -    ICH Harmonized Tripartite Guideline: M4Q: THE CTD - QUALITY

                     Allos Confidential/Baxter Confidential
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF
1934, AS AMENDED.

<Page>

                         RSR13 Injection (efaproxiral sodium) in Glass Container
                                               Regulatory Plan - Issued 12/09/02
                                                                         Page 16

Allos and Baxter will work together to develop the chemistry, manufacturing, and
controls (CMC) information for the regulatory submissions in the CTD format.
SECTION 3.2.P. of the CTD is the primary deliverable of Baxter to Allos. Baxter
US will spearhead the development of this section, with appropriate input from
Baxter Europe and Baxter Canada. Baxter will develop its portions of SECTION
3.2.P and Allos will be responsible for incorporating the Baxter-supplied
information into the file, which [ * ] as a manufacturing site.

All other sections of the regulatory submissions will be the responsibility of
Allos. In general, Baxter will supply information to reflect Baxter-manufactured
product, such as a description of the manufacturing process, executed batch
records, Baxter-generated stability data, etc. Refer to SECTION II.D.

     1.   Allos and Baxter will agree to the format of the CTD for the US NDA,
          EU MAA, and Canadian NDS prior to submission development.
          Consideration should be given to content and format consistent with
          the ICH guidelines on the Common Technical Document for the
          Registration of Pharmaceuticals for Human Use.
     2.   Baxter will develop a preliminary draft of Baxter submission sections
          for review and comment by both companies. The timing for the
          preliminary drafts of the US NDA, EU MAA, and Canadian NDS will be
          determined during the development program.
     3.   Baxter will finalize the submission sections after all comments from
          both companies have been received and addressed.
     4.   Baxter will forward the final documents to Allos after Baxter internal
          approval. Changes to Baxter approved text cannot be made without prior
          Baxter notification and approval.
     5.   Baxter requests that Allos provide copies of the relevant US NDA, EU
          MAA, and Canadian NDS sections, as submitted, and any relevant
          correspondence with regulatory agencies, to Baxter.
     6.   Responsibilities for relevant sections of US NDA, EU MAA, and Canadian
          NDS are outlined in ADDENDUM 1, TABLES 1, 2, AND 3, respectively. The
          content outlined is based on the format and content of the ICH Common
          Technical Document.

                     Allos Confidential/Baxter Confidential
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF
1934, AS AMENDED.

<Page>

                         RSR13 Injection (efaproxiral sodium) in Glass Container
                                               Regulatory Plan - Issued 12/09/02
                                                                         Page 17

                                   ADDENDUM 1

                    SUBMISSION CONTENTS AND RESPONSIBILITIES

Note: Per [ * ] and [ * ], all discrepancies between the Regulatory Plan and the
submission must be documented and justified in the development review summary
prior to the submission of the file to the regulatory agency. Submission
Contents and Responsibilities is included as an Addendum to this Regulatory Plan
because the approach is still evolving and is certain to change as the
development of the program proceeds. Minor changes in submission contents and
responsibilities that do no represent a substantive change in the technical
information required do not, by themselves, require an amendment to the
agreed-upon Regulatory Plan.

                     Allos Confidential/Baxter Confidential
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF
1934, AS AMENDED.

<Page>

                         RSR13 Injection (efaproxiral sodium) in Glass Container
                                               Regulatory Plan - Issued 12/09/02
                                                                         Page 18

                                     TABLE 1

         US NDA SUBMISSION (CTD FORMAT) - CONTENTS AND RESPONSIBILITIES

<Table>
<Caption>
      SECTION                                   DESCRIPTION                                    RESPONSIBILITY
----------------------------------------------------------------------------------------------------------------------
<S>                  <C>                                                                <C>
COVER LETTER         Introduction                                                       Allos

MODULE 1             ADMINISTRATIVE INFORMATION AND PRESCRIBING INFORMATION             Allos (with Baxter input)
                          -   BAXTER REGULATORY AFFAIRS (RA) WILL SUPPLY CROSS-
                              REFERENCE AUTHORIZATION LETTER TO BAXTER DMF.
                          -   BAXTER ENVIRONMENTAL AFFAIRS (EA) WILL PROVIDE INPUT,
                              AS NEEDED, FOR THE ENVIRONMENTAL ASSESSMENT (REQUEST
                              FOR CATEGORICAL EXCLUSION, IF JUSTIFIED)
                          -   BAXTER RA/COMPUTER GRAPHICS AND INFORMATION
                              MANAGEMENT (CGIM) WILL PROVIDE LABELING FOR THE
                              PRODUCT MANUFACTURED AT BAXTER, AS NEEDED.

MODULE 2             COMMON TECHNICAL DOCUMENT SUMMARIES                                Allos (Baxter may provide
                                                                                        input on summary of Module 3)

MODULE 3             QUALITY                                                            Allos

3.1                  Module 3 Table of Contents                                         Allos

3.2                  Body of Data                                                       Allos

3.2.S                DRUG SUBSTANCE                                                     Allos

   3.2.S.1               GENERAL INFORMATION                                            Allos

   3.2.S.2               MANUFACTURE                                                    Allos

   3.2.S.3               CHARACTERIZATION                                               Allos

   3.2.S.4               CONTROL OF DRUG SUBSTANCE                                      Allos

     3.2.S.4.1             Specification                                                Allos (with Baxter input)
                              -    BAXTER PHARMACEUTICAL SCIENCES R&D (PS R&D) WILL
                                   PROVIDE BAXTER'S SPECIFICATIONS AND DESCRIBE TESTS
                                   BAXTER WILL PERFORM ON DRUG SUBSTANCE PRIOR TO USE.

     3.2.S.4.2             Analytical Procedures                                        Allos (with Baxter input)
                              -    BAXTER PS R&D WILL PROVIDE BAXTER'S ANALYTICAL
                                   PROCEDURES THAT BAXTER WILL PERFORM ON DRUG
                                   SUBSTANCE PRIOR TO USE.

     3.2.S.4.3             Validation of Analytical Procedures                          Allos (with Baxter input)
                              -    BAXTER PS R&D WILL PROVIDE BAXTER'S VALIDATION OF
                                   ANALYTICAL PROCEDURES THAT BAXTER WILL PERFORM ON
                                   DRUG SUBSTANCE PRIOR TO USE.

     3.2.S.4.4             Batch Analysis                                               Allos (with Baxter input)
                               -   BAXTER PS R&D WILL PROVIDE CERTIFICATES OF ANALYSIS
                                   OF LOTS USED FOR STABILITY AT BAXTER.

     3.2.S.4.5             Justification of Specification                               Allos

   3.2.S.5               REFERENCE STANDARDS OR MATERIALS                               Allos

   3.2.S.6               CONTAINER CLOSURE SYSTEM                                       Allos

   3.2.S.7               STABILITY                                                      Allos
</Table>

                     Allos Confidential/Baxter Confidential
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF
1934, AS AMENDED.

<Page>

                         RSR13 Injection (efaproxiral sodium) in Glass Container
                                               Regulatory Plan - Issued 12/09/02
                                                                         Page 19

                               TABLE 1 - CONTINUED

         US NDA SUBMISSION (CTD FORMAT) - CONTENTS AND RESPONSIBILITIES

<Table>
<Caption>
      SECTION                           DESCRIPTION                                  RESPONSIBILITY
----------------------------------------------------------------------------------------------------------------------
<S>                   <C>                                                <C>
3.2.P                 DRUG PRODUCT                                       Allos

   3.2.P.1                DESCRIPTION   AND  COMPOSITION  OF  THE  DRUG  Allos - Baxter RA and PS R&D will provide
                      PRODUCT                                            supportive information, as needed, to
                          LIST OF ALL FORMULATION COMPONENTS AND         reflect product manufactured at Baxter.
                          PROVIDE QUANTITATIVE INFORMATION CONSISTENT
                          WITH LABELING.  RA TO PROVIDE
                          CONTAINER/CLOSURE INFORMATION.

   3.2.P.2                PHARMACEUTICAL DEVELOPMENT                     Allos - Baxter will provide input, as
                                                                         needed, to reflect product manufactured at
                                                                         Baxter.

     3.2.P.2.1              Components of the Drug Product               Allos

       3.2.P.2.1.1            Drug Substance                             Allos

       3.2.P.2.1.2            Excipients                                 Allos

     3.2.P.2.2              Drug Product                                 Allos

       3.2.P.2.2.1            Formulation Development                    Allos

       3.2.P.2.2.2            Overages                                   Allos

       3.3.P.2.2.3            Physicochemical and Biological Properties  Allos

     3.2.P.2.3              Manufacturing Process Development            Allos - Baxter PS R&D will provide
                            DISCUSS SELECTION AND OPTIMIZATION OF THE    information relative to the manufacture of
                            MANUFACTURING PROCESS AND ITS CRITICAL       product at Baxter.  Baxter Sterility
                            ASPECTS,[ * ].                               Assurance (SA) will provide [ * ]
                                                                         information.

     3.2.P.2.4              Container Closure System                     Allos - Baxter PS R&D and RA will provide
                            DISCUSS SUITABILITY OF CONTAINER CLOSURE     information relative to the product
                            SYSTEM WITH RESPECT TO CHOICE OF             manufactured at Baxter.  The extractive
                            MATERIALS, PROTECTION FROM LIGHT,            strategy has been developed by Allos.
                            COMPATIBILITY WITH THE DRUG FORMULATION,
                            ETC.  DISCUSS EXTRACTION STUDIES THAT
                            SUPPORT COMPATIBILITY.

     3.2.P.2.5              Microbiological Attributes                   Allos - Baxter SA will provide information
                            DISCUSS CONTAINER CLOSURE INTEGRITY.         relative to the container/closure integrity
                                                                         of product manufactured at Baxter.

     3.2.P.2.6              Compatibility                                Allos

   3.2.P.3                MANUFACTURE                                    Allos - Baxter will provide input, as
                                                                         needed, to reflect product manufactured at
                                                                         Baxter.

     3.2.P.3.1              Manufacturer(s)                              Allos - Baxter PS R&D will provide
                                                                         information to reflect product manufactured
                                                                         at Baxter.

     3.2.P.3.2              Batch Formula                                Allos - Baxter will provide input, as
                                                                         needed, to reflect product manufactured at
                                                                         Baxter.
</Table>

                     Allos Confidential/Baxter Confidential
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF
1934, AS AMENDED.

<Page>

                         RSR13 Injection (efaproxiral sodium) in Glass Container
                                               Regulatory Plan - Issued 12/09/02
                                                                         Page 20

                               TABLE 1 - CONTINUED

         US NDA SUBMISSION (CTD FORMAT) - CONTENTS AND RESPONSIBILITIES

<Table>
<Caption>
      SECTION                                   DESCRIPTION                             RESPONSIBILITY
----------------------------------------------------------------------------------------------------------------------
   <S>                    <C>                                            <C>
     3.2.P.3.3              Description of Manufacturing Process and     Allos - Baxter PS R&D & Plant Quality
                            Process Controls                             Management (Plant QM) will provide
                            INCLUDE A FLOW DIAGRAM AND A NARRATIVE       information to reflect product manufactured
                            DESCRIPTION OF THE MANUFACTURING PROCESS.    at Baxter.
                            A MASTER PRODUCTION RECORD IS ALSO
                            REQUIRED.  MASTER PRODUCTION BATCH SIZE
                            [ * ] - MUST BE SUPPORTED BY [ * ].
                            INCLUDE DESCRIPTION OF FILLED CONTAINER
                            SAMPLING, INSPECTIONS, AND FILLING PROCESS
                            CONTROLS.  [ * ]*.  INCLUDE DESCRIPTION OF
                            PACKING AND SAMPLING FOR RELEASE TESTING
                            AND RELEASE TESTING SPECIFICATIONS.
                            INCLUDE STATEMENT THAT THERE ARE NO
                            PROVISIONS FOR REPROCESSING.

     3.2.P.3.4              Controls of Critical Steps and               Allos - Baxter PS R&D will provide
                            Intermediates                                information to reflect product manufactured
                            PROVIDE TESTS, ACCEPTANCE CRITERIA, AND      at Baxter.
                            JUSTIFICATION.

     3.2.P.3.5              Process Validation and/or Evaluation         Baxter PS R&D and SA will provide
                            PROVIDE A SUMMARY OF PROCESS EVALUATION      information to reflect product manufactured
                            DATA, PROVIDE VALIDATION DATA, AND/OR        at Baxter.
                            STATE THAT CHEMICAL PROCESS VALIDATION
                            WILL BE PERFORMED AT FIRST-OF-CODE
                            PRODUCTION. [ * ]*.

   3.2.P.4                CONTROL OF EXCIPIENTS                          Allos - Baxter PS R&D will provide
                                                                         information to reflect product manufactured
                                                                         at Baxter.

     3.2.P.4.1              Specifications                               Allos - Baxter PS R&D will provide
                                                                         information to reflect product manufactured
                                                                         at Baxter.

     3.2.P.4.2              Analytical Procedures                        Allos - Baxter PS R&D will provide
                                                                         information to reflect product manufactured
                                                                         at Baxter.

     3.2.P.4.3              Validation of Analytical Procedures          Allos - Baxter PS R&D will provide
                            PROVIDE VALIDATION OF NON-COMPENDIAL         information to reflect product manufactured
                            METHODS.                                     at Baxter.

     3.2.P.4.4              Justification of Specifications              Allos - Baxter PS R&D will provide
                                                                         information to reflect product manufactured
                                                                         at Baxter.

     3.2.P.4.5              Excipients of Human or Animal Origin         Allos

     3.2.P.4.6              Novel Excipients                             Allos
</Table>

     *    For the EU and Canada, the required [ * ] information will be included
          in the regulatory submission.

                     Allos Confidential/Baxter Confidential
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF
1934, AS AMENDED.

<Page>

                         RSR13 Injection (efaproxiral sodium) in Glass Container
                                               Regulatory Plan - Issued 12/09/02
                                                                         Page 21

                               TABLE 1 - CONTINUED

         US NDA SUBMISSION (CTD FORMAT) - CONTENTS AND RESPONSIBILITIES

<Table>
<Caption>
      SECTION                           DESCRIPTION                                     RESPONSIBILITY
----------------------------------------------------------------------------------------------------------------------
   <S>                   <C>                                             <C>
   3.2.P.5               CONTROL OF DRUG PRODUCT                         Allos

     3.2.P.5.1             Specifications                                Allos - Baxter PS R&D will provide
                           [ * ], STERILITY, BACTERIAL ENDOTOXINS AND    information to reflect product manufactured
                           OTHER ATTRIBUTES, IF APPROPRIATE.             at Baxter.

     3.2.P.5.2             Analytical Procedures                         Allos - Baxter PS R&D will provide
                                                                         information to reflect product manufactured
                                                                         at Baxter.

     3.2.P.5.3             Validation of Analytical Procedures           Allos - Baxter PS R&D will provide
                                                                         information to reflect product manufactured
                                                                         at Baxter.

     3.2.P.5.4             Batch Analyses                                Allos - Baxter PS R&D will provide
                           PROVIDE A DESCRIPTION OF THE BATCHES AND      information to reflect product manufactured
                           RESULTS OF THE ANALYSES.                      at Baxter.

     3.2.P.5.5             Characterization of Impurities                Allos

     3.2.P.5.6             Justification of Specifications               Allos (with input from Baxter, as needed)

   3.2.P.6               REFERENCE STANDARDS OR MATERIALS                Allos

   3.2.P.7               CONTAINER CLOSURE SYSTEM                        Allos (with input from Baxter, as needed)

   3.2.P.8               STABILITY                                       Allos

     3.2.P.8.1             Stability Summary and Conclusions             Allos - Baxter PS R&D will provide
                           DESCRIBE FORMULATION.                         information to reflect product manufactured
                           DESCRIBE STABILITY BATCHES AND THEIR METHOD   at Baxter.  Allos is responsible for
                           OF MANUFACTURE.                               preparing the stability commentary.
                           DISCUSS STABILITY DATA (REFER TO 3.2.P.8.3).
                           DISCUSS DEGRADANTS/IMPURITIES.
                           PROPOSED EXPIRATION DATING BASED ON
                           INTERNAL STATISTICAL ANALYSIS OF DATA, IF
                           APPROPRIATE, WITH A PROVISION FOR EXTENDING
                           WITH ACCEPTABLE ACCUMULATED DATA FROM THE
                           BATCHES INCLUDED IN THE NDA SUBMISSION.
</Table>

                     Allos Confidential/Baxter Confidential
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF
1934, AS AMENDED.

<Page>

                         RSR13 Injection (efaproxiral sodium) in Glass Container
                                               Regulatory Plan - Issued 12/09/02
                                                                         Page 22

                               TABLE 1 - CONTINUED

         US NDA SUBMISSION (CTD FORMAT) - CONTENTS AND RESPONSIBILITIES

<Table>
<Caption>
SECTION              DESCRIPTION                                         RESPONSIBILITY
----------------------------------------------------------------------------------------------------------------------
<S>                  <C>                                                 <C>
     3.2.P.8.2             Post-approval Stability Protocol and          Allos - Baxter PS R&D will provide
                           Stability Commitment                          information to reflect product manufactured
                           COMMIT TO PLACE [ * ] PRODUCTION BATCHES ON   at Baxter.  If Baxter is contracted to
                           STABILITY.                                    execute the ongoing stability studies,
                           PROVIDE CONTINUING NDA, FIRST PRODUCTION,     Baxter will need to concur with the
                           AND ANNUAL QC TEST SCHEDULES.                 stability commitments.

     3.2.P.8.3             Stability Data                                Allos

3.2.A                APPENDICES                                          Allos

3.2.R                REGIONAL INFORMATION                                Allos

   3.2.R.1               Executed Batch Records                          Baxter RA/Plant QM will supply executed
                         SUPPLY COAs AND BAXTER TEST RESULTS FOR         batch records for the stability batches
                         FORMULATION COMPONENTS USED IN STABILITY        made at Baxter.  Baxter PS R&D will supply
                         BATCHES, INCLUDING STABILITY BATCH SUMMARY      other listed information.
                         TABLES OF FINISHED PRODUCT TEST RESULTS.
                         INCLUDE BATCH RECORDS FOR ALL PRIMARY BATCHES.

   3.2.R.2               Method Validation Package                       Allos - Baxter PS R&D will provide
                         INCLUDE COMPOSITION OF FINISHED DRUG PRODUCT.   information to reflect product manufactured
                         STATE THAT SAMPLES WILL BE PROVIDED UPON        at Baxter.  If this section is simply
                         REQUEST FROM FDA; RESERVE PRODUCT FROM EACH     copied from other sections, Allos will be
                         BATCH.  (SEE SECTION VI OF PLAN)                responsible for assembling package.
                         INCLUDE REGULATORY SPECIFICATIONS FOR DRUG
                         SUBSTANCE AND DRUG PRODUCT.
                         INCLUDE REGULATORY METHODS AND VALIDATION
                         DATA.
                         INCLUDE DRAFT LABELING.

3.3                  Literature References                               Allos

MODULE 4             NONCLINICAL STUDY REPORTS                           Allos

MODULE 5             CLINICAL STUDY REPORTS                              Allos
</Table>

                     Allos Confidential/Baxter Confidential
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF
1934, AS AMENDED.

<Page>

                         RSR13 Injection (efaproxiral sodium) in Glass Container
                                               Regulatory Plan - Issued 12/09/02
                                                                         Page 23

                                     TABLE 2

      EUROPEAN MAA SUBMISSION (CTD FORMAT) - CONTENTS AND RESPONSIBILITIES

<Table>
<Caption>
      SECTION                                   DESCRIPTION                             RESPONSIBILITY
----------------------------------------------------------------------------------------------------------------------
<S>                  <C>                                                   <C>
MODULE 1             ADMINISTRATIVE INFORMATION AND PRESCRIBING            Allos with input from Baxter Europe, if
                     INFORMATION                                                          requested
                     CONTENT AS SPECIFIED BY EU REQUIREMENTS.

MODULE 2             COMMON TECHNICAL DOCUMENT SUMMARIES                                    Allos
                     SAME AS US SUBMISSION, WHERE FEASIBLE.

MODULE 3             QUALITY                                               Allos, Baxter US with input from Baxter
                     SAME AS US SUBMISSION, WHERE FEASIBLE. THE BAXTER                     Europe*
                     SECTIONS WILL BE PREPARED BY BAXTER US WITH INPUT
                     FROM BAXTER EUROPE.

3.2.R                REGIONAL INFORMATION                                  Allos, with input from Baxter Europe if
                     CONTENT AS SPECIFIED BY EU REQUIREMENTS.                             requested

MODULE 4             NONCLINCAL STUDY REPORTS                                               Allos

MODULE 5             CLINCAL STUDY REPORTS                                                  Allos
</Table>

*    Prepared by Baxter US with responsibility as described in TABLE 1, with
     input from EU, Canada, and Allos. Given the different regulatory
     environments of the countries, the final US CTD and the final EU and
     Canadian CTDs may be different.

                     Allos Confidential/Baxter Confidential
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF
1934, AS AMENDED.

<Page>

                         RSR13 Injection (efaproxiral sodium) in Glass Container
                                               Regulatory Plan - Issued 12/09/02
                                                                         Page 24

                                     TABLE 3

      CANADIAN NDS SUBMISSION (CTD FORMAT) - CONTENTS AND RESPONSIBILITIES

<Table>
<Caption>
      SECTION                                   DESCRIPTION                             RESPONSIBILITY
----------------------------------------------------------------------------------------------------------------------
<S>                  <C>                                                   <C>
MODULE 1             ADMINISTRATIVE INFORMATION AND PRESCRIBING            Allos with input from Baxter Canada, if
                     INFORMATION                                                          requested.
                     CONTENT AS SPECIFIED BY CANADIAN REQUIREMENTS.

MODULE 2             COMMON TECHNICAL DOCUMENT SUMMARIES                                    Allos
                     SAME AS US SUBMISSION, WHERE FEASIBLE.

MODULE 3*            QUALITY                                               Allos, Baxter US with input from Baxter
                     SAME AS US SUBMISSION, WHERE FEASIBLE. THE                             Canada*
                     BAXTER SECTIONS WILL BE PREPARED BY BAXTER US
                     WITH INPUT FROM BAXTER CANADA.

3.2.R                REGIONAL INFORMATION                                  Allos with input from Baxter Canada, if
                     CONTENT AS SPECIFIED BY CANADIAN REQUIREMENTS.                       requested

MODULE 4             NONCLINCAL STUDY REPORTS                                               Allos

MODULE 5             CLINCAL STUDY REPORTS                                                  Allos
</Table>

*    Prepared by Baxter US with responsibility as described in TABLE 1, with
     input from EU, Canada, and Allos. Given the different regulatory
     environments of the countries, the final US CTD and the final EU and
     Canadian CTDs may be different.

                     Allos Confidential/Baxter Confidential
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF
1934, AS AMENDED.

<Page>

                                    EXHIBIT D
                        DEVELOPMENT FEE AND DELIVERABLES

<Table>
<Caption>
                               DEVELOPMENT                     US/EU STABILITY STUDIES            FDA/WMA SUBMISSION AND APPROVAL
------------------------------------------------------------------------------------------------------------------------------------
<S>               <C>                                    <C>                                  <C>
DEVELOPMENT       1. TECHNICAL TRANSFER AND VALIDATION   6. DEVELOP REGULATORY PLAN,          11. CMC PREPARATION, SITE INSPECTION
ACTIVITIES           WHERE APPROPRIATE (E.G. ASSAY)         PROJECT SUPPORT, NDA SECTION          PREPARATION
                     -MIXING PROCEDURE                      PREPARATION                           [ * ]
                     -TEST METHODS, USP & EP                [ * ]
                     -ABSENCE OF DRUG PROCEDURE                                               12. DEVELOP CONTAINER LABELS
                     -PRODUCT SPECIFICATIONS             7. STABILITY PLAN, STABILITY UNIT        [ * ]
                     -FORMULATION REQUIREMENTS:             TESTING, EXPIRATION DATING
                     [ * ]                                  RECOMMENDATION                    13. ASSAY TRANSFERS (TO BAXTER PLANT)
                     [ * ]                                  [ * ]                                 [ * ]

                  2. FORMULATION EVALUATION [ * ]        8. STABILITY BATCH PRODUCTION [ * ]  14. REGULATORY SUPPORT - POST FILING
                     [ * ]                                  [ * ]                                 [ * ]

                  3. STERILIZATION CYCLE DEVELOPMENT     9. BACTERIAL ENDOTOXIN               15. PACKAGING DEVELOPMENT
                     AND VALIDATION,                        [ * ]                                 [ * ]
                     [ * ]
                                                         10. PROGRAM MANAGEMENT               16. PROGRAM MANAGEMENT
                  4. CHEMICAL PROCESS EVALUATION            [ * ]                                 [ * ]
                     [ * ]

                  5. PROGRAM MANAGEMENT
                     [ * ]

TOTAL US BASED    DEVELOPMENT TOTAL: [ * ]               STABILITY TOTAL: [ * ]               SUBMISSION TOTAL: [ * ]
COST: [ * ]       GLASS PRE-STABILITY TOTAL: [ * ]

ANNUAL            TOTAL COSTS YEAR 1 = [ * ]             TOTAL COSTS YEAR 2 = [ * ]           TOTAL COSTS YEAR 3 = [ * ]
/QUARTERLY COSTS  QUARTERLY COSTS YEAR 1 = [ * ]         QUARTERLY COSTS YEAR 2 = [ * ]       QUARTERLY COSTS YEAR 3 = [ * ]

ASSUMPTIONS       -   ABBREVIATED FORMULATION STUDY      -   [ * ] FORMULATION DATA TO        -   SUBMIT WITH [ * ] MONTHS RT
AND TIMING            TO EVALUATE [ * ] EXTREMES             PROCEED TO STABILITY                 STABILITY DATA/[ * ] MONTHS
                  -   VALIDATION CONSISTS OF METHOD      -   TOTAL OF [ * ] STABILITY             40 DEG. C DATA
KEY:                  TRANSFER AND SPECIFICITY TOWARD        BATCHES OF ONE CONCENTRATION     -   ONE CMC AND ONE WMA SUITABLE FOR
G = GLASS             CONTAINER, AND ISSUE                   ONLY; [ * ] BATCHES [ * ] AND        ALL COUNTRIES
DEVELOPMENT           SPECIFICATION                          [ * ] BATCHES [ * ]              -   BAXTER TO PROVIDE SUPPLEMENTAL
PRIOR TO          -   ALLOS WILL SUPPLY [ * ] TO                                                  VALIDATION INFORMATION TO INCLUDE
STABILITY             BAXTER FREE OF CHARGE FOR                                                   IN ALLOS' CMC DOCUMENT
PRODUCTION [ * ]      DEVELOPMENT WORK [ * ]                                                  -   FINAL CONTAINER LABELING IN UP TO
                  -   [ * ] AS CONTINGENCY IF [ * ] IS                                            4 LANGUAGES (ENGLISH + 3
                      NOT AVAILABLE IN TIME-FRAME                                                 ADDITIONAL)
                      NEEDED                                                                  -   ALLOS TO PROVIDE AVAILABLE
                                                                                                  ENVIRONMENTAL ASSESSMENT
                                                                                                  INFORMATION
                                                                                              -   ALLOS RESPONSIBLE FOR MSDS FOR API
                                                                                                  AND FINAL PRODUCT
</Table>

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       D-1
<Page>

                               RSR13 DELIVERABLES

<Table>
<Caption>
              DESCRIPTION                       ALLOS THERAPEUTICS TO DELIVER                      BAXTER TO DELIVER
----------------------------------------------------------------------------------------------------------------------------------
<S>                                     <C>                                             <C>
          ANALYTICAL METHOD
            EVALUATIONS:

-   UV Identification Test              Drug materials and  reference standards

                                        MSDS for drug and related substances

                                        Approval of evaluation protocol and report      UV Identification evaluation report

        ANALYTICAL VALIDATION

-   HPLC Assay(s) for drug and          Reference standard and drug material            Assay transfer report and method procedure
    degradates                                                                             -  Transfer from Allos to Baxter-Product
                                        Approval of method transfer protocol and              Development
                                        report                                             -  Transfer from Product Development to
                                                                                              Manufacturing plant
                                                                                           -  Transfer from Product Development to
                                                                                              Stability Operations

-   UV Identification Method for raw    Reference standard and drug material for        UV Identification validation report and
    material and RSR13 Injection        validation study                                method  procedure

                                        Approval of validation protocol and report

-   Drug by UV assay                    Reference standard for validation study         Assay validation and method  procedure

-   Absence-of-Assay for RSR13          Reference standard for validation study         Validation report for Absence-of-Assay (UV)

-   Sterility Test Procedure            Approval of validation protocol and report      Assay validation report and method procedure

-   Bacterial Endotoxins                Approval of validation protocol and report      Assay validation report and method procedure
</Table>

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       D-2
<Page>

                               RSR13 DELIVERABLES

<Table>
<Caption>
              DESCRIPTION                       ALLOS THERAPEUTICS TO DELIVER                      BAXTER TO DELIVER
----------------------------------------------------------------------------------------------------------------------------------
<S>                                     <C>                                             <C>
Develop Mixing Procedure                Historical product mixing procedure             Collaborate with Allos Therapeutics to
                                                                                        identify Baxter mixing process for product

                                        Approve study design                            Perform RSR13 Feasibility study at
                                                                                        manufacturing plant to evaluate mixing
                                                                                        parameters and process controls

                                        Approve mixing procedure                        Issue mixing procedure (3-15)

                                        Review and accept report                        Feasibility Batch Production report

Chemical Process Evaluation             Review and approve Chemical Process             Chemical Process Evaluation protocol and
                                        Evaluation protocol and report                  report

[ * ] Development and Validation        RSR13 raw material as needed                    Identification of RSR13 as needed

                                                           ----                         Manufacture pilot batch of Product and fill
                                                                                        into containers

                                                           ----                         Develop, test, validate, and report the
                                                                                        results [ * ] for the product
</Table>

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       D-3
<Page>

                               RSR13 DELIVERABLES

<Table>
<Caption>
              DESCRIPTION                       ALLOS THERAPEUTICS TO DELIVER                      BAXTER TO DELIVER
----------------------------------------------------------------------------------------------------------------------------------
<S>                                     <C>                                             <C>
Develop Regulatory Plan]                Collaborate with Baxter to finalize a           Collaborate with Allos Therapeutics to
                                        Regulatory Plan for the premixed product        finalize a Regulatory Plan for the
                                                                                        premixed product

Develop Stability Plan                  Collaborate with Baxter to finalize Stability   Collaborate with Allos Therapeutics to
                                        Plan for product - primary stability            finalize Stability  Plan - primary
                                        (registration) batches                          stability (registration) batches

Stability Batch Production              Collaborate with Baxter to define batch sizes   Collaborate with Allos Therapeutics to
                                                                                        finalize batch sizes

                                        Review and approve Stability Production         Stability Production Protocol and Report
                                        protocol

                                        RSR13 raw material as needed                    All cGMP resources required to manufacture
                                                                                        stability batches (personnel, facilities,
                                                                                        equipment, excipients etc)

Stability Testing                       Conduct stability program for registration      Future stability testing (marketed product)
                                        batches prior to approval of NDA                will be negotiated separately

Evaluate Stability Data and Assign      Provide expiry dating rationale and supporting  Review expiration dating and supporting
Expiration Date                         documentation                                   documentation

Draft IND and NDA Sections              Collaborate with Baxter to define information   Collaborate with Allos Therapeutics to
                                        needed for IND or NDA reporting formats         define information needed for IND or NDA
                                                                                        reporting formats

                                        Review and accept information reported by       Provide IND and NDA submission components
                                        Baxter                                          as stated in the Regulatory Plan
</Table>

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       D-4
<Page>

                               RSR13 DELIVERABLES

<Table>
<Caption>
              DESCRIPTION                       ALLOS THERAPEUTICS TO DELIVER                      BAXTER TO DELIVER
----------------------------------------------------------------------------------------------------------------------------------
<S>                                     <C>                                             <C>
Site Inspection (PAI) Preparation                         --------                      Prepare for pre-approval inspections of
                                                                                        Facility by Regulatory Agencies

Develop Labels                          Collaborate with Baxter to establish label      Collaborate with Allos Therapeutics to
                                        text and formats in support of filings with     establish label text and formats in support
                                        Regulatory Agencies                             of filings with Regulatory Agencies

Address Regulatory Questions            Collaborate with Baxter to respond to           Address all regulatory questions in a
                                        regulatory questions                            timely manner. Obtain Allos Therapeutics
                                                                                        concurrence on responses relating to the
                                                                                        solution and formulation product

Prepare First of Code Batches           Compound as needed                              Identify compound needed for batch
                                                                                        production

Chemical Process Validation             Review and approve Chemical Process Validation  Conduct and report Chemical Process
                                        reports                                         Validation studies
</Table>

[ * ]

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       D-5
<Page>

                                    EXHIBIT E
        MINIMUM LOT SIZES, MANUFACTURING FEE AND PRODUCT MAINTENANCE FEE

MINIMUM LOT SIZES:

     Allos shall purchase Product in lot sizes of [ * ] (# of units expected
     from a [ * ] batch) units or multiples thereof.

                          MANUFACTURING FEE PER UNIT*:

<Table>
<Caption>
                                                US PRODUCT                               NON-US PRODUCT
     --------------------------------------------------------------------------------------------------------------
                                  [ * ] UNIT
     ANNUAL UNIT VOLUME             PRICE           [ * ] UNIT PRICE*        [ * ] UNIT PRICE)    [ * ] UNIT PRICE
     --------------------------------------------------------------------------------------------------------------
     <S>                            <C>                   <C>                      <C>                  <C>
     [ * ]                          [ * ]                 [ * ]                    [ * ]                [ * ]

     [ * ]                          [ * ]                 [ * ]                    [ * ]                [ * ]

     [ * ]                          [ * ]                 [ * ]                    [ * ]                [ * ]

     [ * ]                          [ * ]                 [ * ]                    [ * ]                [ * ]
</Table>

* Pricing based upon Allos' projections and specifications as of the Effective
Date. Pricing may be adjusted if projections or specifications change.

         Baxter's billing for Manufacturing Fees will be based upon Allos's
         cumulative volume in each Contract Year and will be reconciled based
         upon actual year-to-date annual sales on an individual purchase order
         basis, with an applicable credit to Allos which may be applied against
         future Product purchases.

         The Manufacturing Fee includes all of the following labels, components
         and excipients identified as Baxter's responsibility in the following
         table:

<Table>
<Caption>
                                                Baxter's Responsibility            Allos Responsibility
                                              (Included in manufacturing      (provided to Baxter at no
        Item                                             fee)                 cost)
        ----------------------------------------------------------------------------------------------------
        <S>                                               <C>                             <C>
        API (efaproxiral sodium)                           No                             Yes
        API reference standard                             No                             Yes
        API related impurity standards                     Na                             Yes
        [ * ]                                             Yes                              No
        Bottle, stopper, crimp cap                        Yes                              No
        NaCl, USP                                         Yes                              No
        Na2HPO4, USP                                      Yes                              No
        NaH2PO4, USP                                      Yes                              No
        WFI, USP                                          Yes                              No
        Label                                             Yes                              No
        Product/package insert                            Yes                              No
        Intermediate carton                               Yes                              No
</Table>

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       E-1
<Page>

<Table>
        <S>                                               <C>                              <C>
        [ * ]                                             Yes                              No
        Shipper                                           Yes                              No
</Table>

                       TABLE 2: ALLOS'S SALES PROJECTIONS:

                                      [ * ]

PRODUCT MAINTENANCE FEE:

The Product Maintenance Fee will be [ * ] commencing with the calendar quarter
that is the earlier of (i) receipt by Allos of the first Regulatory Approval in
the Territory for the Product or (ii) the quarter in which First of Code batches
of Product are released pursuant to the provisions of the Quality Agreement, if
done prior to the event described in (i). The [ * ] amount will also apply to
the subsequent three (3) calendar quarters. Commencing with the fifth calendar
quarter and continuing thereafter on a quarterly basis during the Term of this
Agreement, the Product Maintenance Fee will be [ * ].

<Table>
<S>                                       <C>          <C>         <C>         <C>
Yield:

         Mix Tank Volume (Liters)         [ * ]        [ * ]       [ * ]       [ * ]
         Final Batch Yield to Allos       [ * ]        [ * ]       [ * ]       [ * ]
</Table>

The two inputs for the yield calculation are the [ * ] and the total number of
units produced (commercial units delivered + any units used for testing). The
formula looks like the following:

         Final Batch Yield = [ * ]
                           = [ * ]
                           = [ * ]

Minimum Purchase Requirements if [ * ].
[ * ], Allos shall purchase Product in the [ * ] Container per the schedule
below.

<Table>
<Caption>
         Year [ * ]                 Allos' Minimum Purchase Requirement
         ----------                 -----------------------------------
         <S>                                       <C>
         Year 1                                    [ * ]
         Year 2                                    [ * ]
         Year 3 through end of Term                [ * ]
</Table>

While Allos will not be committed for long term purchase requirements, if Allos
desires to have Baxter continue to manufacture Product [ * ] or any subsequent
year after [ * ] development, Allos shall purchase a minimum of [ * ] units per
year for the term of the agreement.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       E-2
<Page>

                                    EXHIBIT F

                        CONFIDENTIAL DISCLOSURE AGREEMENT

              AMENDMENT TO MUTUAL CONFIDENTIAL DISCLOSURE AGREEMENT

THIS AMENDMENT TO THE MUTUAL CONFIDENTIAL DISCLOSURE AGREEMENT ("AMENDMENT") is
made and entered this 20th day of February 2002 by and between BAXTER HEALTHCARE
CORPORATION ("BAXTER"), and ALLOS THERAPEUTICS INC. ("ALLOS").

WHEREAS, Baxter and Allos are parties to a Mutual Confidential Disclosure
Agreement and Supplement, with an Effective Date of March 31, 1997 (the
"ORIGINAL AGREEMENT");

AND WHEREAS, Baxter and Allos wish to amend a certain provision of the Original
Agreement;

NOW, THEREFORE, in consideration of the foregoing recitals and the mutual
promises hereinafter set forth Baxter and Allos agree that the following
amendment shall be made to the Original Agreement, effective as of the date
given above:

1.  In Paragraph 2.0, the phrase "five (5) years" as it appears in the Original
Agreement shall be deleted in its entirety and replaced with the following:

                                "eight (8) years"

2.  The phrase "this Agreement" as it appears in the Original Agreement or this
Amendment shall be deemed to refer to the Original Agreement, as modified by
this Amendment.

3.  Except as modified by this Amendment, the terms of the Original Agreement
shall continue in full force and effect.

4.  For convenience this Amendment may be executed in counterparts with the same
force and effect as if each of the signatories had executed this same
instrument.

IN WITNESS WHEREOF, the parties have caused this Amendment to be executed by
their duly authorized representatives.

<Table>
<S>                                     <C>
ALLOS THERAPEUTICS INC.                 BAXTER HEALTHCARE CORPORATION

By: /s/ Michael E. Hart                 By:/s/ Arthur G. Mollenhauer
   ----------------------------------      -----------------------------------------
Name:  Michael E. Hart                  Name:  Arthur G. Mollenhauer
     --------------------------------        ---------------------------------------
Title: President & CEO                  Title: Vice President of Global Strategy
      -------------------------------          and Business Development
                                              --------------------------------------
</Table>

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       F-1
<Page>

                    MUTUAL CONFIDENTIAL DISCLOSURE AGREEMENT

This Agreement dated this 31ST day of March 1997 ("Effective Date"), by and
between Baxter Healthcare Corporation, through its I.V. Systems Division, having
a principal place of business at One Baxter Parkway, Deerfield, Illinois 60015
("Baxter") and Allos Therapeutics Inc., having a principal place of business at
7000 North Broadway, Suite 310, Denver, Colorado, 80221 ("Allos").

WHEREAS, Baxter is skilled in the art of manufacturing medical grade product
containers and filling the containers with medical solutions including but not
limited to I.V. solutions, dialysis products, and other related medical
products; and is skilled in the development, manufacture, and marketing of
medical products;

WHEREAS, Allos is skilled in the development and marketing of medical grade
products including RSR13;

WHEREAS Allos and Baxter desire to undertake preliminary discussions to explore
a potential business arrangement in which Baxter would develop a premix product
and package the product for Allos, initially in clinical batches, and ultimately
in market batches;

WHEREAS, Allos and Baxter intend to limit the exchange of confidential or
proprietary information during preliminary discussions to specific defined areas
and intend that all other information and discussions be exchanged on a
non-confidential basis;

NOW, THEREFORE, the parties agree as follows:

1.0      General: Confidential Disclosure.

         1.1    DEFINED. Each party agrees to keep  confidential  the  following
information which is disclosed to it by the other ("Confidential Information"):

                (a)   the formulation and stability of RSR13;

                (b)   data generated by Allos related to RSRl3's interaction
with [ * ] containers; Baxter proprietary information related to [ * ]
containers;

                (c)   special manufacturing procedures known to Allos unique to
the premix procedure for RSR13; Baxter proprietary manufacturing procedures or
protocols;

                (d)   information known to Allos which is unique to the
sterilization of RSR13; Baxter proprietary sterilization information;

                (e)   analytical methodology known to Allos which is unique to
the tests to release RSR13; Baxter proprietary product testing and release
information;

                (f)   the technical transfer package.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       F-2
<Page>

Allos acknowledges that it is aware of, and does not object to, Baxter's present
or future internal initiatives, and initiatives with third parties, in the
development, manufacture, packaging and marketing of drugs and other products
for use in cancer radiation therapy, whether or not such products are
competitive with RSR13, and whether or not Baxter employees or agents
interfacing with RSR13 are engaged in such other initiatives, PROVIDED that
Baxter does not breach its obligations under this Agreement. Accordingly, Baxter
does not want to receive any Confidential Information from Allos which would
compromise such Baxter initiatives and any such information which Allos does
disclose to Baxter shall be deemed disclosed on a non-confidential basis.

     1.2    WRITING. Confidential Information shall be disclosed to the other
party in writing or other tangible form, or if disclosed verbally, shall be
reduced to writing by the discloser and supplied to the recipient within 30 days
of disclosure. Except as provided in paragraph 1.0, or until otherwise agreed to
by the parties in writing, all information disclosed or exchanged by the parties
during their discussions regarding RSR13 shall be disclosed on a
NON-confidential basis.

     1.3    USE; DISCLOSURE. Each party agrees to use the Confidential
Information disclosed to it solely for evaluation of a potential business
arrangement with the other, and without the written consent of the other, agrees
not to disclose such Confidential Information to any other person or entity
other than those of its employees or agents who must have access to such
Confidential Information for evaluation purposes. All such employees and agents
shall be bound to maintain such Confidential Information in confidence and each
party will take such reasonable steps to require its employees and agents to
preserve such trust and confidence.

     1.4    PROTECTION; RETURN. Each of the companies shall in all respects
treat such Confidential Information disclosed to it hereunder at least as
carefully as that accorded its own trade secrets or Confidential Information and
will carry out with respect to it those security measures which it follows for
its own trade secrets or Confidential Information. Upon the request of the
disclosing party, each party as a receiving party will return to the disclosing
party all Confidential Information (including copies) provided by the disclosing
party under this Agreement.

     1.5    EXCEPTIONS. The term Confidential Information shall not apply to
information which:

            (a)   is known to the receiving party before receipt thereof under
this Agreement, or is independently developed by the receiving party;

            (b)   is disclosed to the receiving party after the date of this
Agreement by a third party who has no obligation of confidentiality to the
disclosing party;

            (c)   is or becomes reasonably part of the public domain through no
fault of the receiving party.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       F-3
<Page>

2.0  TERM. The term of this Agreement shall be five (5) years from the Effective
     Date of this Agreement, except that Baxter's obligations with respect to
     Allos' Confidential Information shall terminate on either of the following
     dates, if occurring earlier: (a) the market launch of RSR13 or (b) Allos'
     effective discontinuation of development work or marketing of cancer
     radiation therapy indications for RSR13.

3.0  MISCELLANEOUS.

     3.1    EXPORT. A recipient shall adhere to the U.S. Export Administration
Laws and Regulations and shall not export or re-export any technical data or
products received from the discloser or the direct product of such technical
data to any proscribed country listed in the U.S. Export Administration
Regulations unless properly authorized by the U.S. Government.

     3.2    COMPLETENESS; AUTHORITY. This Agreement contains the entire
understanding between the parties related to the subject matter hereof, and
supersedes all prior written and verbal negotiations, representations, and
agreements concerning the subject matter. Each party represents that it has the
right to deliver the Confidential Information it discloses to the recipient
pursuant to this Agreement.

     3.3    AMENDMENT. The obligations of this Agreement shall not be altered,
amended or superseded by any subsequent agreement except by written instrument
signed by both parties. Neither party is obligated to enter into any further
agreements with the other party following the preliminary discussions. Any
intention of the parties to proceed with a further business arrangement with
respect to RSR13, including the packaging of clinical batches or marketing
batches, shall be set forth in a separate written agreement.

     3.4    Laws. This Agreement shall be governed by the laws of the State of
Illinois.

IN WITNESS WHEREOF, the parties have executed this Agreement as of the Effective
Date set forth above by their duly authorized representatives.

ALLOS THERAPEUTICS INC.                 BAXTER HEALTHCARE CORPORATION

By:/s/ Stephen Hoffman                  By: /s/ David F.  Drohan
   -------------------                     -------------------------------
Name:                                       David F.  Drohan
     --------------------------------
Title: President                            I.V. Systems President
      -------------------------------
Date: 3/30/97                               Date: 4/11/97
     --------------------------------            --------------------------

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       F-4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00061-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00061-of-00352.parquet"}]]